The role of the apoptotic pathway in hormone resistant breast cancer by Cannings, Elizabeth
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
The Role of the Apoptotic 
Pathway in Hormone Resistant
Breast Cancer
Elizabeth Cannings MBChB MRCS
Section of Surgical Sciences and Translational Research 
Division of Cancer Sciences and Molecular Pathology
Submitted for the degree of MD to the 
University of Glasgow 
November 2006
© Copies of this thesis may be produced by photocopying
ProQuest Number: 10391017
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391017
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
ü n iVe r s i t y I
J U B R A R N :
Abstract
Activation of the PI3K/Akt signal transduction pathway has been linked to endocrine 
resistance in tamoxifen treated breast cancer patients. Activation of the PDK/Akt 
pathway causes phosphorylation of Bad leading to modulation of cellular apoptosis. 
This study was carried out to test the hypothesis that disruption of apoptosis in breast 
cancer, via Akt activation, is linked with hormone resistance.
Immunohistochemistry (IHC) was performed on 402 oestrogen receptor (ER) positive 
breast cancers using antibodies against PTEN, Bad, pBad (ser 112), Bax, Bcl-2, Bcl- 
xl, P70S6K, pP70S6K (thr 389) and pP90RSK (thr 359/ser363). In addition FISH was 
performed on the same cohort for HER2. This was compared with the results for the 
herceptest performed on the same tumours. I also performed pilot studies looking at 
the amplification and deletions of PI3K and PTEN respectively in this cohort of 
patients.
Patients whose tumours had high levels of PTEN expression had a favourable 
outcome compared to those patients with a low PTEN expression. Patients, whose 
tumours had high levels of Bad expression, had a significantly improved disease-free 
survival when compared to patients whose tumours had low levels of Bad expression. 
There were no associations with disease free or overall survival in the remaining 
antibodies investigated. Pilot studies did not suggest that it would be fruitful to 
perform FISH on the whole tumour cohort for either PI3K or PTEN.
Data presented here shows that reduced Bad expression is associated with relapse in 
tamoxifen-treated breast cancer patients, supporting our hypothesis that the apoptosis 
pathway is involved in tamoxifen resistance. My results also show an association 
between increased expression of PTEN and a reduced overall and disease free 
survival.
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Chapter 1
Introduction 
1.1 Breast Cancer
Breast cancer is the second major cause of cancer related death among women in the 
United States and Europe (www.uicc.org). The incidence is increasing and the 
lifetime risk for a woman to develop breast cancer is 1 in 9 (www.statistics.gov.uk). 
Breast cancer is uncommon in women under 25 years of age. Thereafter the incidence 
steadily increases until the menopause when the rate slows again. There is a familial 
disposition in 10% of cases but for the majority the cause is not known. The risk 
factors for developing breast cancer, in addition to familial factors include increased 
age, early menarche, late menopause, exogenous oestrogens, increased alcohol intake, 
dietary factors, late first pregnancy and nulliparity.
1.2 Oestrogen Receptor
Oestrogen (E2) is a steroid hormone. It is mainly produced in the ovary in 
premenopausal patients with a switch to production in the peripheral adipose tissue 
through aromatisation of androgens (Korach KS, 1996) in post menopausal women.
In men the main site of sythesis are the Leydig cells of the testis. E2 is essential for 
reproductive function (testis, ovary, endometrium), anabolic functions (bone and 
muscle mass) and also plays a central role in the central nervous system and the 
cardiovascular system(Hess et al., 1997). The oestrogen receptor was identified in the 
1960s^ and shown to control expression of oestrogen responsive genes. Further
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studies investigating the mechanism of action of other steroid hormones (especially 
gluco-corticosteroids) led to the classification of the ER as a member of the steroid 
receptor superfamily(Yamamoto, 1985). In 1996 a second oestrogen receptor, ER(3 
was found(Kuiper et al., 1996). Despite the identification of ERp, most of the 
knowledge about the role played by ER in breast cancer relates to ERa.
ERa is a 65kDa nuclear transcription factor receptor expressed in 46-77% of breast 
cancers (Robertson, 1996). ERa exists as an inactive monomer bound by heat shock 
proteins (especially Hsp90) in the cell cytoplasm or nucleus. Subsequent ligand 
binding causes dissociation of the heat shock proteins and alteration of receptor 
conformation. The activated receptors then homodimerize, translocate to the nucleus, 
form a complex with co-regulatory molecules and bind to oestrogen response 
elements (ERE) in the promoter region of target genes, to alter transcription of ERa 
regulated genes (Klein-Hitpass et ah, 1988; Kumai' and Chambon, 1988) (figurel). 
The targets of proliferative E2/ERa action include genes such as fos, jun-B and 
myc(Weisz and Bresciani, 1993), cell cycle-regulators such as cyciin D1 (Musgrove 
et ai., 1993), cyclin-dependent kinase inhibitors (Planas-Silva and Weinberg, 1997) 
and growth factors and their signalling pathways (Migliaccio et al., 1996; Dickson 
and Lippman, 1995).
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ER
CDERER
P R O M O T E R  R E G IO N  GENE
Figure 1
The ER is composed o f an N-terminal domain (NTD), a central DNA binding domain 
(DBD) and a C-terminal ligand-binding domain (LBD). Oestrogen binding to the ER 
causes dissociation of the heat shock proteins (HSP). The activated receptor 
subsequently homodimerize and form a complex with co-activators (A) and co­
repressors (R), which binds to oestrogen response elements (ERE) in the promoter 
region o f target genes.
ERa is composed of different domains, i.e. the ligand binding domain (LBD) which 
contains the binding region for oestrogens and anti-oestrogens(Brzozowski et al., 
1997; Shiau et al., 1998; Tanenbaum et al., 1998). The LBD also contains a ligand 
activated transcription activation function, AF-2, as well as sequences required for 
ligand-dependent dimerisation(Ali and Coombes, 2000c). The N-terminal 180 amino 
acids contain transcription activation function AF-l(Ali and Coombes, 2000b). 
Extensive studies using ERE-containing reporter genes have shown that AF-1 and
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AF-2 can act both independently and synergistically in a promotor and cell specific 
manner(Gronemeyer, 1991; Tsai and O'Malley, 1994; Beato et a l, 1995).
1.2.1 Receptor Phosphorylation
ERa is phosphorylated and consequently activated at several sites (Le Goff et a l, 
1994b) {Figure 2). Growth factor signal transduction pathways or cyclin dependent 
kinases can activate ER a in a ligand-independent manner by phosphorylation at 
specific serine residues (Joel et a l, 1998) . Phosphorylation of ER a at Ser-167 is 
mediated by the phosphoinositide 3-kinase (PI3K)/Akt pathway, whilst the mitogen- 
activated protein kinase (MAPK) pathway phosphorylates ER a at Ser-118; both sites 
are in the hormone-independent AF-1 region. Phosphorylation is an important 
mechanism by which the activity of transcription factors is modulated(Shao and 
Lazar, 1999). Phosphorylation of ER a at serines 104, 106, 118, 167, 236 and tyrosine 
537 has been demonstrated using deletional or point mutation analysis(Ali et a l, 
1993; Castoria et a l, 1993; Le Goff et a l, 1994a; Chen et a l, 1999a). {Figure 2) 
(Campbell et a l, 2001a) (Chen et a l, 2000; Rogatsky et a l, 1999) The DNA binding 
domain (DBD) can be phosphorylated by protein kinase A (PKA) (Chen et a l, 1999b) 
to inhibit transcriptional activity via decreasing DNA binding and regulation of 
dimerization. In addition the AF2 region can be phosphorylated by Src kinases on 
tyrosine 537 (Arnold et ah, 1997) to enhance dimerization, ligand binding and co­
regulator recruitment.
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POST TRANSLATIONAL MODIFICATION: 
PHOSPORYLATION
Src KINASESPKAAKTMAPKCDK2
S104/106 1 ^ 8  I SI67 S236 Y537
AF2AFl NTD DBD LED
TRANSACnVATTOI D IM ERIZA TI^
Figure 2
The AFl region can he phosphorylated by MAPK kinases, Akt or cyclin dependent 
kinases. The DBD has been shown to be phosphorylated by PKA and the AF2 region 
by Src kinases.
1.2.2 Ligand Independent Action
The AF-1 region controls ligand-independent receptor activation. Cells with high 
levels of HR expression may demonstrate ligand independent AF-1 transactivation 
and growth (Fowler et al., 2004).
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1.2.3 Non-genomic Action
There is increasing evidence for “non-genomic” actions of ERa, particularly to 
explain its rapid non-nucleai' effects, such as activation of the calcium channel and the 
MAPK pathway(Simoncini et al., 2000). These non-genomic, extranuclear, membrane 
mediated effects take place outside the nucleus. There is evidence that that the non- 
genomic actions of oestrogen are mediated by membrane associated ER a which 
functions as an atypical G-protein coupled receptor(Evinger, III and Levin, 2005; 
Watson and Gametchu, 1999). Functionally, oestrogen initiated non-genomic events 
like those induced by many cytokines, have important physiological consequences 
leading to DNA synthesis, cell proliferation and protection against cell death(Castoria 
et al., 1999; Kousteni et al., 2001; Song et al., 2005a). O’Malley suggested that 
activation of cytoplasmic kinases through membrane initiated events results in the 
phosphorylation and activation of co-activators, which enhance nuclear transcriptional 
events(Song et al., 2005b; OMalley, 2005). Because ERa has no intrinsic kinase 
domain and therefore is not capable of phosphorylating other proteins, the signalling 
molecules must function directly downstream of, and physically associate with ERa. 
At the same time, the signalling moleeule must transduce ERa signal to downstream 
eascades, leading to rapid activation of MAPK and Akt(Cheskis, 2004). Some 
evidence exits that this membrane receptor may directly signal via activation/cross 
talk with the membrane growth factor EGER (Razandi et al., 2000). This would also 
provide a mechanism for a positive feedback loop as downstream growth factor 
pathway members such as MAPK and Akt may then phosphorylate ERa
25
1.2.4 ERp
ERP is homologous to ERa, particulai'ly in the DNA-binding domain (95% amino 
acid identity). The human ERp gene has been mapped to band q22-24 of chromosome 
14(Enmark et al., 1997) and the human ER a gene has been mapped to the long arm of 
chromosome 6, excluding the possibility of differential splicing to explain the 
formation of ERP(Enmai’k and Gustafsson, 1999). E2 binds to ER a and ERP with 
similar affinities(Kuiper et al., 1998) and activates expression of reporter genes 
containing estrogen response elements in an estrogen-dependent manner. However, in 
addition to acting as a homodimer, ERB also heterodimerizes with ERa(Pace et al., 
1997). Evidence suggests that the expression of functional ERa/p heterodimers, may 
result in unique patterns of gene regulation, many of which are distinct from the genes 
regulated by the ER homodimers (Monroe et al., 2005).
1.3 Endocrine Therapy
In 1898 Beatson discovered the benefits of oophorectomy in young women with 
locally advanced breast cancer and ERa expression in breast tumours is today a 
strong predictor of response to endocrine therapy. There are several well-known types 
of endocrine therapy. Aromatase inhibitors act by blocking conversion of androgens 
to oestrogens. Lutenising hormone releasing hormone analogues (such as goserlin) 
prevent the release of LH from the pituitary thus depriving the thecal and granulosa 
cells of the ovary of stimulation and reducing oestrogen synthesis in the ovary of 
oestrogen from the ovaries. Alternatively, there is the ‘selective oestrogen receptor 
modulator (SERM)’, Tamoxifen. Tamoxifen works by competing with E2 to bind to 
ER a receptor (Jordan and Dowse, 1976) and was originally developed as an oral
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contraceptive, but its potential anti-oestrogenic properties were subsequently 
reeognised(Harper and Walpole, 1966) and it was introduced as an endocrine agent 
for the treatment of breast cancer. Initially hormone treatment was given to all 
patients but trial evidence confirmed responsiveness in the ER a positive patients 
only(1998).
Studies have shown that the agonist activity of Tamoxifen derives from activation of 
the AF-1 and antagonist activity derives from inhibition of AF-2(Ali and Coombes, 
2000a).
The primary mechanism of action of tamoxifen is via competitive inhibition of E2 
binding to ERa. This disrupts a series of cellular- mechanisms that regulate cellular 
replication. This disruption caused by tamoxifen changes the growth factor profile in 
responsive tissues and causes cells to be held in the G1 phase of the cell 
cycle(Osborne et al., 1983; Colletti et al., 1989; Gradishar, 2004). This produces 
changes in tumour cell proliferation and cell death and consequently the observed 
anti-tumour responses (Cameron et al., 2000d; Cameron et al., 2001) and improvement 
in overall survival(Yao and Jordan, 1998; Gradishar, 2004). Tamoxifen is not a pure 
antagonist, but rather a partial agonist therefore exerting both agonist and antagonist 
effects. It is an agonist in bone(Love et al., 1992b) and endometrium(Kedai' et al., 
1994). It is used for its antagonist effect on genes important for cell proliferation or 
survival in the breast.
In the Early Breast Cancer Trialists’ collaborative Groups overviews of 1998 and 
2005, there was a 50% proportional reduction in the recurrence rate and a 28% 
proportional mortality reduction for ERa positive patients taking adjuvant tamoxifen 
for 5 years. These overviews demonstrated a long term and increasing benefit of 
Tamoxifen with survival benefits maximised at 5 years of treatment. Tamoxifen,
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taken for 5 years, has been the standard adjuvant endocrine treatment for post­
menopausal women with primary ER a positive breast cancer since the 1970’s. 
Tamoxifen can also achieve tumour regression in patients with locally advanced or 
metastatic disease. Its side effects include those related to its anti-oestrogen effects 
(flushes, vaginal dryness) and those related to its agonist effects (risk of endometrial 
cancer (Bergman et al., 2000) and increased risk of thromboembolic events (Falkson et 
al., 1990)). A positive side effect of Tamoxifen’s paitial agonist activity is its effect 
on bone mineralisation(Love et al., 1992a). It produces an increase and stabilisation of 
bone mineral density. Unfortunately, approximately one fourth of ERa breast cancers 
exhibit either de novo (present before tamoxifen treatment) or acquired resistance 
during the course of therapy(Gradishar, 2004). Those patients that relapse on 
tamoxifen therapy generally retain their nuclear steroid receptors(Clarke et al., 2001). 
However it appeal's that a proportion of ER a positive tumours are intrinsically 
hormone independent(McGuire, 1980)
Recently alternative endocrine therapies, such as treatment with Aromatase Inhibitors 
(AI), have shown to be effective after disease relapse following tamoxifen treatment 
since most tumours remain ERa-positive(Coombes et al., 2004d) and thus retain the 
potential to respond to anti-oestrogen therapies. Aromatase is a cytochrome p450- 
dependent enzyme, which acts at the last step in the synthesis of E2 by catalysing the 
conversion of androgens to oestrogens. Aromatase inhibitors work by inhibiting this 
peripheral conversion of androstenedione to oestrone and oestradiol (the primary 
source of oestrogen in post menopausal women). The Arimidex versus Tamoxifen 
alone or in combination (ATAC)(Baum et al., 2002b) trial compared five years of 
therapy using anastrazole (Arimidex) alone with five years of tamoxifen alone. With a 
combination of the two drugs, there was a small but significant DES for the
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anastrazole ai'm compared with the tamoxifen aim (89.4% versus 87.4% respectively 
p=0.013). Results from the combination arm were not significantly different from the 
tamoxifen aim and this arm was discontinued(Baum et al., 2002a). The AT AC trial 
was updated in 2005 with 68 months follow up and the benefit of anastrazole over 
tamoxifen was maintained(Howell et al., 2005b) but only in terms of disease free 
survival No increase in overall survival has yet been demonstrated. The Intergroup 
Exemestane Study (IBS) randomised ER positive postmenopausal women who had 
completed 2-3 years of tamoxifen to either complete 5 years of tamoxifen or switch to 
exemestane for the remaining 2-3 yeai’s of therapy(Coombes et al., 2004c). After a 
median follow up of 36 months switching to exemestane resulted in a 4.7% decrease 
in the absolute risk of recurrence (p=0.00005). A recent update of this trial showed a 
significant advantage in terms of overall survival in ER positive cases recruited to this 
trial. The National Cancer Institute of Canada Clinical Trials Group M.A 17 evaluated 
the benefit of 5 years of letrozole or placebo after completion of five years of 
tamoxifen therapy. After a median follow up of 2.4 years, the use of letrozole resulted 
in a 43% proportional reduction in the risk of reeurrence when compared with placebo 
(p=0.00008)(Goss et al., 2003). As a result of these trials, patients whose tumours are 
of higher risk (higher grade, nodal metastasis, PR negativity, HER2 positivity) may 
get an aromatase inhibitor as first line adjuvant therapy or switch from tamoxifen to 
an aromatase inhibitor after 3 years or giving 5 years of an aromatase inhibitor after 5 
years of tamoxifen. There is much debate about when to start AIs but at present those 
post-menopausal patients who are Her 2 positive are treated from the outset with an 
AI as the main effect of Her2 positivity is seen within the first three years (early 
effect)(Tovey et al., 2005b) Patients whose tumours are Her 2 negative but with a 
higher grade and nodal positivity either have extended adjuvant therapy (AI for 5
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years after 5 years Tamoxifen therapy or a switch to an AI after 2-3 years Tamoxifen 
therapy. The rationale behind 2-3 years of tamoxifen therapy, then a switch to an AI is 
that women would have increased bone protection from initial exposure to 
Tamoxifen, and consequently may have a reduced risk of fracture whilst on aromatase 
inhibitor therapy(Spicer and Ellis, 2006). A study by Kennecke(Kennecke et al.,
2006) et al has suggested that there is a subset of post-menopausal women who are at 
increased risk of relapse after 5 years standaid Tamoxifen therapy and those include 
node negative grade 2 or 3 tumours (10% risk of relapse after 5 years Tamoxifen 
treatment), and node positive grade 2 tumours (15% risk of relapse after 5 years 
Tamoixfen therapy). Continuing Tamoxifen therapy for longer than 5 years is no 
longer recommended as it has been shown that its agonist activity starts to 
predominate and therefore the risks associated with its use increase whilst the benefits 
decrease(Fisher et al., 2001). Further data is expected from the AT AC and lES trials 
soon. Whilst data suggests that AIs are also of value in the adjuvant treatment of 
breast cancer, switching therapeutic agents in early breast cancer may be unnecessary 
since about 75% of patients treated with tamoxifen remain alive and disease-free up to 
15 years after treatment(2005). AIs are not without risk such as the increased risk of 
bone demineralisation and increased cholesterol levels(Perez, 2006).
Indiscriminate implementation of AIs in eaidy breast cancer may both remove viable 
treatment options from patients who subsequently relapse and lead to over treatment 
of many women for whom tamoxifen is essentially curative. There is a need to 
identify the molecular mechanisms involved in development of tamoxifen resistance. 
The aim is the selective targeting of patients with early breast cancer at high risk of 
developing tamoxifen resistanee, who would derive maximum benefit from selective 
targeting of other drugs such as AIs (Howell et al., 2005a).
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1.4 Potential mechanisms of tamoxifen resistance
Selective ER a modulators (SERMs) have been the most commonly used neoadjuvant 
therapy for hormone-dependent breast eancer. Resistance to endocrine therapy (either 
de novo or acquired) is a major challenge in the management of breast cancer. The 
causes of resistance to hormone therapy have been a subject of intensive 
investigations but aie still not well understood. Several mechanismsm have been 
suggested to promote tamoxifen resistance(Shou et al., 2004b; Jordan et al., 2004b; 
Knuefermann et al., 2003) : modulation of ER activity via phosphorylation by growth 
factor receptors (eg HER2)(Shou et al., 2004a; Schiff et al., 2004; Tovey et al., 
2004a); phosphorylation/overexpression of steroid receptor cofactors (Osborne et al., 
2003; Fleming et al., 2004; McKenna et al., 1999), non-genomic ER activity(Johnston 
et a l, 2003) and increase in cell survival independent of ER(Zhou et a l, 2000b; 
Treeck et a l, 2004d; Jordan et a l, 2004a),. It is thought decreasing sensitivity of 
ER a positive breast cancer cells to anti-oestrogens is caused by several factors: Each 
of these activities may contribute to the tamoxifen resistance phenotype(Clark et a l, 
2002a; West et al, 2002a; Tsuruo et a l, 2003a). Previous work in our group shows 
Her l-3(Tovey et a l, 2004a), Akt(Kirkegaard et a l, 2005e) and AIBI (in press) are 
linked to de novo tamoxifen resistance.
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1.4,1 Loss of ERa
Loss of ERa expression, particularly in metastasis, has been proposed as a mechanism 
for the development of resistance to hormonal therapy(Graham et al., 1992b) . Most 
ERa positive breast cancers will also contain populations of ERa negative cells. 
Under the selective pressure of anti-oestrogen treatment, ERa negative cells may 
come to predominate so accounting for an apparent switch in their tumour receptor 
status (Graham et al., 1992a)Two thirds of tumours that become resistant to tamoxifen 
continue to express ERa (Encarnacion et al., 1993). Tamoxifen resistant cell lines 
frequently demonstrate sustained ERa content and remain responsive to pure anti­
oestrogen therapy (Brunner et al., 1993). ERa positive tumours that have become 
resistant to Tamoxifen as an initial endocrine therapy will often go on to respond to a 
2"  ^ line anti-hormonal treatment such as an aromatase inhibitor or oophorectomy 
(Murray and Pitt, 1982; Robertson et al., 1989; Sawka et al., 1986), indicating the 
continued presence of a functional Era.
1.4.2 Expression of ERp
In breast cancer archives, ERp positivity was reported to be approximately 50-70% by 
immunohistochemistry(Speirs et al., 2004). Recent progress in cellular experiments 
has shown that ERp works as a counter paitner to ERa thiough inhibition of the 
transactivating function of ERa by heterodimerisation, distinct regulation on several 
specific promoters by ERa or ERp, and ERp-specific regulated genes which are 
probably related to its anti-proliferative properties (Saji et al., 2005). When ERa 
works as a transcriptional activator on ERE, the function of ER a is suppressed by
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dimerization with ERP(Lindberg et al., 2003). The activity of the AF-1 region in the 
ERp receptor is weak compared with the ER a receptor(Cowley and Parker, 1999). 
Microarray analysis has demonstrated the presence of oestrogen-regulated genes that 
are only enhanced by ER a or ERp(Stossi et al., 2004). The expression of ERp 
appeal's to be reduced during cai'cinogenesis (Roger et al., 2001; Shaaban et al., 2003; 
Skliris et al., 2003) although levels are high in normal mammary tissue. At present the 
exact role of ERP in breast cancer is not clear.
1.4.3 ER mutations
Re-arrangements and/or amplifications of the ER a gene are rare in breast cancer. 
Some variants have been found that lack specific exons that code for active forms of 
ERa. However analysis of clinical material failed to find a significant role for these 
variants in disease progression and/or resistance to endocrine therapies(Hopp and 
Fuqua, 1998)
1.4.4 PR Expression
PR expression is thought to reflect a functional ER transcription pathway. The lES 
study (Coombes et al., 2004b) showed benefit in DES with exemestane regardless of 
PR status. Data from Tovey et al (Tovey et al., 2004a) showed significant differences 
in relapse rates on tamoxifen when patients with ER positive and PR negative 
tumours were compared to those with ER positive and PR positive tumours after 3 
years of tamoxifen therapy. This supports the conclusion that PR negativity identifies 
a group of patients whose tumours have de novo resistance to tamoxifen. The AT AC
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(Baum et al., 2002c) trial also supports this conclusion by showing a superior disease 
free survival for patients whose tumours were ER positive/PR negative with 
anastrazole as compared to Tamoxifen treatment. However in contrast to the findings 
of the AT AC trial the Breast International Group (BIG) l~98(ThurUmann et al., 2005) 
(which looked at Letrozole as an initial therapy as compared to Tamoxifen) showed 
that the hazard ratio in favour of the use of letrozole was similar in both the Er+/PR+ 
and ER+/PR- groups.
1.4.5 Modulation of apoptosis
There is increasing evidence that hormone resistance is linked with the modulation of 
apoptosis(Treeck et al., 2004c; Fernando and Wimalasena, 2004g). This is further 
explored in 1.5, 1.7 and 1.8
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1,5 Apoptosis and Tamoxifen resistance
1.5.1 Apoptosis
There are 3 different mechanisms by which a cell commits suicide by apoptosis.
1. Generated by signals arising within the cell;
2. Triggered by death activators binding to receptors at the cell surfaces
3. Triggered by reactive oxygen species
There is some evidence that the modulation of apoptosis triggered by internal signals:
(the intrinsic or mitochondrial pathway) is linked to endocrine resistant breast cancer. 
In a healthy cell, the outer membranes of its mitochondria display the proteins Bcl- 
2/Bcl-xl on their surface.
Internal damage to the cell (e.g., from reactive oxygen species) causes Bcl-2/Bcl-xl to 
activate a related protein, Bax (see 1.7), which punches holes in the outer 
mitochondrial membrane, causing cytochrome c to leak out.
The released cytochrome c binds to apoptotic protease activating factor-1 (Apaf-1) 
using energy provided by adenosine tri-phosphatases (ATPs). These complexes 
aggregate to form apoptosomes. Apoptosomes bind to and activate caspase-9.
Caspase-9 is one of a family of over a dozen caspases. They are all proteases, which 
cleave other proteins (mainly other caspases). Caspase-9 cleaves and, activates other 
caspases (caspase-3 and -7).
These caspases create an expanding cascade of proteolytic activity, which leads to 
digestion of structural proteins in the cytoplasm, degradation of chromosomal DNA, 
and phagocytosis of the cell.
The apoptosis pathway is, in part under the control of the PI3K/AKT and RAF-1 
pathways(Tan et al., 1999e) (figure 3) which are, in turn under the control of the
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Human Epidermal growth factor Receptor (HER) family of receptors. The PI3K/AKT 
and RAF-1 pathways, activate (phosphorylate) p70S6K (Tan et al., 1999d) and 
p90RSK respectively which in turn modulate apoptotic activity via phosphorylation of 
members of the Bcl-2 family.
HER signalling pathways
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Thr3S9
Sc 153
Figure 3. HER signalling pathways showing the proposed apoptotic pathways and 
activation o f the oestrogen receptor.
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1.6 HER 1-4 Family
The Human Epidermal growth faetor Receptor (HER) family of type-1 receptor 
tyrosine kinases consists of four members, EGFR/HERl, HER2/ErbB-2, HER3/ErbB- 
3 and HER4/ErbB-4 that modulates cell proliferation, survival, adhesion, migration 
and differentiation. Growth factor induced signalling is essential for normal eellulai" 
processes and plays a key role in the aberrant growth and development of tumour 
cells(Yarden, 2001c). The HER receptors are trans-membrane receptors. Each HER 
family member is composed of an extracellular ligand binding domain, a lipophilic 
transmembrane segment and cytoplasmic tyrosine kinase region with a regulatory 
carboxy-terminal segment (Ullrich and Schlessinger, 1990; van der et al., 1994). Her 
2 has no ligands. Ligand binding to the extracellular domain induces the receptors to 
form hetero- or homo-dimers. Cross-phosphorylation of the tyrosine residues then 
occurs resulting in the docking sites for signalling complexes. The subsequent release 
of enzymes and adapter proteins into the cytoplasm stimulates multiple signal 
transduction eascades.
Three layers of interaction have been identified as being key factors in the generation 
of the diverse pattern of signalling messages (Alroy and Yarden, 1997).
Firstly, 2 main groups have been identified as HER ligands (Mendelsohn and Baselga, 
2000). There are 6 direct ligands of HERE Epidermal growth factor (EGF), 
amphiregulin and transforming growth factor alpha (TGFa) only bind to HERE 
Heparin binding EGF (HB-EGF), betacellulin, and epiregulin can bind to both HERl 
and HER4. A second class of ligand called neuregulins bind to HER3 and HER4. 
Neuregulin-1 and -2  bind to either receptor, while neuregulin-3 and -4 bind to HER4 
only. Recent work has shown that 2 different ligands activating the same receptor can 
have a differential impact on transcriptional outcome (Amin et al., 2004b).
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Secondly, each of the ligands has a different preference for stabilising particular 
receptor dimers. It appears that the most potent dimer is HER2-HER3 (Yarden, 
2001a).
Thirdly, each ligand receptor dimer directs its signal through a unique but overlapping 
set of signalling pathways (Olayioye et al., 2000). These signal transduction cascades 
include the MAPK pathway, PKC, phosphoinositol kinase, Akt and several 
transcription regulators. Ultimately these signals reach the nucleus and lead to nuclear 
gene activation.
Further complexity is highlighted by the fact that HER2 enhances and stabilises 
dimerization but apparently has no ligand (Klapper et al., 1999a) whereas HER3 has 
no inherent kinase activity so must be dimerised with another HER family member to 
exert an influence on downstream signalling (Guy et al., 1994b).
1.6.1 HERl
HERl is a 170kD transmembrane receptor that is expressed on the surface of most 
cell types and is encodeed by a gene on human chromosome 7q21. HERl is expressed 
in a variety of human cancers, including non-small cell lung cancer, head and neck, 
gastric, colorectal, oesophageal, prostate, bladder, renal, pancreatic and ovarian 
cancers (Salomon et al., 1995). Osborne et al showed that the HERl ligand EGF was 
a potent mitogen in the breast cancer cell line MCF-7 (Osborne et al., 1980). The first 
reports of HERl expression in human breast cancers were in 1985 (Sainsbury et al., 
1985).
Sainsbury et al were the first to identify a link between HERl and prognosis in breast 
cancer (Sainsbury et al., 1987). Since then, many studies have examined this 
relationship, not always with conclusive results (reviewed (Klijn et al., 1992) and
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(Nicholson et al., 2001)). One of the largest studies was recently performed using 
immunohistochemistry in 1029 patients (Tsutsui et al., 2002). Multivariate analysis 
demonstrated that HERl was an independently significant prognostic factor for 
disease free and overall survival. Certainly we know there is a significant negative 
correlation between EGER positivity and ER status (Koenders et al., 1991). Tovey et 
al (Tovey et al., 2004a) showed that Her 1 expression was predictive for early relapse 
on Tamoxifen which increased when increased associated with over-expression of 
Her 2 and 3. There has also been speculation as to the future of HERl as a predictive 
factor alone for selection of various treatment modalities. ZD 1839 (Iressa) is an orally 
active selective HERl tyrosine kinase inhibitor which has shown promise in 
preclinical trials, and is currently undergoing phase II clinical trials in breast cancer 
(Morris, 2002). High expression of HERl has been associated with resistance to 
radiotherapy (Sartor, 2000) .
1.6.2 HER 2
The HER2 proto-oncogene encodes an 185kD transmembrane glycoprotein and is 
mapped to chromosome 17q21. Despite apparently having no ligand, HER2 
homodimers form avidly and HER2 is the preferred dimerization partner for other 
HER members (Graus-Porta et al., 1997; Tzahai' et al., 1996). This may help explain 
the high oncogenic potential of HER2. HER2 heterodimers have particularly high 
ligand-binding and signalling potency (Sliwkowski et al., 1994) with the most potent 
dimer in terms of cell growth and transformation being HER2-HER3 (Pinkas- 
Ki'amarski et al., 1996). It has been proposed (Klapper et al., 1999b) that HER2 may 
be the ultimate co-ordinator of the signalling network, amplifying signalling by 
multiple ligands.
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HER2 is normally expressed in a variety of cell and tissue types and is frequently 
overexpressed in a number of human cancers (Hynes and Stern, 1994). HER2 
overexpression and amplification is found in lung, gastric and ovarian cancers 
(Schneider et al., 1989; Yoshida et al., 1989; Berchuck et al., 1990).
Both preclinical and clinical studies indicate that HER2 amplification and 
overexpression is involved in oncogenic transformation and tumourigenesis in breast 
cancer. Cell lines that overexpress the HER-2 gene product display a highly 
transformed and tumourigenic phenotype as compared with control cells (Chazin et 
al., 1992; Di Fiore et al., 1987). In addition HER2 gene amplifieation or protein 
overexpression has been demonstrated in 15-30% of invasive breast cancers (Berger 
et al., 1988; Slamon et al., 1987c). The majority of cases of HER2 overexpression 
appeal' to be as a consequence of HER2 gene amplification (Pauletti et al., 1996). 
Slamon et al (Slamon et al., 1987b) first linked HER2 with poor prognosis in breast 
cancer in 1987. Since then there have been multiple studies investigating this 
relationship. A meta-analysis of 47 trials (Ross and Fletcher, 1998) demonstrated 
HER2 was an independent predictor of prognosis in 60% of the trials involving 67% 
of patients. Of note all the studies that used FISH to detect gene HER2 amplification 
concluded that there was a clear association between HER2 status and prognosis. 
Herceptin (trastzumab) is a HER2 monoclonal antibody against its extracellular 
domain. The HERA trial (a large multi centre trial of Herceptin) (Piccart-Gebhart et 
al., 2005a) showed a significant improvement in disease free survival in Her2 positive 
breast cancer patients. Tovey et al (Tovey et al., 2004a) demonstrated that those 
patients with over-expression of Her 2 had an increased chance of early relapse on 
Tamoxifen treatment compared with those with a low expression of Her 2. They also 
showed that those patients whose tumours had increased levels of Her 1-3 exhibited
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de novo resistance as evidenced by early relapse on Tamoxifen compared to those 
with reduced expression levels of Her 1-3(Tovey et al., 2004a).
1.6.3 HER3
In 1989 a 3*^  ^member of the HER family was identified (Kraus et al., 1989b) as a 148- 
kDa transmembrane polypeptide encoded to a gene located on chromosome 12ql3. 
Due to substitutions in critical residues in its catalytic domain, HER3 has an impaired 
kinase (Guy et al., 1994a), and thus can only process its signalling in the context of a 
reeeptor heterodimer. HER3 is found in cells of the developing gastrointestinal, 
reproductive and urinary tracts as well as the skin, endocrine and nervous systems 
(Prigent et al., 1992). HER3 is expressed in tumours of the skin, ovary and 
gastrointestinal tract (Bodey et al., 1997; Maurer et al., 1998; Simpson et al., 1995). 
There is also evidence for its role in breast cancer. Markedly elevated HER3 mRNA 
levels have been demonstrated in certain human mammary tumour cell lines (Kraus et 
al., 1989a). In addition HER3 is overexpressed in 15 -52% of breast cancers 
(Lemoine et al., 1992; Naidu et al., 1998a; Travis et al., 1996a).
Conflicting evidence has been produced on the prognostic significance of HER3. 
Some (Witton et al., 2003a; Naidu et al., 1998b; Tovey et al., 2004b; Travis et al., 
1996b) have demonstrated a relationship between HER3 and markers of poor 
prognosis in breast cancer. Others have concluded that HER3 overexpression is 
consistent with a good prognostic outlook (Pawlowski et al., 2000b). Again Tovey et 
al (Tovey et al., 2004a) demonstrated that over-expression of Her 1-3 predicted de- 
novo resistance to Tamoxifen (as evidenced by early relapse on Tamoxifen).
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1.6.4 HER 4
The HER4/erbB4 gene encodes a 180-kDa transmembrane tyrosine kinase (Plowman 
et al., 1993b) on chromosome 2 (Zimonjic et ah, 1995). HER4 is widely expressed in 
many adult and fetal tissues and is generally found in the differentiated compartments 
(Srinivasan et al., 1998a). In normal breast tissue HER4 appears to play a critical role 
in the late differentiation of mammary gland function (Jones et al., 1999) especially 
during pregnancy and lactation (Tidcombe et al., 2003). This is consistent with data 
from cell lines showing that whilst HER4 can support proliferation and 
transformation, in some lines it has also been shown to induce growth aiTest and 
differentiation (Sartor et al., 2001b; Williams et al., 2003b). Evidence from cell lines 
using agonistic monoclonal antibodies, showed the HER4 antibody inhibited eell 
growth in contrast to the HER2 antibody which stimulated growth (Amin et al., 
2004a). HER4 is expressed in several breast cancer cell lines (Plowman et al., 1993a). 
Studies have demonstrated the expression (29 -82%) of the HER4 protein in breast 
cancers (Srinivasan et al., 1998b; Srinivasan et al., 2000b; Suo et al., 1998; Suo et al., 
2002b) although they also suggested that this expression may be decreased when 
compai’ed to normal breast tissue. Gene amplification has been demonstrated in 13% 
of breast cancers (Vogt et al., 1998).
It has been shown that, in contrast to other HER family members, HER4 expression is 
associated with increased survival and lower proliferation indices (Tovey et al., 
2004b; Witton et al., 2003b). These results are supported by data linking HER4 to 
established good prognostic indicators such as a lower grade of tumour (Kew et al., 
2000; Srinivasan et al., 2000a), ER positivity (Pawlowski et al., 2000a) and low 
proliferation indices (Knowlden et al., 1998). Other groups have demonstrated a link 
between HER4 positivity and a longer disease free interval (Suo et al., 2002a) .
42
However there have also been conflicting reports associating HER4 with an adverse 
prognostic significance (Lodge et al., 2003). More recently there has been evidence 
from a large series of patients suggesting that the prognostic value of HER4 
overexpression is dependent on coexpression with other HER family members (Abd 
El-Rehim et al., 2004d). In this study, when the group was looked at as a whole, 
HER4 status was not related to survival. However in cases showing expression of one 
family member only (homodimers), they found a significant association between 
HER4 homodimer-expressing tumours and improved disease free survival. . Tovey et 
al did not show any association between expression of the HER4 receptor and disease- 
free survival on tamoxifen. Previous studies have linked HER4 to improved survival 
and good prognostic markers (Abd El-Rehim et al., 2004c; Witton et al., 2003c). 
However, the study from Abd El-Rehim(Abd El-Rehim et al., 2004b) also suggests 
that the "protective" effect of HER4 may be abrogated if expression of other members 
of the type I receptor tyrosine kinases is also present. This is consistent with data from 
cell lines showing that whereas HER4 can support proliferation and transformation, in 
some lines, it has also been shown to induce growth arrest and differentiation(Saitor et 
al., 2001a; Williams et al., 2003a). Conversely, when coexpressed with other 
receptors, such as HER2 and HER3, signaling through these receptors promotes 
proliferation and overrides the effects seen when HER4 is expressed in 
isolation(Yai’den, 2001b). In Tovey et al’s study, few tumours expressed HER4 in 
isolation and this may have precluded the identifieation of a distinct HER4 effect.
The role of HER4 in tumour biology as well as its elinical relevance is still emerging.
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1.6.5 HER 1-4 and Tamoxifen resistance
The role of the HER family in tamoxifen resistance was initially shown by in-vitro 
studies, where ER positive hormonally sensitive MCF-7 cells transfected with very 
high levels of HER2 became resistant to tamoxifen(Benz et al., 1993). MCF-7 cells 
derived in vitro have increased levels of both HERl and HER2(Nicholson et al.,
2002; Knowlden et al., 2003). Restoration of tamoxifen sensitivity can be achieved by 
HERl inhibitors (Iressa) and HER2 blockade (Herceptin (Kurokawa et al., 2000; 
Pietras et al., 1995)).
HER 1-3 expression is associated with high proliferation indices (Tovey et al., 2004a). 
There is an increased risk of relapse if ER positive with Her 1-3 expression than if PR 
negative(Tovey et al., 2004a)Tovey et al (Tovey et al., 2004a) showed that HER 1-3 
predicts tamoxifen resistance in hormone responsive breast cancer. This applies in the 
first three years of tamoxifen therapy only (early effect).
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1.7 PI3K/Akt Pathway
1.7.1 PI3K Activation
Upon ligand activation, the HER receptors form homo- or heterodimers and 
subsequently activate downstream signal transduction pathways such as the PI3K/Akt 
and mitogen-activated protein kinase (MAPK) pathways.
Activated Her receptors activate PI3K by phosphorylating specific tyrosines on the 
cytoplasmic tails of their partner’s receptors. The p85 subunit binds to these receptors 
and undergoes conformational changes, which lead to PI3K activation. PI3K is a 
heterodimer consisting of a 110 kDa catalytic subunit and a 55-85 kDa regulatory 
subunit(Vanhaesebroeck and Waterfield, 1999; Fry, 1994). This leads to the 
production of PIP3 and activation of PDK’s, which then phosphorylate Akt(Franke et 
al., 1995c) (figure 3).
Cytoplasm
Figure 4. Activation o f Akt via phosphorylation o f PI3K which catalyses the formation 
o f PIP3 and leads to the phosphorylation o f Akt
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Mutations in the PIK3CA gene which encodes the PI3K pi 10a catalytic subunit are 
seen in 20-40% of breast tumours(Crowder and Ellis, 2005; Samuels and Velculescu, 
2004a; Bachman et al., 2004c; Campbell et al., 2004a; Saal et al., 2005b).
Akt is first phosphorylated at Thr 308 but additional phosphorylation at Ser473 is 
necessary for full activation. Once activated, Akt can phosphorylate other downstream 
members of the pathway such as mTOR, p70S6K, which in turn activate ER by 
phosphorylation at Seri67 which directly or indirectly phosphorylates substrates that 
directly or indirectly regulate apoptosis such as Bad (Figure 3).
Recent research has highlighted the central involvement of the PI3K/AKT pathway in 
multiple resistance mechanisms (Clark et al., 2002b; West et al., 2002b; Tsuruo et al., 
2003b). Previous work in this laboratory(Kirkegaard et al., 2005d) has demonstrated 
that up-regulation of this pathway is associated with endocrine resistance.
1.7.2 PTEN
PTEN encodes a protein product that has sequence homology with dual specificity 
phosphatases capable of dephosphorylating both tyrosine phosphates and serine 
threonine phosphate residues on proteins (Li et al., 1997b; Steck et al., 1997; Li and 
Sun, 1997). PTEN dephosphorylates PIP2 and PIP3; lipids that are normally absent 
from quiescent cells but appear on stimulation with growth factors. They are involved 
in the activation of AKT(Franke et al., 1997) via the activation of PDK’s, which then 
phosphorylate Akt(Franke et al., 1995b) (figure 3). Panigrahi et aTs study(Panigrahi 
et al., 2004a) has indicated that loss of PTEN expression is infrequent in breast cancer. 
It did not show a prognostic significance of PTEN. This study used IHC on wildtype 
PTEN it did not use mutation analysis.
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It has been shown that PTEN activation contributes to tumour inhibition by 
trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients(Nagata et 
al., 2004).
The PTEN gene is frequently mutated or inactivated in a high proportion of human 
cancers(Risinger et al., 1997; Tashiro et al., 1997), including up to 30% of human 
breast cancers, resulting in hyper-activation of the PI3K/Akt pathway. Germline 
mutations have been associated with three autosomal dominant cancer syndromes: 
Cowden disease, Lhermitte-Duclos disease and Bannayan-Zonana syndromes(Liaw et 
al., 1997c; Marsh et al., 1998). The significance of PTEN mutations and loss of PTEN 
expression in primary sporadic breast cancer is at present unclear. Estimates of the 
mutation and loss of expression rate range from 1-48% (various IHC and mutational 
analysis studies(Depowski et al., 2001b; Freihoff et al., 1999)). The estimated rate of 
PTEN mutations in sporadic breast cancer is only 5%. Promoter hypermethylation 
has been identified as an alternative mechanism of PTEN inactivation. One 
study(Garcia et al., 2004b) found that 48% of sporadic breast cancers had 
hypermethylation of the PTEN promotor. PTEN hypermethylation was also 
associated with HER2 overexpression, larger size and higher histiologic grade.
It has been demonstrated that PTEN mutations derived from sporadic tumours as well 
as Cowden disease patients, retain protein phosphatase activity but loose the ability to 
dephosphorylate inositol phospholipids (Myers et al., 1998). This provides strong 
evidence that the loss of ability to dephosphorylate inositol phospholipids is vital to 
the tumour suppressor role of PTEN.
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1.73 AKT
AKTs (protein kinase B or RAC-PK) are a family of serine/threonine protein kinases 
with three mammalian isoforms (AKTl/PKJ3s, AKT2/PKB|3, and AKT3/PKBY), 
activated by growth factors in a PDK-dependent manner(Franke et ah, 1995a). Three 
AKT isoforms, AKT 1-3, are encoded by distinct genes localized on different 
chromosomes(Hill and Hemmings, 2002a; Thompson and Thompson, 2004c). They 
have similar structures with approximately 80% amino acid identity(Thompson and 
Thompson, 2004a; Hill and Hemmings, 2002b), but their expression patterns and 
biological activities differ. In normal physiology, AKTl is involved in placental 
development and maintenance; AKT2 in glucose metabolism, adipogenesis, and {3- 
cell function; whereas AKT3 plays a role in postnatal development of the brain 
(reviewed in (Yang et ah, 2004b)). They also act co-operatively, since double 
knockouts (AKT 1/2 and AKT 1/3) exhibit severe developmental abnormalities (Yang 
et ah, 2004a).
Whilst tissue distribution and function of the AKT proteins are not identical, 
activation of all three isoforms occurs in a similar fashion (reviewed in (Datta et ah, 
1999)). AKT activation occurs at the plasma membrane, through PI3K and 3- 
phosphoinositide-dependent kinases (PDKs)(see 1.7.1). AKT is first phosphorylated 
at Thr-308 but additional phosphorylation at Ser-473 is necessary for full activation 
(reviewed in (Luo et al., 2003a)). Once activated, AKT activates ERa by 
phosphorylation at Ser-167(Campbell et al., 2001b; Stoica et ah, 2003) or 
phosphorylates substrates that directly or indirectly regulate apoptosis, such as 
Bad(Datta et ah, 1997), caspase 9(Cardone et ah, 1998) or forkhead transcription 
family members(Brunet et ah, 1999).
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AKTl is overexpressed in 20% of gastric tumours(Staal, 1987), and AKT3 is over 
expressed in hormone-independent breast and prostate cancer cell lines(Nakatani et 
ah, 1999b). AKT activity is present in primary carcinomas of the breast, colon, ovary, 
and prostate(Nakatani et ah, 1999a; Sun et ah, 2001; Yuan et ah, 2000; Roy et ah, 
2002).
In a study looking at MCF-7 cells that expressed a constituitively active form of Akt, 
and were therefore able to proliferate under reduced oestrogen conditions and were 
resistant to the growth inhibitory effects of tamoxifen, co-treatment with the mTOR 
inhibitor rapamycin inhibited mTOR activity and restored oestrogen 
sensitivity(deGraffenried et ah, 2004a). Kirkegaard et al(Kirkegaard et ah, 
2005c)performed a study using immunohistochemistry (IHC) with antibodies against 
AKTl-3, pan-AKT, pAKT (Thr-308), pAKT (Ser-473), pER (Ser-167), and pHER2 
on the same 402 ER a positive breast carcinomas used in this study. High pAKT (Ser- 
473) activity (p ~ 0.0406) and low AKT2 expression (p = 0.0115) alone, or in 
combination [high pAKT (Ser-473)/low AKT2; ‘high-risk’ patient group] (p =
0.0014), predicted decreased overall survival in tamoxifen-treated patients with ERa- 
positive breast cancers. There was no significant association between tumour levels of 
AKT expression or activity and disease-free survival (DFS); however, the ‘high-risk’ 
patient group was significantly more likely to relapse (p = 0.0491). During tamoxifen 
treatment, neither AKT2 nor pAKT predicted DFS. They also showed that activation 
of AKT, via phosphorylation, was linked to activation of both HER2 and ERot. in this 
patient cohort. This reinforces the differential functions of the AKT isoforms. The 
mechanism by which increased AKT2 expression may modulate breast cancer 
survival is, however, unclear. High AKT2 expression did not predict AKT activity.
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1.7.4 mTor
mTor is a member of the phosphoinositide kinase-related kinase (PIKK) family, 
consisting of large serine/threonine kinases including ATM, ATR and DNA- 
PK.(Abraham, 2004). mTor activates P70S6K and the eukaryotic initiation factor 4E- 
binding protein-1 (Mita et al., 2003). mTor activates P70S6K by phosphorylating it at 
thr 389and thr 229(Weng et ah, 1998a). PTEN-negative cell lines have been shown to 
elevate P70S6K activation that is abrogated in the presence of the mTOR inhibitor 
CCI-779, an ester of rapamycin. This supports the theory that mTOR is an important 
downstream signalling mediator in PTEN-negative tumours(Podsypanina et al., 2001; 
Neshat et al., 2001). Inhibition of mTOR by rapamycin results in cell-cycle arrest, 
p53-dependent and independent apoptosis and tumour growth inhibition(Huang et ah, 
2001; Hosoi et al., 1999; Grewe et al., 1999; deGraffenried et al., 2004b)
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1.8 Apoptotic Pathway
As described previously the apoptotic pathway is partly under control of the PBK/Akt 
pathway The PI3K/AKT and RAF-1 pathways, activate (phosphorylate) p70S6K (Tan 
et ah, 1999c) and p90RSK respectively which in turn modulate apoptotic activity via 
phosphorylation of members of the Bcl-2 family (figure 3).
1.8.1 P70S6K
P70S6K is a mitogen activated Ser/Thr protein kinase that is required for cell growth 
and cell cycle progression(Pullen and Thomas, 1997d). There are multiple 
phosphorylation sites on P70S6K located within the catalytic, linker and 
pseudosubstrate domains (Pullen and Thomas, 1997a). P70S6K is activated by mTor 
via phosphorylation at thr 389/229(Pullen and Thomas, 1997b). Thi* 389 is located in 
P70S6K’s linker domain and thr 229 is located in its catalytic domain (Pullen and 
Thomas, 1997c). Phosphorylation of thr 389 is thought to most closely correlate with 
P70S6K activity (Weng et ah, 1998b). Activated P70S6K phosphorylates Bad at 
Serl36(Harada et ah, 200Ig). Lin et al(Lin et ah, 2005b)showed that pP70S6K 
expression was increased in primaiy breast cancers. They also showed negative 
expression in normal breast epithelial tissues. Enhanced phosphorylation was 
positively associated with disease progression from normal breast epithelial tissue to 
invasive breast carcinoma (p<0.05). P70S6K was shown to be amplified in 
approximately 10% of the breast cancers looked at by Bailund et al (Barlund et ah, 
2000a; Andersen et ah, 2002b) In another study(van der Hage et ah, 2004a) that 
looked at 452 node negative tumours from pre-menopausal women (drawn from the 
EORTEC trial) over-expression of P70S6K was found to be associated with an 
increased risk of loco-regional recurrence.
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1.8.2 P90RSK
P90RSK is composed of two functional kinase domains that are activated in a 
sequential manner by a series of phosphorylations(Frodin and Gammeltoft, 1999). 
Phosphorylation at Ser 380, Thr 359, Ser 363 and Thr 353 are important for its 
activation(Dalby et al., 1998). P90RSK is phosphorylated via the RAF-1 pathway (see 
figures). Activated P90RSK phosphorylates BAD at SeiT 12(Harada et ah, 2001f). 
There is very little in the literature looking at P90RSK expression and survival in 
breast cancer. Most of the studies concentrate on looking at its role in phosphorylating 
the pro-apoptotic protein Bad(Harada et al., 2001e).
1.8.3 Bd-2 Family
The Bcl-2 family of proteins control a critical intra-cellular checkpoint in the 
apoptotic pathway. Bcl-2 expression blocks cell death following multiple 
physiological and pathological stimuli.(Danial and Korsmeyer, 2004b) Pro-survival 
members of the bcl-2 family include Bcl-2 and Bcl-xl. There are two pro-apoptotic 
groups: the Bax group (Bax, Bak and Bok) and the BH-3 only proteins (which include 
Bim, Bad, and Bmf).
The BH-3 only proteins monitor cellular health and, when activated by cytotoxic 
signals, engage pro-survival relatives by inserting the BH-3 domain, an amphipathic a 
helix, into a groove on their surface (Willis and Adams, 2005b). This primes the cell 
for apoptosis but commitment also requires the activation of Bax or Bak(Willis and 
Adams, 2005a). Once activated, Bax and Bak form oligomers in intracellulai- 
membranes, including the mitochondrial outer membrane. The resulting membrane
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permeabilization releases pro-apoptotic proteins, such as cytochrome c, that provokes 
activation of the caspases mediating cell demolition. Bad and Bmf bind only Bcl-2, 
Bcl-xl and Bcl-w(Willis and Adams, 2005c).
Bad is a BH-3 only pro apoptotic, member of the Bcl-2 family of proteins. Its 
structure has not yet been fully mapped, however it is known to have multiple 
phosphorylation sites
Phosphorylation of P70S6K and P90RSK leads to phosphorylation of Bad via various 
sites; P90RSK phosphorylates BAD at Seri 12(Haiada et ah, 200Id), whilst p70S6K 
phosphorylates BAD at Serl36(Harada et ah, 2001c). Other phosphorylation sites, 
include Ser 155, that is phosphorylated by protein kinase A, RSKl and survival factor 
signalling have also been identified.(Tan et ah, 2000a; Zhou et ah, 2000c). 
Phosphorylation (activation) of Bad blocks the binding of Bad to Bcl-2/Bcl-xl 
(figures). When Bad is in complex with Bcl-2 or Bcl-xl it is in its pro-apoptotic state. 
However, when Bad is phosphorylated, Bcl-2/Bcl-xl are released from the complex 
allowing Bcl-2/Bcl-xl to form a complex with Bax. The BaxiBax homo dimer is 
required for apoptosis. Bcl-2:Bax hetrodimerisation therefore prevents apoptosis. This 
is the key and all other interactions modulate levels of Bax:Bax and thus apoptosis. 
The ratio of anti-apoptotic to pro-apoptotic members such as Bcl-2/Bax constitutes an 
internal rheostat that sets the threshold of susceptibility to apoptosis for the intrinsic 
pathway, which uses organelles such as mitochondrion to amplify death 
signals.(Danial and Korsmeyer, 2004a)
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Figure 5. Figure illustrating the effects o f phosphorylation o f the pro-apoptotic 
protein Bad
Increased expression o f Bcl-2 may therefore also be implicated in the resistance of 
cancer cells to apoptosis. Bad is released from its heterodimer with Bcl-2/Bcl-xl after 
it is phosphorylated. Phosphorylated Bad then forms a complex with 14-3-3, which 
also inhibits cell death.
RSKl phosphorylates Bad at both Ser 112 and ser-155 and prevents Bad mediated 
cell death in a manner dependent upon phosphorylation at both sites. The BAD 
protein acts as a switch that integrates the anti-apoptotic effects of the EGFR/MAPK 
and PI3K/Akt pathways. Inhibition of both pathways is required to release Bad from 
14-3-3 and activate its pro-apoptotic functions!Antonsson et ah, 2001 )
Activation of the PI3K/Akt signal transduction pathway has been implicated in 
endocrine resistance(Kirkegaard et ah, 2005b). Activation of the P13K/Akt pathway 
causes phosphorylation o f Bad, which causes release of Bcl-2/Bcl-xl and disruption of
54
the Bax;Bax homodimer and prevents apoptosis The phosphorylated Bad binds to 14- 
3-3 and this also prevents apoptosis. Previous in-vitro studies suggest that long term 
treatment with tamoxifen modulates the expression of apoptotic key genes impairing 
the apoptotic response of MCF-7 breast cancer cells(Treeck et ah, 2004b). In vitro 
studies have shown that oestrogen-mediated phosphorylation of Bad prevents 
apoptosis(Fernando and Wimalasena, 20041). The ability of oestrogen to prevent 
apoptosis was blocked by over expression of Bad where the phosphorylation sites 
have been mutated (S112A/S136A) but not by the wild type Bad. Bad S 112A/S136A, 
which lacks the phosphorylation sites, was not phosphorylated in response to 
oestrogen in vi7ro(Fernando and Wimalasena, 2004e).
The anti-apoptotic proteins Bcl-2 and Bcl-xl are thought to play important roles in 
inhibiting mitochondria-dependent pathways (Kim, 2005d). Some studies suggest that 
these two proteins have distinct functions for inhibiting extrinsic and intrinsic cell 
death pathways. The over expression of Bcl-2 has been shown to be associated with 
cell cycle arrest in the G1 phase, which may promote cellulai* senescence. The over 
expression of Bcl-2 may also have the ability to enhance cell death in the interaction 
of Bcl-xl with other factors(Kim, 2005a). An earlier study looking at the prognostic 
significance of p53, Bcl-2 and Bax expression in early breast cancer(Linjawi et ah, 
2004b), did not find a correlation between Bax or Bcl-2 and OS or DFS. However 
Bcl-2 correlated significantly with favourable tumour features such as DNA diploid 
status and expression of oestrogen and progesterone receptors(Linjawi et ah, 2004a). 
This has also been seen in other studies(Baccouche et ah, 2003b). Another study 
showed that reduced expression of Bax (p=0.03) and Bcl-2 (p=0.03) was associated 
with lymph node metastasis in multivariate analysis(Bukholm et ah, 2002b). 
Expression of Bcl-2 was associated with improved patient survival in univariate
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analysis (p=0.04) but lost its predictive value in multivariate analysis 
(p=0.2)(Cameron et al., 2000c).
The present study was carried out to test the hypothesis that disruption of apoptosis in 
breast cancer, via Akt activation is linked with hormone resistance.
1.9 Statement of Aims
Hypothesis:
The present study was carried out to test the hypothesis that activation of the 
PI3K/Akt pathway and the part of the apoptotic pathway activated by the PI3K/Akt 
pathway is linked to Tamoxifen resistance
1. To test the hypothesis that disruption of the apoptotic pathway is linked with 
hormone resistance. The PI3K/Akt and MAPK pathways appear to inhibit the 
apoptotic pathway by phosphorylation of Bad. Expression levels of Bad, 
pBad (Seri 12), Bax, Bcl-2, Bcl-xl, P70S6K, pP70S6K (Thr389) and 
pP90RSK (Thr359/Ser363) are to be assessed in the tumour samples using 
antibodies against these proteins with IHC. The expression levels of these 
proteins will then be correlated against data previously obtained on the level of 
apoptosis (TUNEL data).
2. To investigate the role of specific members of the PI3K/Akt pathway in 
mediating hormone resistant breast cancer (in conjunction with other 
researchers in our unit). Tumour samples will analysed for PTEN and PI3K 
expression (IHC) and preliminary studies using FISH will be carried out on a 
limited number of the samples to assess gene copy number status. This data
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will then be correlated with other proteins in the pathway (as investigated by 
our lab).
3. To investigate using fluorescence in situ hybridisation (FISH) on the tissue 
microarrays (TMA’s) made by Sian Tovey HER2 gene amplification status, 
and to compare these results with previously obtained results on HER2 over­
expression in this patient cohort. This is to look at the number of false 
positives/negatives obtained using the HercepTest (IHC) and to see how many 
of them are picked up by the current standard of performing FISH on all 
patients whose tumours were categorized as 2+ using the HercepTest.
A summai y of aims would therefore be
l.IHC on proteins in the part of the apoptosis pathway controlled by the 
PI3K7Akt and RAF-1 pathways (Bad, Bax, Bcl-2, Bcl-xl, P70S6K, 
p90RSK and their phosphorylated versions where applicable). Correlation 
of these results with the clinical progression of these patients on tamoxifen 
plus correlation with other proteins in the pathway, hi addition correlation 
of the expression level of these proteins with previously obtained data 
(TUNEL data) on the level of apoptosis in the tumours.
2.IHC for PTEN, phospho PTEN, PI3K and FISH for PTEN and PI3K . 
Correlation of these results with the clinical progression of these patients 
on tamoxifen plus correlation with other proteins in the pathway.
3.FISH for HER2 to compare with HerceptTest results
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Chapter 2. Methodology
2.1 Patient Selection
2.1.1 Ethical clearance
Ethical clearance was obtained from the Glasgow Royal Infirmary LREC committee 
(LREC 02SG007).
2.1.2 Patient Database
Details of sequentially diagnosed breast cancer patients, suitable for surgical excision, 
from years 1980 -1999 were kept in a registered database within the University 
Department of Surgery. These patients had surgery and subsequent adjuvant therapy 
according to protocols at the time of diagnosis. Patients who had neo-adjuvant 
treatment in terms of endocrine treatment, chemotherapy and radiotherapy prior to 
their surgery were also included in the database. The total number of patients in the 
database is 1116. Patient follow-up details have been entered prospectively since 
diagnosis. These entries include information on attendances, recurrence and 
metastasis details, date and cause of death and adjuvant therapy details (including 
tamoxifen treatment duration).
From this database, patients were selected who had been treated with adjuvant 
tamoxifen therapy and who were either known to be ER positive or who did not have 
a record of oestrogen receptor (ER) status being tested. Patients with an unknown ER 
status were included to increase the numbers available for analysis, on the basis that 
all patients in the study would have their ER status re-tested. The number of 
tamoxifen treated ER positive or ER unknown tumours were 685. For full patient 
details see appendix 1.
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2.1.3 Patient Exclusion
From this group of 685 patients, further exclusions were made on the following basis:
1. If their follow up and full tamoxifen history was not complete in terms of 
details of any relapse or duration of tamoxifen treatment (n=52).
2. If the tumour blocks from pathology were not available or deemed unsuitable 
by the pathologist (Baibaia Dunne; BD) because of limited tissue availability, 
which may have compromised further diagnostic testing (n=177).
456 patients were therefore eligible for the study. 75 of these patients were ER non­
specified, with the remainder having being tested positive for ER by either ligand 
binding (n=130) or immunohistochemistry (IHC) (n=251).
2.2 TMA Construction
TMAs were made by Sian Tovey using the following methods:
2.2.1 Technique
This department has been using TMA technology for some time in IHC and 
fluorescence in situ hybridisation (FISH) analysis of breast, ovarian and prostate 
tissue. We are currently involved in the construction of TMAs for the TEAM and 
NEAT (National Epirubicin Adjuvant Trial) trials. The TMAs were constructed for 
this study under guidance from pathology MLS Os working within the department. 
Formalin fixed paraffin embedded tissue blocks, prepared after surgical excision of 
the tumours, were obtained from the depaitment of pathology. Bouins was not used in 
the fixation of these specimens. A tissue section from each block was stained using 
haematoxylin and eosin (H&E) to identify areas of tumour. Representative areas on
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the H&E were identified by a pathologist (BD) and marked on the slide. This is 
essential as it ensures the core taken contains representative tumour cells.
Prior to removing the cores, 5 X 3pM sections were cut from each pathology block by 
a MLSO in the laboratory. These sections have been stored and may be used in the 
case of any missing samples from the TMA slides or to validate the TMAs in any 
cases where there are doubts about the heterogeneity of tissue staining for a particular 
antibody. Subsequently 3 x 0.6mm cores of tissue were removed from each block at 
the area marked by BD using a tissue arrayer (Beecher instrument). This precision 
instrument uses 2 separate core needles for punching the donor and recipient blocks, 
together with a precise co-ordinate system to place and locate the tissue samples in the 
array. These cores of tissue were then transferred to 3 recipient blocks (80-120 cores 
per block) to form triplicate tissue arrays. In total, 5 different arrays each in triplicate 
(total 15 donor blocks) were constructed.
2.2.5 TMA Layout
The cores were placed at 1 mm intervals, with regular larger gaps as to ensure ease of 
identification of core position during analysis (Figure 4).
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row normal tissues
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Figure 6
Illustration o f typical core placement layout in TMA.
2.2.2 Control Tissues
Cores were taken from 10 blocks containing samples of normal tissue (sourced from 
USA commercial). These normal tissues consisted of skeletal muscle, smooth muscle, 
normal breast, lung, placenta, prostate, tonsil, lymph node, skin and testis. A core 
from each of these was placed in order, in a row, above the tumour cores in each of 
the 15 donor blocks. This provides the basis of controls for each of the antibodies, 
which have known staining patterns in normal tissues. This row of normal tissues 
also provided a mechanism for correct orientation of the TMA section after 
sectioning.
The completed tissue array blocks were heated at 37° for 10 minutes to ensure the 
tissue cores adhere to the recipient paraffin block.. Serial 3|lM sections were then cut 
from each TMA by a MLSO and placed on silanised slides to improve section contact 
with the slide during high temperatures used in some antigen retrieval protocols.
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2.3 Immunohistochemistry
Immunohistochemistry (IHC) is the localization of antigens in tissue sections by the 
use of labelled antibodies as specific reagents through antigen-antibody interactions 
that are visualized by a marker such as stain. Advantages of IHC include the ability to 
detect location of staining (i.e. membranous, cytoplasmic or nuclear) as well as 
providing a semi quantitative assessment of intensity (0, 1, 2, or 3). Difficulties with 
IHC can occur in relation to the specificity of the antibody as well as the need to 
expose antigenic sites to the antibody, particularly in formalin fixed tissues.
The 10 antibodies I have chosen to work with for this project are PTEN, PI3K, Bad, 
phospho-Bad (Ser 112), Bax, Bcl-2, Bcl-xl, P70S6K, phospho-P70S6K (Thr 389) and 
phospho-P90RSK (Thr 359/Ser 363).
2.3.1 General Principles of IHC and Protocols
All of the antibodies were fully worked up by E C and all of the IHC procedures were 
carried out by E.C. During the work up of the antibodies I followed a set of general 
principles described below which were subsequently tailored to each antibody as 
described in Table 1. .
A. Dewax, rehydration
Prior to any immunohistochemical staining on formalin fixed, paraffin embedded 
tissue, paiaffin must be removed from the tissue to allow the water-based buffers and 
antibodies to penetrate. For all antibody protocols this was done using the following 
treatment: dewax in xylene (Fishers chemicals) ( 2 x 2  minutes). Rehydrate in
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graduated alcohol washes: 100% alcohol ( 2 x 2  minutes), 90% alcohol ( 2 x 2  
minutes), 70% alcohol ( 2 x 2  minutes). Finally rinse in water.
B. Antigen retrieval
As a result of formalin-fixation and wax embedding, the antigen under investigation 
may lose its immunoreactivity, thus either binding weakly to the appropriate primary 
antibody or not at all. This is due to the formation of methylene bridges during 
fixation, which cross-link proteins and therefore mask antigenic sites. To facilitate the 
antibody - antigens reactions in fixed tissue, it may be necessary to unmask or 
“retrieve” the antigens through pre-treatment of the specimens. This antigen-retrieval 
step breaks the protein cross-links and exposes the antigen-binding site. Antigen 
retrieval has been shown to increase reactivity of the majority of antigens in tissues. 
This was done by one of the below mentioned methods under routine use in the lab, 
depending on the antibody used. These methods were:
1. Sections were microwaved under pressure (approximately 15 psi) in TE solution 
(5mM Tris base pH 8.0 (VWR International Ltd) and ImM Sodium EDTA (BDH 
Laboratory Supplies)).
2. Sections were microwaved under pressure (approximately 15 psi) in lOmM citrate 
buffer (Epitope retrieval solution x 10, K-5205, Dako or Antigen unmasking solution 
(Vector)).
Microwave irradiation of formalin-fixed, paraffin-embedded specimens in buffer has 
been found to markedly enhance the retrieval of antigens. During this procedure the 
energy provided helps break some of the bonds formed during fixation, thus 
increasing the intensity of reactions.
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3. Sections were incubated in Tris EDTA buffer (10 mmol/L Tris, 1 mmol/L EDTA) 
or 1:10 citrate buffer (Antigen unmasking solution (Vector)) for 20, 25 or 40 minutes 
depending on the specific antibody protocol at 96°C in a standard water bath.
C. Block o f endogenous peroxidase activity
Breast tissue is known to contain endogenous peroxidase. To minimise background 
staining from this, TMA’s were treated with hydrogen peroxidase (VWR International 
Ltd; supplied at concentration ~ 30%), which is known to irreversibly inactivate 
endogenous peroxidase. This was done after antigen retrieval at a concentration of 
0.3%, 1% or 3% for 10 minutes depending on the protocol determined for each 
antibody.
D. Blocking non-specific background staining
Any non-specific background staining was blocked using one of the following 
methods:
Applying normal horse serum (Vector) to the tissue at a concentration of 15 pl/ml for 
1 hour or 0.1 % casein (Vector) for 1 hour. Following incubation with blocking agent 
the solution was tapped off the tissue and the TMA’s were blotted and ringed with 
Dako pen to create a barrier.
E. Incubation with Primary antibody
The TMA’s were incubated with the primary antibodies at optimum concentrations 
and conditions determined for the individual antibodies (as described later in Table 1). 
Antibodies (including the negative control antibodies) were always diluted in
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antibody diluent (Dako). Slides were washed twice in TBS buffer for 5 minutes 
following incubation.
F. Quality Assurance
For each IHC experiment, it is essential to have both a positive and a negative control. 
These controls were performed on the same tissue. The positive control confirmed 
that the chosen IHC method gives the same level of staining in every run, whilst the 
negative control (performed exactly the same way as the other slide except that the 
primary antibody is substituted with isotype matched control reagent (Dako)) was 
done to substantiate that the staining was not due to unspecific binding. Tonsil tissue, 
placenta tissue or breast tissues previously shown to have strong expression of the 
desired antigen were incubated with the appropriate antibody and used as positive 
controls.
G. Visualisation Methods
EnVision™ System from Dako was used as visualisation. The En Vision™ System is 
a simple, two-step visualization system of very high sensitivity. It is based on a 
unique enzyme-conjugated polymer backbone, which, in addition, also carries 
secondary antibody molecules. Endogenous biotin will not affect EnVision™ staining 
results. Slides were washed in TBS buffer (lOx: O.IM Tris/HCL and 1.5M NaCL per 
IE dH20 (pH to 7.5). Before use lOx TBX is diluted 10 times in dHiO) between and 
after incubations with the link antibody and Strepavidin peroxidase solutions.
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Detection was then completed with incubation with a 3, 3’diaminobenzidine (DAB) 
solution (Vector Laboratories) for 2-10 minutes. The DAB solution was washed off in 
running water for 10 minutes.
H. Counterstaining, Dehydration and Mounting
The sections were counterstained, and then dehydrated using the following method: 
Haemoxylin 45 seconds followed by rinse in running H2 O. Then wash with Scotts tap 
water substitute (about 45 seconds), this produced a blue colour, in contrast to the 
brown positive staining of the antigen. Rinse in running H2 O. The last steps involved 
dehydrating the tissues through a series of alcohol washes: 70% (1x1 minute), 90% 
(1x1 minute), 100% (2x1 minute) and xylene (2x1 minute, and then mounting the 
slides onto coverslips using DPX mountant (Dibutyl Phtalate containing Xylene).
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Protein Antibody Antigen
Retrieval
H2O2
Cone"
Blocking
Solution
Antibody
Cone"
Incubation 
Time & 
Temperature
PTEN PTEN 
(2689) Cell 
Signalling 
Technology
Citrate Buffer 
(microwave)
1% 1:10
1% Casein 
solution
1:100
20pl/ml
Overnight at 
4°C
Bad Bad (9292) Cell
Signalling
Technology
Citrate Buffer 
(water bath for 
25 mins)
0.3% 1.5%
normal
horse
serum
1:25
7.8pl/ml
Overnight at 
4°C
Bax Bax (A3533) 
DAKO
Citrate Buffer 
(water bath for 
40 mins)
1% 1.5%
normal
horse
serum
1:1500
0.46|il/ml
Overnight at 
4°C
Bcl-2 Bcl-2 (M0887) 
DAKO
TRIS EDTA 
(microwave)
1% 1.5%
normal
horse
serum
1:100
28pl/ml
One hour at 
25"C
Bcl-xl Bcl-xl (2762) 
Cell Signalling 
technology
TRIS EDTA 
(microwave)
3% 1.5%
normal
horse
serum
1:500
0.46|il/ml
Overnight at 
4°C
pBad 
(Ser 112)
pBad (Ser 112) 
(7E ll)C ell 
Signalling 
Technology
Citrate Buffer 
(microwave)
1% 1.5%
normal
horse
serum
1:25
40p.l/ml
Overnight at 
4°C
pP90RSK 
(Thr 359/ 
ser 363)
PP90RSK (Thr 
359/ser 363) 
(9344)Cell 
Signalling 
technology
Citrate Buffer 
(water bath for 
25 mins)
3% 1.5%
normal
horse
serum
1:25
2.4p.l/ml
Overnight at 
4°C
P70S6K P70S6K (2708) 
Cell Signalling 
Technology
Citrate Buffer 
(microwave)
3% 1.5%
normal
horse
serum
1:50
2|il/ml
Overnight at 
4°C
pP70S6K 
(Thr 389)
PP70S6K (Thr 
389) (9206) Cell 
Signalling 
Technology
Citrate Buffer 
(microwave)
1% 1.5%
normal
horse
serum
1:1000 
1 pl/ml
Overnight at 
4°C
PI3K PI3K (4254) Cell
Signalling
Technology
Citrate Buffer 
(microwave)
1% 1.5%
normal 
horse 
1 serum
1:50
3.8|ul/ml
Overnight at 
4°C
Table 1. IHC antibody information 
2.3.2 Scoring Principles
Two observers using a semi-quantative weighted histoscore method(McCaity, Jr. et 
al., 1986) independently evaluated the staining of the TMA’s. The interobserver
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variation within the scoring of tumour cell immunoreactivity was assessed by 
measuring interelass correlation coefficient (ICCC) statistics by using SPSS statistical 
package (version 9.0 for Windows). ICCC is a measurement of reliability assessing 
the amount of overall data variance by comparing the variability of each independent 
observer for each case to the overall variation between all scorings. An ICCC value of 
1 representing a perfect correlation, an ICCC value below 0.40 regarded as poor, an 
ICCC value between 0.40 and 0.59 regarded as fair, an ICCC value between 0.6 and 
0.74 regarded as good and an ICCC above 0.74 regarded as excellent correlation 
between observers (Kirkegaard et al., 2006b). ICCC were calculated and were greater 
than 0.80 for all stainings. ICCC was used as opposed to kappa as we were using a 
continuous scoring system. Kappa depends on a categorical system and a published 
study from our laboratory supports the use of ICCC in this context(Kirkegaard et al., 
2006a).
2.3.3 Statistical Analysis
All statistics were analysed using the SPSS statistical package (version 9.0 for 
windows). Kapian-Meier life tables with log-rank testing were plotted to assess 
overall (OS), disease-free survival (DFS), DFS on and off tamoxifen and OS and DFS 
after 3 years tamoxifen treatment. Spearman rank tests were conducted to test the 
association between the expressions of the various antibodies. Cox’s multivariate 
analysis (Cox regression) and hazard ratio analysis were performed with inclusion of 
biological markers alongside known predictive factors, size, nodal status and grade. 
A value o fp  < 0.05 was considered statistically significant.
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2.4 FISH
2.4.1 General Principles of FISH
Fluorescence in situ hybridisation (FISH) uses fluorescent molecules to vividly paint 
genes or chromosomes. FISH involves the preparation of short sequences of single 
stranded DNA, called probes, which are complimentary to the sequences that we wish 
to examine. These probes hybridise (bind) to the complementary DNA and because 
they are labelled with fluorescent tags allow us to see the location of those sequences 
of DNA. FISH does not need cells to be actively dividing (unlike most other 
techniques to study chromosomes) and can be used on paraffin embedded tissue. The 
FISH procedures were fully worked up by E.C and performed by E.C except where 
stated.
2.4.2 Her2
The PathVysion HER-2 DNA Probe Kit (PathVysion Kit) is designed to detect 
amplification of the HER-2M^w gene via fluorescence in situ hybridisation (FISH) in 
formalin fixed, paraffin-embedded human breast cancer tissue specimens. The HER- 
2/neu gene codes for a 185 kd transmembrane cell surface receptor that is a member 
of the tyrosine kinase family.
The PathVysion HER-2 DNA Probe Kit consists of two labelled DNA probes. The 
LSI HER-2 probe that spans the entire HER-2 gene is labelled in SpectrumOrange. 
The CEP 17 probe is labelled in SpectrumGreen and hybridizes to the alpha satellite 
DNA located at the centromere of chromosome 17 (1 7 p ll.l-q ll.l) . Inclusion of the 
CEP 17 probe allows for the relative copy number of the HER-2 gene to be 
determined.
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Results on enumeration of 20 interphase nuclei from tumour cells per target are 
reported as the ratio of average HER-2/ngw copy number to that of CEP 17. The 
manufacturers clinical study found that specimens with amplification showed a LSI 
HER-2/Mgn and CEP 17 signal ratio of > 2.0; normal specimens showed a ratio of less 
than 2.0. The manufacturers suggest that results at or near the cut-off point (1.8-2.2) 
should be interpreted with caution.
The tissue was incubated for one hour at 56°C prior to being dewaxed and rehydrated 
through a series of xylene (2x5 minutes) and alcohol washes ((95% (2x5 minutes)). 
The tissue was then washed in 0.2N hydrochloric acid (HCl) for 20 minutes followed 
by 3 minutes wash in water. The tissue was then treated with protease K for 29 
minutes. The protease buffer should be pre-heated to 37°C, and the protease added 
immediately before the addition of the slides. Slides were then washed for 2 minutes 
in water dehydrated through a graded series of ethanol washes (70% for 2 minutes, 
85% for 2 minutes and 99% for 2 minutes) and subsequently air-dried. The slides 
were mounted in DAPI and the tissue digestion was checked under the microscope. If 
digestion was sufficient then the coverslips were removed, the tissue washed for 2x3 
minutes in distilled water and subsequently placed in 10% formalin for 10 minutes. 
Following formalin treatment, the tissue was washed (2x3 minutes), dehydrated in 
graded series of ethanol (70% for 2 minutes, 85% for 2 minutes and 99% for 2 
minutes) and subsequently air-dried. 100|il of denaturing solution (49mls formamide, 
14mls distilled water, 7mls 20x SSC (3 M NaCl, 0.3M Na citrate, pH5.3); pH 7.0-8.0) 
was added and the slides covered with parafilm and incubated for 5 minutes at 72°C. 
The slides were then dehydrated through a graded series of ethanol’s (70% for 2 
minutes, 85% for 2 minutes and 99% for 2 minutes) and air-dried. lOfxl of probe was
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added to each slide, covered with a coverslip and sealed with rubber sealant. The 
slides were then placed in a Hybaid omnislide at 37®C overnight.
The following morning the coverslips were removed the slides placed in Post- 
Hybridisation Wash Buffer (PHWB) (100 ml 20 x SSC, 2 ml NP-40 make up to IL 
with distilled water (pH 7-7.5)) at room temperature (see below). Care was taken to 
protect the slides from the light. PHWB was heated to 72^C and the slides added for 2 
minutes. The slides were then removed, allowed to air dry in the dark, and mounted 
onto coverslips using Vectashield mounting media with 4’-6-Diamidino-2- 
phenylindole (DAPI) (135]ll1 Vectashield with DAPI: 565fil Vectashield) (Veetor 
Laboratories). Prior to viewing the slides were sealed with clear nail varnish.
2.4.3 PTEN and PI3K
The PTEN and PI3K probes were prototypes made at Dako, and are not commercially 
available. The PTEN gene is located on 10q23.31 and PIK3CA (pi 10 catalytic 
subunit of PI3K) is located on chromosome 3 band q26.32.
FISH was performed on the TMA’s using a probe mix consisting of Texas Red- 
labeled DNA cosmid clones covering PIK3CA or PTEN (Dako Denmark A/S, 
Glostrup, Denmark) and fluorescein isothiocyanate (FITC)-labeled DNA cosmid 
probes directed against the centromeric region of ehromosome 10 or 3, respectively 
(Dako Denamrk A/S, Glostrup, Denmark). To confirm the specificity of the probe 
mix, it was tested on metaphase spreads of normal cells and showed hybridization to 
10q23 and 3q26, respectively (These control experiments were performed at Dako). 
FISH was performed using buffers from Dako’s Histology FISH Accessory Kit (Dako 
A/S, Glostrup, Denmark).
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Prior to the FISH experiments, the tissue was incubated at 56°C for 1 hour. Tissue 
was then dewaxed and rehydrated in series of ethanol and incubated in pre-treatment 
solution for 10 minutes at 96°C. After 2x3 minutes wash in wash buffer (Dako A/S, 
Glostrup, Denmark), the tissue was treated with pepsin for 18 minutes at 25°C, 
washed, dehydrated and air-dried. Ten |il of probe mix was applied, denatured at 
82°C for 22 minutes and tissue incubated overnight at 45 °C in a humidified 
hybridization chamber. Tissue was washed in stringent wash buffer (Dako A/S, 
Glostrup, Denmark) for 10 minutes at 65°C, dehydrated, air-dried and the slides 
mounted in 0.5 |Xg/ml 4,6-diamindino-2 phenylindole-2 hydrochloride (DAPI) in 
Vectashield antifade (Vector Laboratories, CA, USA). Gene copy number status was 
determined as the ratio of red signals (PTEN or PIK3CA) over the number of green 
signals (chromosome) in 20 cancer cell nuclei for each TMA core. The tumour was 
considered amplified if the gene/chromosome ratio in at least one of the cores was 
more than 2 and deleted if the ratio was below 0.8.
The FISH experiments were performed for the P13K and PTEN probes using buffers 
from Dako’s Histology FISH Accessory kit. Initially the tissue was incubated for one 
hour at 56"C before being dewaxed and rehydrated through a series of xylene (2x5 
minutes) and alcohol washes ((100% (2x2 minutes)), 90% (1x2 minutes), 70% (1x2 
minutes)).
Following this the slides were rinsed twice in wash buffer (diluted 1:20) (DAKO), for 
three minutes. The TMA’s were then incubated for 10 minutes at 96°C in pre­
treatment buffer (diluted 1:20) (DAKO), followed by a 15-minute cool down period. 
Next the tissue was rinsed twice in wash- buffer (diluted 1:20) for three minutes.
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before treatment with cold ready to use Pepsin reagent (Dako) for 19 minutes at 25°C. 
The pepsin was removed and the slides rinsed twice in wash buffer. Slides were again 
rinsed twice in wash buffer for three minutes, dehydrated through a graded series of 
ethanol washes (70% 1x2 minutes, 85% 1x2 minutes and 99% 1x2 minutes) and 
subsequently air dried. The tissue digestion was checked under the microscope. If the 
digestion was sufficient lOfxl of probe was added, and the tissue sections concealed 
with a coverslip and sealing agent. The probe and tissue were denatured at 82°C for 
22 minutes and then the probe allowed to bind to its complimentary sequence, by 
placing the slides in a pre-heated humidified chamber for 14-20 hours at 45°C.
The following morning the tissue was rinsed in cold stringent wash buffer (diluted 
1:20) (Dako) and subsequently washed in stringent wash buffer (diluted 1:20) 
(DAKO) for 10 minutes at 65°C. Slides were rinsed twice in wash buffer for three 
minutes before being dehydrated through a series of alcohol washes (70% 1x2 
minutes, 85% 1x2 minutes and 99% 1x2 minutes). Finally slides were allowed to air 
dry before being mounted onto coverslips using Vectashield mounting media with 4’- 
6-Diamidino-2-phenylindole (DAPl) (135pl Vectashield with DAPI: 565pl
Vectashield) (Vector Laboratories). DAPI is known to form fluorescent complexes 
with natural double-stranded DNA, making it a nuclear counterstain in fluorescent 
techniques. Signals corresponding to both gene and chromosome were visualised 
using a fluorescent microscope.
2.4.4 Scoring Principles
For each TMA core analysed, red (gene) and green (chromosome) signals were 
counted in 20 cells and the results reported as the ratio of average gene copy number 
to that of the corresponding chromosome. As recommended by Dako, a ratio of
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greater than two was considered an amplification whilst a ratio of less than 0.8 was 
considered a deletion. All of the FISH experiments were scored by E.C and all of the 
HER2 FISH samples were double scored by T.K whilst 20% of the FBK and PTEN 
FISH samples were doubled scored by F.C. In all cases an ICCC greater than 0.85 
was achieved.
2.4.5 Statistical Analysis
All statistics were analysed using the SPSS statistical package (version 9.0 for 
windows). For HER2 Kaplan-Meier life tables with log-rank testing were plotted to 
assess overall (OS) and disease-free survival (DFS). Spearman rank tests were 
conducted to test the association between the 2+ and 3+ on the Herceptest and 
amplification of HER2 as analysed by FISH. Cox’s multivariate analysis (Cox 
regression) and hazard ratio analysis were performed with inclusion of biological 
markers alongside known predictive factors, size, nodal status and grade. A value of 
p < 0.05 was considered statistically significant. FISH was performed only on TMA B 
with PI3K and PTEN and this was compared with the results from IHC on the same 
TMAs.
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2.5 Western Blotting
2.5.1 General Principles of Western Blotting
Western blotting is a technique that enables the detection and quantification of the 
levels of a specific protein in tissue or cell samples. Essentially proteins are separated 
by electrophoresis in 10% SDS gels and transferred to nitrocellulose membranes by 
electroblotting. After blocking in milk the blots are incubated first with primary 
antibody overnight at 4°C and then with a secondary antibody, recognizing the 
antibody-antigen complex. Proteins aie detected using a chemiluminsecent method. 
Western blotting was used to verify the specificity of all the antibodies used. The 
details of the primary and secondary antibodies used can be found in Table 5. We 
used Western blotting instead of siRNA knockdown as siRNA knockdown is a 
technique that silences RNA and although, very accurate would not detect the 
phosphorylated proteins (as it looks at the RNA stage before this occurs). It is also a 
very time consuming and expensive technique that was outwith the scope of this 
project.
2.5.2 Western Blotting of Protein Samples
Preparation of the SDS-PAGE (Sodium Dodecyl Sulphate -  PolyAcrylamide Gel 
Electrophoresis) gels.
All western blots were performed using the Bio-Rad Mini-PROTEAN 3 
Electrophoresis system. For all the proteins analysed, 10% resolving gels (10% 
Acrylamide/Bis-Acrylamide (Sigma), 3.3mM EDTA, 0.3M Tris, pH 8.9, 0.1%
SDS, 0.06% APS and 0.06% TEMED) were used. Gels are formed from the
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polymerisation of the acrylamide and N-N-methylene-bis-acrylamide (bis). Bis acts 
as the cross linking agent for the gel, and the TEMED and APS are the catalysts for 
gel polymerisation. The separation of proteins within the gel is governed by the size 
of the pores within the gel, which is determined by the amount (percentage) of 
acrylamide-bis present. As the percentage of acrylamide present increases, the pore 
size decreases. Generally a higher percentage of resolving gels are used for smaller 
proteins and vice-versa.
The gels were prepared as follows: A short plate was placed on top of the larger 
spacer Plate (0.75mm used). The two plates were slid into the casting frame keeping 
the short plate facing front. The pressure cams were locked to secure the glass plates 
and the casting frame secured in the casting stand by engaging the spring-loaded 
lever. The resolving gel was slowly poured in between the two plates. Isopropanol 
was then poured along the top of the gel to remove any air bubbles and flatten it. The 
gel was left to set for approximately 20 minutes. Once set, the isopropanol was 
removed, and the 4.5% acrylamide stacking gel (4.5% Acrylamide/Bis-Acrylamide 
(Sigma), 4mM EDTA, O.IM Tris, pH 8.9, 0.1% SDS, 0.006% APS and 0.006% 
TEMED). The stacking gel was carefully poured on top of the resolving gel until it 
reached the top of the plates. The 10 well gel comb was then inserted and the gel 
allowed to polymerise for 30 minutes.
Protein dénaturation
To enable the primary antibody to recognise and bind to its epitope, it is necessary to 
denature the proteins. Denaturing the proteins also allowed them to run more 
efficiently through the gels. Having previously measured the concentration of protein 
within each sample, the same amount of protein (25|Xg) was removed from each
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sample and transferred to a new tube. This was stored on ice and 2x Laemmli’s 
sample reducing buffer (60mM Tris-HCL pH 6.8, 10% Glycerol, 20% sodium 
dodecyl sulphate (SDS), 5% 2-Mercaptoethanol, 2.5% Bromophenol Blue (0.5% 
w/v)) was added to each sample. The samples were thoroughly mixed and boiled for 2 
minutes. The SDS within the sample buffer is a detergent, with a highly negative 
charge that has a hydrophobic tail that binds to the proteins, causing them to become 
negatively charged. Additionally SDS disrupts the tertiary structure of the proteins, 
resulting in their unfolding. The 2-Mercaptoethanol prevents the reformation of the 
disulphide bonds and helps maintain the protein in its denatured state. Boiling of the 
samples also contributes to the denaturing of the proteins by unfolding them 
completely. Boiled samples were immediately stored back on ice. The molecular 
weight marker (Biotinylated Protein Ladder (Cell Signalling Technology), used to 
determine the size of the proteins, was boiled together with the samples.
Gel Electrophoresis
The principal behind electrophoresis is that an electrical charge moves the proteins 
down the polyacrylamide gel. This is made possible by the SDS, which transfers a 
negative charge onto the proteins, thus allowing them to be attracted towards the 
positive anode. The pores result in the smaller proteins travelling through the gel 
faster than the larger molecules, therefore they progress further down the gel. The 
proteins are therefore separated according to their weight.
To load the samples onto the gel, the comb was carefully removed and the wells 
rinsed with running buffer. The gel cassette sandwich was removed from the casting 
frame and placed gel into the electrode assembly with the short plate facing inward. 
The gel cassette sandwiches and electrode assembly were then slid into the clamping
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frame. This inner chamber was then lowered into the mini tank and the tank filled 
with Ix running buffer (details in Table 2). Denatured protein samples and ladder 
(7p,l) were then loaded into the wells using a fine tipped pipette and the gel was run at 
40mA for one hour.
Protein Transfer
The transfer was achieved using the Mini-Trans Blot Cell (Bio-Rad). The membrane 
was pre-treated in methanol for 1 minute and then placed in Ix transfer buffer for 15 
minutes (see Table 2) together with 2 fiber pads and 6 sheets of Whatmann 3M paper. 
The gels were then carefully removed from the glass plates and the stacking gel 
discarded. The remaining resolving gel was then equilibrated, for approximately 5 
minutes in transfer buffer. This step prevented the gel from shrinking during the 
transfer process. The transfer sandwich was assembled on the blotter cassette surface 
in transfer buffer as follows: One fiber pads was placed on the black side of the 
cassette, next 3 sheets of filter paper, the gel, the membrane and the sandwich was 
completed by placing a further 3 sheets of filter paper on the membrane followed by 
the last fiber pad and any air bubbles removed using a glass tube. The assembled 
sandwich was then slotted into the electrode assembly and placed in the mini-tank 
which was filled with transfer buffer. To reduce the temperature of the buffer during 
the transfer process, the Bio-Ice cooling unit was used. Additionally a magnetic stirrer 
was used to maintain even buffer temperature and ion distribution. Proteins were 
transferred from the gel (negative/cathode) to the membrane (positive/anode) 
overnight (approximately 18 hours) at lOvolts.
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Blocking of Membrane
Since the proteins transferred from the gel bind to the PVDF membrane, it was 
equally likely that the antibody used to detect the protein would also bind non- 
specifically to the membrane. Therefore to prevent these interactions between 
antibody and membrane it was necessary to mask the membrane. This was achieved 
by incubating the membrane in 5% Non-Fat Dry Milk (Marvel) blocking solution, 
prepared in TBS-Tween (TTBS) (see table 2) for 1 hour at room temperature. This 
step and all further steps were performed on an orbital shaker.
Buffer Reagents
lOx Running Buffer 200mM Tris, 2M Glycine, 1% SDS
lOx Transfer Buffer 248mM Tris, 1.3M Glycine, 20% 
Methanol
lOx TBS O.IM Tris/HCL, 1.5M NaCl, pH=7.4 (for 
Ix dilute in dHaO)
0.001% TTBS lOOOjLil Tween 20 per litre of Ix TBS
Table 2. Buffers used in Western Blotting 
Incubation of the membrane with primary antibody
Having sufficiently blocked the membrane, the next step was incubation with primary 
antibody. All antibodies were prepared in 5% Non-Fat Dry Milk/TTBS solution to 
further reduce non-specific binding. Membranes were incubated with primary 
antibody overnight (approximately 18 hours) at 4“C. For the size of membrane being 
used lOmls of antibody was sufficient to cover the entire membrane. Table 3 lists the 
dilutions/concentrations of the antibodies used in western blotting.
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Antibody Clone Supplier Cat no Positive
Control
Concentration Species 2^ ’Ab
Bad Cell
Signalling
technology
#9292 HELA,
Jurkat,
Bad
(control
cells)
1:1000 
0.2 pl/ml
Rabbit Anti­
rabbit,
1:5000
PBad
(serll2)
7E11 Cell
signalling
Technology
#9296 MCF-7,
MDA-MB-
361-
unstini/stim
1:1000 
1 pl/nil
Mouse Anti­
mouse,
1:10000
Bax Dako A3533 MCF-7,
MDA-MB-
361
1:2000 
0.35 pl/ml
Rabbit Anti­
rabbit,
1:5000
Bcl-2 124 Dako M0877 Jurkat,
HELA
1:1000 
2.8 |il/ml
Mouse Anti­
mouse,
1:10000
Bcl-xl Cell
signalling
Technology
#2762 MCF-7,
MDA-MB-
361
1:500 
0.46 gl/ml
Rabbit Anti­
rabbit,
1:5000
P70S6K 49D7 Cell
Signalling
Technology
#2708 MDA-
MB-361
1:2000 
0.05 gl/ml
Rabbit Anti­
rabbit,
1:5000
PP70S6K 
(thr 389)
1A5 Cell
Signalling
Technology
#9206 MCF-7,
MDA-MB
361
unstim/stim
1:2000 
0.5 pl/ml
Mouse Anti­
mouse,
1:10000
PP90RSK
(thr
359/ser
363)
Cell
signalling
Technology
#9344 MDA-MB- 
361, BT474 
unstim/stim
1:500 
0.12 pl/ml
Rabbit Anti­
rabbit,
1:5000
PI3K Cell
signalling
Technology
#4254 1:1000 
0.19 pl/ml
Rabbit Anti­
rabbit,
1:5000
PTEN 26H9 Cell
signalling
Technology
#9556 1:1000 
2 |Xl/ml
Mouse Anti­
mouse,
1:10000
Table 3. Table showing the primary and secondary antibodies and proteins used in 
the Western Blots
In addition Bad, pBad (Ser 112), bax, bcl-2, Bcl-xl and P70S6K were run on 
membranes that were probed with the antibody to them, in MDA-MB-361 breast 
cancer cells stimulated in the presence or absence of heregulin and oestrogen. Before 
treatment, cells were starved in phenol red free, serum free Duibeccos modified Eagle 
media (DMEM) for 24 hours. To study endogenous gene expression, cells were 
stimulated in the presence or absence of heregulin (10 nM) and oestrogen (10 nM)
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alone or in combination for 15 hours. After stimulation, cells were washed in PBS and 
lysed immediately in lysis buffer (Cell signalling Technology, Beverly, USA).
Incubation of the membrane with secondary antibody
Following incubation with primary antibody, the membrane was washed in TBST 
three times to remove any excess antibody. Detection of the protein required a 
secondai'y antibody bound to either a biotin or enzyme conjugate, such as horseradish 
peroxidase (HRP) that was species specific to the primary antibody. The secondary 
antibodies used were HRP-linked anti-mouse IgG (Cell Signalling Technology) or 
anti-rabbit IgG (Cell Signalling Technology). The anti-mouse antibody was used at a 
dilution of 1:5000 and the anti-rabbit antibody at a dilution of 1:10000 concentration. 
For each experiment, a secondary antibody was also needed for detection of the 
biotinylated ladder. The anti-biotin HRP linked antibody (Cell Signalling 
Technology) was used at a dilution of 1:1000 concentration. The anti-mouse/rabbit 
and anti-biotin secondary antibodies were prepared together in lOmls of 5% Non-Fat 
Dry Milk/TTBS solution and were incubated with the membranes for one hour at 
room temperature. Table 3 lists the secondary antibodies used for each primary 
antibody.
Protein visualisation
The protein was detected using a chemiluminescent method. Luminescence is the 
emission of light due to the dissipation of energy from a substance in an excited state. 
Horseradish peroxidase catalyses the oxidation of luminol, a chemiluminescent 
substrate, in alkaline conditions. Oxidation results in the luminol being in an excited 
state which then decays to ground state via a light-emitting pathway. For this method
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ECL Plus (Amersham) was used. The principle behind this is that horseradish 
peroxidase, conjugated to the secondary antibody, oxidises the ECL Plus 
chemiluminescent substrate Lumigen PS-3 Acridan, which produces thousands of 
acridinium ester intermediates per minute. These intermediates then interact with the 
peroxidase to produce a sustained, high intensity chemiluminescence with a 
maximum emission at 430nm. This light is then detected on autoradiology film. 
Following incubation with the secondary antibody, membranes were washed three 
times in TTBS for 10 minutes. While the membranes were washing the ECL Plus 
reagents were warmed to room temperature. Once the reagents had warmed 
sufficiently, the 2 solutions (A and B) were mixed in a ratio of 40:1. A total of 3 mis 
of solution was adequate for each membrane. When using ECL reagents all steps were 
performed in semi-darkness. Membranes were placed protein side up on a sheet of 
Saran wrap. The ECL solution was pipetted onto the membranes ensuring complete 
coverage. The membrane was incubated with the reagents for 5 minutes, excess 
solution removed and the membrane wrapped in Saran wrap. Finally the membrane 
was exposed to autoradiology film for vaiious times. Generally the incubation times 
were 1, 15 and 30 minutes. The film was then developed and both the maiker and 
protein bands visualised.
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Chapter 3 Results
In the survival and disease free analyses only those tumours that were ER positive 
were analysed (402 out of the 456 available).
3.1 IHC for PTEN
3.1.1 PTEN expression and staining patterns using IHC
Initially, the specificity of the antibody was confirmed by Western Blotting, a clear 
single band at 54 kDa, the size of PTEN, was seen. A total of 51 out of 456 (11.2%) 
cases were unavailable for analysis for PTEN expression either due to core loss or 
insufficient tumour material in cores and these patients were therefore excluded from 
further analysis. Both nucleai' and cytoplasmic immunohistochemical staining was 
noted (see Figure 5a-c). Staining was found in both the normal and invasive tumour 
components of the breast tissue. The staining was scored as described previously and 
scores for each core were then averaged. 15% of the cores were double scored by T.K 
achieving an ICCC of 0.96 (excellent). 18% of the cores were negative for PTEN and 
6% had low expression.
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Figure 7. a) Histogram showing distribution o f cytoplasmic scores for PTEN IHC 
b) Histogram showing distribution o f nuclear scores for PTEN IHC c) Breast tumour 
stained with PTEN antibody. Staining was seen in both the nucleus and cytoplasm d) 
Western Blot for PTEN antibody. The protein used was MDA-361 cells (L=ladder, 
US= unstimulated. E= .stimulated with oestrogen. Band at 54 kDa (ladder slightly 
skewed)
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3.1.2 PTEN expression and patient outcome
The PTEN scores were categorised as high (above median histoscore) or low (below 
median histoscore) for subsequent analysis. Staining was seen in both the nucleus and 
cytoplasm.
Cytoplasmic PTEN histoscores
Survival Category P Value
Overall survival 0.013
Disease free survival 0.018
Disease free survival on tamoxifen 0.233
Disease free survival off tamoxifen 0.022
Disease free survival after 3 yeais 
tamoxifen
0.048
Overall survival after 3 yeai's tamoxifen 0.009
Table 4. Table showing OS and DFS p-values for PTEN cytoplasmic expression. P 
values represent log-rank testing o f the difference in survival
Using these cut offs, patients whose tumours had high levels of PTEN cytoplasmic 
expression had a reduced OS (p = 0.013, log rank test, Figure 6) compared to those 
patients whose tumours had low levels of PTEN cytoplasmic expression. The median 
OS for patients whose tumours had low PTEN cytoplasmic expression is 14.84(12.02, 
14.96) years compared to 14.84(13.98, 15.71) years for patients whose tumours had 
high PTEN cytoplasmic expression.
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PTEN cytoplasmic OS
Low PTEN (n=259)
  ....
High PTEN (n=115)
P=0.013
Follow up  (y ears)
Figure 8. Kaplan-Meier survival plots showing percentage OS in patients whose 
tumours had low versus high cytoplasmic PTEN expression. The cut o ff for high and 
low levels o f  PTEN is defined as above and below median histoscore. P values 
represent log-rank testing o f the difference in survival
Patients whose tumours had high levels of PTEN expression had a reduced DFS 
(p=0.018, log rank test. Figure 7) compared to those patients whose tumours had low 
levels of PTEN expression. The median DFS for patients whose tumours had low 
PTEN cytoplasmic expression is 12.80 (11.61, 13.98) years compared to 10.43 (8.87,
11.99) years for patients whose tumours had high PTEN cytoplasmic expression.
PTEN cytop lasm ic  D FS
Low PTEN 
(n=259)
High PTEN (n=l15)
P=0.018
G e n era l re c u rre n c e  follow up  (y e ars)
Figure 9. Kaplan-Meier survival plots showing percentage DFS in patients whose 
tumours had low versus high cytoplasmic PTEN expression. The cut o ff for high and 
low levels o f PTEN is defined as above and below median histoscore. P values 
represent log-rank testing o f the difference in survival
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Patients whose tumours had high levels of PTEN expression had a reduced DFS after 
finishing tamoxifen treatment (p=0.022, log rank test, Figure 8) compared to those 
patients whose tumours had low levels of PTEN expression. The median DFS after 
finishing tamoxifen treatment for patients whose tumours had low PTEN cytoplasmic 
expression is 10.83(9.88, 11.78) years compared to 8.14 (6.35, 9.94) years for patients 
whose tumours had high PTEN cytoplasmic expression. We need to assume that as 
the OS survival curves separate and the DFS curves do not, that gain of PTEN is a late 
event that occurs following relapse.
PTEN cyto DFS off Tam oxifen
100
Low PTEN (n=183)
High PTEN (n=71)40
P=0.022
80 2 4 6 10 12
Follow up  off tam oxifen (years)
Figure 10. Kaplan-Meier survival plots showing percentage DFS after end tamoxifen 
treatment in patients whose tumours had low versus high cytoplasmic PTEN 
expression. The cut offfor high and low levels o f PTEN is defined as above and below 
median histoscore. P values represent log-rank testing o f the difference in survival
Patients whose tumours had high levels of PTEN expression had a reduced DFS after 
3 years Tamoxifen treatment (p==0.048, log rank test, figure 9) compared to those 
patients whose tumours had low levels of PTEN expression. The median DFS after
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three years tamoxifen treatment for patients whose tumours had low PTEN 
cytoplasmic expression is 11.45 (10.23, 12.66) years compared to 9.43 (7.72, 11.13) 
years for patients whose tumours had high PTEN cytoplasmic expression.
PTEN cyto DFS after 3 years Tamoxifen
Low PTEN (n=216)
High PTEN (n=85)
P=0.048
R ecurrence follow up after 3 years  tamoxifen
Figure 11. Kaplan-Meier survival plots showing percentage DFS after 3 years 
tamoxifen treatment in patients whose tumours had low versus high cytoplasmic 
PTEN expression. The cut offfor high and low levels o f PTEN is defined as above and 
below median histoscore. P values represent log-rank testing o f the difference in 
survival.
Patients whose tumours had high levels of PTEN expression had a reduced OS after 3 
years Tamoxifen treatment (p=0.009, log rank test, figure 10) compared to those 
patients whose tumours had low levels of PTEN expression. The median OS after 
tliree years tamoxifen treatment for patients whose tumours had low PTEN 
cytoplasmic expression is 13.83(13.31, 14.36) years compared to 11.64 (10.46, 12.83) 
years for patients whose tumours had high PTEN cytoplasmic expression.
PTEN cyt OS after 3 years Tamoxifen
I 60 High PTEN (n=84)
Low PTEN (n=215)
P=0.009
0 4 8 12
Overall survival follow up after 3 years Tamoxifen
Figure 12. Kaplan-Meier survival plots showing percentage OS after 3 years 
tamoxifen treatment in patients whose tumours had low versus high cytoplasmic 
PTEN expression. The cut offfor high and low levels o f PTEN is defined as above and 
below median histoscore. P values represent log-rank testing o f the difference in 
survival.
Patients whose tumours had high levels of PTEN expression had a 0.55-fold (95% Cl 
0.35-0.89, p=0.01) chance of survival as compared to those patients whose tumours 
had low levels of PTEN expression and a 0.62-fold (95% Cl 0.42-0.93, p=0.02) risk 
of relapse as compared to those patients whose tumours had low levels of PTEN 
expression.
Patients whose tumours had high levels of PTEN cytoplasmic expression had a 1.82- 
fold increased risk of dying from their cancer compared to patients whose tumours 
had low levels of PTEN cytoplasmic expression and a 1.62 increase risk of relapse as 
compared to those patients whose tumours had low levels of PTEN
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Ab Median
histoscore
(inter­
quartile
range)
OS
hazard
ratio
DFS
hazard
ratio
DFS on 
tamoxifen 
hazard 
ratio
DFS off 
tamoxifen 
hazard 
ratio
DFS after 
3y
tamoxifen
hazard
ratio
Survival 
after 3y 
tamoxifen 
hazard 
ratio
PTEN 33.33
(11.25-
60.83)
0.55
(0.35-
0.89)
p=0.01
0.62
(0.42-
0.93)
p=0.02
0.75
(0.47-
1.20)
(NS)
0.42
(0.20-
0.90)
p=0.03
0.56
(0.31-
1.00)
p=0.05
0.34
(0.15-
0.79)
p=0.01
Table 5. Median histoscore and relative risk (hazard ratio) for PTEN cytoplasmic 
expression.
Multivariate analysis suggested that PTEN cytoplasmic expression was an 
independent predictor of decreased DFS after 3 years of tamoxifen treatments only (p 
= 0.01, Cox regression) and OS after 3 years tamoxifen therapy (p = 0.0443, Cox 
regression) when analyzed alongside known prognostic markers such as tumor size, 
grade and nodal status. There was a trend towards significance for OS (p=0.08) and 
DFS off tamoxifen (p=0.06).
Nuclear PTEN histoscores
When patients were divided into those whose tumours exhibited high or low PTEN 
nuclear scores, there was no statistically significant association between tumour levels 
of nuclear PTEN and patient OS or DFS.
Survival Category P Value
Overall survival 0.997
Disease free survival 0.762
Disease free survival on tamoxifen 0.313
Disease free survival off tamoxifen 0.515
Disease free survival after 3 years 
tamoxifen
0.843
Overall survival after 3 years tamoxifen 0-558
Table 6. Table showing OS and DFS p-values for PTEN nuclear expression. P values 
represent log-rank testing o f the difference in survival
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3.1.3 C orrelations between PTEN scores and o ther m em ber of the 
PI3K /A kt pathw ay
High levels o f cytoplasmic PTEN were significant associated with high levels of 
cytoplasmic PI3K (p<0.0001, R=0.51, Spearman Rank Test) and cytoplasmic pAkt 
(473) (p<0.0001, R=0.364; Spearman Rank Test) (Figure 11 and 12)
Scatter Plot of PTEN cyto scores 
correlated with PI3K ctyto scores
I
;
0 100
PI3K cytoplasmic histoscores
Figure 13. Scatter plot o f the association between cytoplasmic PTEN and PI3K scores
Scatter plot of PTEN cyto scores 
correlated with pAkt (473) cyto scores
• T
100 200 
P-Akt (473) cytoplasmic histoscores
Figure 14. Scatter plot of the association between cytoplasmic PTEN and pAkt (473) 
scores
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3.2 IHC for Bad
3.2.1 Bad expression and staining patterns using IHC
To check the specificity of the Bad antibody. Western Blotting was carried out. A 
single band was seen at 21 kDa corresponding to the size of Bad (Figure 13b). Using 
western blot, the expression levels of Bad in growth-factor- or hormone-stimulated 
cell lines (MDA-361) were investigated. No changes in Bad expression was observed 
in non-stimulated cells compared to cells stimulated with oestrogen or heregulin alone 
or in combination
For immunohistochemical analyses of Bad, 58 out of 456 (12.7%) cases were 
unavailable for analysis either due to core loss or insufficient tumour material in the 
cores and these patients were therefore excluded from further analysis. Only 
cytoplasmic staining was noted (Figure 13c), and the staining was confined to the 
invasive tumour components, with no staining in normal breast epithelial cells. The 
staining was scored as described previously and scores for each core were then 
averaged. 15% of the cores were double scored by T.K achieving an ICCC of 0.94 
(excellent).
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Figure 15. a) Histogram showing distribution of cytoplasmic scores for Bad IHC 
(curve shows normal distribution) b) Western Blot for Bad antibody. The protein 
used was MDA-361 cells (L=ladder, US= unstimulated, H= stimulated with 
heregulin, E= stimulated with oestrogen, H+E= stimulated with heregulin and 
oestrogen. Band at 21 kDa, c) Breast tumour stained with Bad antibody
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3.2.2 Bad expression and patient outcome
Survival Category P Value
Overall survival 0.051
Disease free survival 0.049
Disease free survival on tamoxifen 0.278
Disease free survival off tamoxifen 0.252
Disease free survival after 3 years 
tamoxifen
0.019
Overall survival after 3 years tamoxifen 0.010
Table 7. Table showing OS and DFS p-values for Bad cytoplasmic expression
When patients were divided into those with high (above median histoscore) and low
(below median histoscore) Bad tumours expression, patients whose tumours had high
levels o f Bad expression had a trend toward improved OS (p = 0.051, log rank test.
Figure 16) as compared to those patients whose tumours had low levels of Bad
Bad os
 High Bad (1^182)^ ^
Low Bad (n=175)
P=0.051
Follow up (years)
Figure 16. Kaplan-Meier survival plots showing percentage OS in patients whose 
tumours had low versus high Bad expression. The cut o ff for high and low levels o f 
Bad is defined as above and below median histoscore. P values represent log-rank 
testing o f the difference in survival.
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Patients whose tumours had high levels of Bad expression had improved DFS (p = 
0.049, log rank test. Figure 17) with a 1.49-fold (95% Cl 1.00-2.22, p=0.05) 
decreased risk of relapse as compared to those patients whose tumours had low levels 
o f Bad expression. The median DFS for patients whose tumours had low Bad 
cytoplasmic expression is 11.31(10.02, 12.61) years compared to 12.83 (11.44, 14.21) 
years for patients whose tumours had high Bad cytoplasmic expression.
Bad DFS
100
High Bad (n=182)80
60
Low Bad (n=175)
40
P=0 049
20
0
0 5 10 15 20
General recurrence follow up (years)
Figure 17. Kaplan-Meier survival plots showing percentage DFS in patients whose 
tumours had low versus high Bad expression. The cut o ff for high and low levels o f 
Bad is defined as above and below median histoscore. P values represent log-rank 
testing o f the difference in survival.
Further analysis showed that patients whose tumours had high levels of Bad 
expression had a significantly improved DFS and OS after three years tamoxifen 
treatment (p=0.019, log rank test; Figure 18 and p=0.010, log rank test. Figure 19 
respectively) as compared to patients whose tumours had low levels of Bad 
expression. Patients with high Bad tumour levels had a 1.98-foId (95% Cl 1.10-3.55) 
decreased risk of relapse after 3 years of tamoxifen treatment as compared to patients 
with low tumour levels of Bad (p=0.05) (Table 6). The median DFS after three years
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Tamoxifen treatment for patients whose tumours had low Bad cytoplasmic expression 
is 10.00(8.62, 11.36) years compared to 11.55 (10.14, 12.96) years for patients whose 
tumours had high Bad cytoplasmic expression.
Bad DFS after 3years Tamoxifen
100 High Bad (n=155)
60
Low Bad (n=131)
40
qÜ P=0 01920
8 102 60 4
Time to R ecurrence After 3 Y ears on Tam oxifen
Figure 18. Kaplan-Meier survival plots showing percentage DFS after 3 years o f 
tamoxifen treatment in patients whose tumours had low versus high Bad expression. 
The cut o ff for high and low levels o f Bad is defined as above and below median 
histoscore. P values represent log-rank testing o f the difference in survival
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Bad OS after 3 years Tamoxifen
1 0 0  T-
High Bad (n=155)
Low Bad (n=129)I3  60c/5
P=0 01
0 2 64 8 10
Overall Survival Follow Up After 3 years Tamoxifen
Figure 19. Kaplan-Meier survival plots showing percentage OS after 3 years o f  
tamoxifen treatment in patients whose tumours had low versus high Bad expression. 
The cut o ff for high and low levels o f Bad is defined as above and below median 
histoscore. P values represent log-rank testing o f the di fference in survival
In multivariate analysis the level of Bad expression was not an independent 
prognostic marker for disease free survival or overall survival (p = 0.083 and p=0.113 
respectively, Cox regression) when analysed alongside known conventional 
prognostic indicators o f overall survival such as tumour size, grade and nodal status. 
We need to assume that as the OS survival curves separate and the DFS curves do not. 
that gain of Bad is a late event that occurs following relapse.
3.2.3 C orrelations between Bad and o ther m em bers of the PI3K /akt 
pathw ay
High tumour levels of Bad expression were weakly but significantly associated with 
high cytoplasmic tumour levels o f Akt 1 (p = 0.029; R= 0.117) and Akt 3 (p = 0.032; 
R= 0.116). However scatter plots revealed that the main reason for correlation was the
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significant number of tumours with no staining (histoscore = 0). There were no 
significant correlations between bad expression and apoptosis. as measured by 
TUNEL assay (data not shown).
S catter plot of Bad cyto sco res  correlated 
against Akt 1 cyto sco res
I
Akl1 cy toplasm ic hisloscores
Figure 20. Scatter plot of the association between cytoplasmic Bad and Akt J 
cytoplasmic histoscores.
S catter plot of Bad cyto sco res  correlated 
against Akt 3 cyto sco res
AM3 cytoplasm ic histoscores
Figure 21. Scatter plot o f the association between cytoplasmic Bad and Akt J 
cytoplasmic histoscores.
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3.3 IHC for Bax
3.3.1 Bax expression and staining patterns using IHC
The specificity of the antibody was checked using Western Blotting. A single band 
was seen at 21kDa corresponding to the size of Bax (Figure 19b). For 
immunohistochemical analyses of Bax, 62 out of 456 (13.6%) cases were unavailable 
for analysis either due to core loss or insufficient tumour material in cores and these 
patients were therefore excluded from further analysis. Only cytoplasmic staining was 
noted (Figure 22c). Staining for the antibody was confined to the invasive tumour 
components, with no staining in normal breast epithelial cells. The staining was 
scored as described previously and scores for each core were then averaged. 15% of 
the cores were double scored by T.K achieving an ICCC of 0.89 (excellent).
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Figure 22. a)Histogram showing distribution o f cytoplasmic scores for Bax IHC. b) 
Western Blot o f Bax antibody showing band at 2 IkDa (MCFU ==MCF-7 cells 
unstimulated, MDAU = MDA-MB-361 cells unstimulated, MCFS ==MCF-7 cells 
stimulated with oestrogen, MDAS = MDA-MB-361 cells stimulated with oestrogen) , 
c)breast tissue stained with Bax antibody
3.3.2 Bax expression and  patien t outcome
When patients were divided into those with high or low levels of Bax (above or below 
median histoscore) there was no significant association with overall or disease free 
survival.
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Survival Category P Value
Overall survival 0.433
Disease free survival 0.778
Disease free survival on tamoxifen 0.892
Disease free survival off tamoxifen 0.530
Disease free survival after 3 yeai's 
tamoxifen
0.952
Overall survival after 3 yeai's tamoxifen 0.103
Table 8. OS and DFS p-valuesfor cytoplasmic expression of Bax
3.3.3 Correlations between Bax and other members of the PI3K/Akt 
pathway
There were no significant correlations between Bax and pAkt or between Bax and 
apoptosis, as measured by TUNEL assay (data not shown).
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3.4 IHC for Bcl-2
3.4.1 Bcl-2 expression and staining patterns using IHC
The specificity of the antibody was checked using Western Blotting. A single band 
was seen at 26kDa corresponding to Bcl-2 (Figure 20b). For immunohistochemical 
analyses of Bcl-2, 50 out of 456 (11.0%) cases were unavailable for analysis either 
due to core loss or insufficient tumour material in cores and these patients were 
therefore excluded from further analysis. Only cytoplasmic staining was noted (Figure 
23c). Staining for the antibody was confined to the invasive tumour components, with 
no staining in normal breast epithelial cells. The staining was scored as described 
previously and scores for each core were then averaged. 15% of the cores were 
double scored by T.C achieving an ICCC of 0.96 (excellent).
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Figure 23. a) Histogram showing distribution o f cytoplasmic scores for Bcl-2 IHC, 
b) Western blot o f Bcl-2 showing a single band at 26kDa (JS=Jurkat cells 
stimulated with oestrogen, HS=Hela cells stimulated with oestrogen, L=ladder), c) 
Breast tissue stained with Bcl-2 antibody
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3.4.2 Bcl-2 expression and patient outcome
When patients were divided into those with high or low levels o f Bcl-2 (above or 
below median histoscore) there was no significant association with overall or disease 
free survival.
Survival Category P Value
Overall survival 0.893
Disease free survival 0.267
Disease free survival on tamoxifen 0.068
Disease free survival off tamoxifen 0.309
Disease free survival after 3 years 
tamoxifen
0.869
Overall survival after 3 years tamoxifen 0.244
Table 9. OS and DFS p-values for Bcl-2 cytoplasmic expression 
3.4.3 Correlations between Bcl-2 and other member of the PI3K/Akt 
pathway
High tumour levels of Bcl-2 expression were significantly associated with high 
cytoplasmic tumour levels of Akt 1 (p < 0.0001; R= 0.362) (figure 19), Akt 3 (p 
<0.0001 ; R= 0.429) (Figure 20) and p Akt (Ser 473) nuclear scores (p<0.0001 ; R= 
0.233) (Figure 24). There was no significant association between apoptosis as, 
measured by TUNEL assay and Bcl-2 expression.
Scatter Plot of Bcl-2 cyt scores correlated 
with Akt 1 cyt scores
Akt1 cy toplasm ic h isto sco res
Figure 24. Scatter plot o f Bcl-2 cytoplasmic histoscores correlated with Akt I 
cytoplasmic histoscores
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Scatter Plot of Bcl-2 cyt scores correlated
with Akt 3 cyt scores
A kt3 c y to p la sm ic  h is to sc o re s
Figure 25. Scatter plot o f Bcl-2 cytoplasmic histoscores correlated with Akt 5 
cytoplasmic histoscores
Scatter Plot of Bcl-2 cyt scores correlated 
with pAkt(473) cyt scores
P-Akt (473 ) cy top lasm ic  h is to sc o re s
Figure 26. Scatter plot o f Bcl-2 cytoplasmic histoscores correlated with p Akt (473) 
cytoplasmic histoscores
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3.5 IHCforBcl-xl
3.5.1 Bcl-xl expression and staining patterns using IHC
The specificity of the antibody was checked using Western Blotting. A single band 
was seen at 30kDa corresponding to Bcl-xl (Figure 24b). For immunohistochemical 
analyses of Bcl-xl, 54 out of 456 (11.8%) cases were unavailable for analysis either 
due to core loss or insufficient tumour material in cores and these patients were 
therefore excluded from further analysis. Only cytoplasmic staining was noted (Figure 
27c). Staining for the antibody was confined to the invasive tumour components, with 
no staining in normal breast epithelial cells. The staining was scored as described 
previously and scores for each core were then averaged. 15% of the cores were double 
scored by T.K achieving an ICCC of 0.95 (excellent).
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Figure 27. a) Histogram showing distribution o f cytoplasmic scores for Bcl-xl IHC, b) 
Western blot showing single band at SOkDa (MCFU ==MCF-7 cells unstimulated, 
MCFS ^=MCF-7 cells stimulated with oestrogen, MDAS = MDA-MB-361 cells 
stimulated with oestrogen, L=ladder) c)Breast tissue stained with Bcl-xl antibody
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3.5.2 Bcl-xl expression and patient outcome
When patients were divided into those with high or low levels of Bcl-xl (above or 
below median histoscore) there was no significant association with overall or disease 
free survival.
Survival Category P Value
Overall survival 0.411
Disease free survival 0.284
Disease free survival on tamoxifen 0.594
Disease free survival off tamoxifen 0.151
Disease free survival after 3 years 
tamoxifen
0.751
Overall survival after 3 years tamoxifen 0.978
Table 10. OS and DFS p-valuesfor Bcl-xl cytoplasmic expression
3.5.3 Correlations between Bcl-xl and other members of the 
PI3K/Akt pathway
High tumour levels of Bcl-xl expression were (weakly) associated with high 
cytoplasmic tumour levels of Akt 2 (p = 0.014; R= 0.133) (figure 25) and Akt 3 (p = 
0.033; R= 0.114) (figure 26). However scatter plots revealed that the main reason for 
correlation was the significant number of cores with weak staining. There was no 
significant association between apoptosis as, measured by TUNEL assay and Bcl-2 
expression
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Scatter plot of Bcl-xl cyto scores correlated
against Akt 2 cyto scores
200
Akt2 cytoplasmic histoscores
Figure 28. Scatter plot of Bcl-xl cytoplasmic histoscores correlated with Akt 2 
cytoplasmic histoscores
Scatter plot of Bcl-xl cyto scores correlated 
against Akt 3 cyto scores
«I
Akt3 c y to p la sm ic  h is to s c o re s
Figure 29. Scatter plot o f Bcl-xl cytoplasmic histoscores correlated with 
Akt 3 cytoplasmic histoscores
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3.6 IHC for pBad (Serll2)
3.6.1 pBad (Serll2) expression and staining patterns using IHC
Western blot analysis was used to assess the specificity of the pBad (Ser 112) 
antibody. A single band was seen at 23kDa corresponding to pBad (Seri 12). 
Stimulation with heregulin alone or in combination with oestrogen induced 
phosphorylation of Bad at Ser 112 whilst oestrogen alone had no effect (Figure 23b). 
For immunohistochemical analyses of pBad (ser 112), 66 out of 456 (14.5%) cases 
were unavailable for analysis either due to core loss or insufficient tumour material in 
the cores and these patients were therefore excluded from further analysis. Only 
cytoplasmic staining was noted (Figure 30c). Staining for the antibody was confined 
to the invasive tumour components, with no staining in normal breast epithelial cells. 
The staining was scored as described previously and scores for each core were then 
averaged. 15% of the cores were double scored by T.C achieving an ICCC of 0.96 
(excellent).
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Figure 30. a) Histogram showing distribution o f cytoplasmic scores for p-Bad (ser 
112) IHC, b) Western blot showing single band at 23kDa (L=ladder, MCFU= MCF-7 
cells unstimulated, MCF-H=MCF-7 cells stimulated with heregulin, MCF-E= MCF-7 
cells stimulated with oestrogen, MCF- HE= MCF-7 cells stimulated with heregulin 
plus oestrogen
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3.6.2 Bad activity and patient outcome
When patients were divided into those with high or low levels of p-Bad (Seri 12) 
(above or below median histoscore) there was no significant association with overall 
or disease free survival.
Survival Category P Value
Overall survival 0.778
Disease free survival 0.830
Disease free survival on tamoxifen 0.783
Disease free survival off tamoxifen 0.966
Disease free survival after 3 years 
tamoxifen
0.236
Overall survival after 3 years tamoxifen 0.583
Tablell. OS and DFSp-values for pBad (ser 112) cytoplasmic expression
3.6.3 Correlations between pBad (Ser-112) and other members of 
the PI3K/Akt pathway
High pBad (Ser 112) was associated with high levels of apoptotic activity (p<0.0001 
R=0.211) as measured by TUNEL assay. However scatter plot (figure 28) revealed 
that the main reason for correlation was the significant numbers of low scores.
Scatter plot of pBad (S er  1 12)cyto sc o r e s  
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Figure 31. Scatter plot o f pBad (Ser 112) cytoplasmic histoscores correlated with 
TUNEL data (measure o f apoptotic activity)
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M e d ia n  H is to s c o r e s  
( in te r - Q u a r t i le  r a n g e )
D is e a s e  F r e e  
s u r v iv a l  h a z a r d  r a t i o
D is e a s e  f r e e  
s u r v iv a l  a f t e r  
t h r e e  v e a r s  
t a m o x i f e n  h a z a r d  
r a t i o
B a d 67 (34-100) 1.49 (1.00-2.22), 
d=0.05
1.98 (1.10-3.55). 
d=0.022
P B a d  f s e r  112) 7 (0-33) 1.00 (0.67-1.48), NS 1.26 (0.70-2.26), 
NS
B a x 27 (7-50) 1.06 (0.71-1.57), NS 1.02 (0.57-1.83), 
NS
B c l-2 53 (20-104) 1.24(0.85-1.82), NS 1.05 (0.60-1.82). 
NS
B c l-x l 143 (103-175) 1.13 (0.77-1.68). NS 1.10 (0.62-1.97), 
NS
NS=non significant
Table 12. Median histoscore and relative risk (hazard ratio) for Bad, pBad (Seri 12), 
Bax, Bcl-2 and Bcl-xl
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3.7 IHC for P-P90RSK (Thr 359/Ser 363)
3.7.1 P-P90RSK (Thr 359/Ser363) expression and staining patterns 
using IHC
The specificity of the antibody was checked using Western Blotting. A single band 
was seen at SOkDa corresponding to p-P90RSK (Figure 29b). For 
immunohistocheiTiical analyses of pP90RSK (Thr359/Ser 363), 100 out of 456 
(21.9%) cases were unavailable for analysis either due to core loss or insufficient 
tumour material in cores and these patients were therefore excluded from further 
analysis. Only nuclear staining was noted (Figure 32c). Staining for the antibody was 
confined to the invasive tumour components, with no staining in normal breast 
epithelial cells. The staining was scored as described previously and scores for each 
core were then averaged. 15% of the cores were double scored by T.K achieving an 
ICCC of 0.94 (excellent).
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Figure 32. a) Histogram showing distribution of nuclear histoscores for pP90rsk Thr 
359Sser363) IHC, b) Western blot showing single band at SOkDa,(474S=BT474 cells 
stimulated by oestrogen, 474US =BT474 cells unstimulated, 361S=MDA-MB36l cells 
stimulated by oestrogen, 361U= MDA-MB36I cells unstimulated c)Breast tissue 
stained with pP90RSK (Thr 359/Ser 363)
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3.7.2 pP90RSK and patient outcome
When patients were divided into those with high or low levels of p-P90RSK 
(Thr359/Ser363) (above or below the median) there was no significant association 
between p-p90RSK expression and overall or disease free survival.
Survival Category P Value
Overall survival 0.450
Disease free survival 0.676
Disease free survival on tamoxifen 0.607
Disease free survival off tamoxifen 0.734
Disease free survival after 3 years 
tamoxifen
0.993
Overall survival after 3 years tamoxifen 0.880
Table 13. OS and DFS p-valuesfor pP90RSK nuclear expression
3.7.3 Correlations between pP90RSK (thr 359/Ser 363) and other 
members of the PI3K/Akt pathway
There was a weak but significant correlation between phosphorylated MAPK (42/44) 
cytoplasmic expression and pP90RSK nuclear expression (P<0.0001, R=0.211)(figure 
30). There was also a weak but significant correlation between pP90RSK nuclear 
expression and pBad (Seri 12) expression (R=0.384, p<0.0001)(figure 31), and 
between pP90RSK nucleai- expression and p-mTOR cytoplasmic expression 
(R=0.340, p<0.0001)(figure 32) (Immunohistochemistry for mTOR was performed by 
T.K). Scatter plots revealed that the main reason for the correlations was the 
significant number of tumours with weak staining.
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Figure 33. Scatter plot showing the association between cytoplasmic expression 
pP90RSK (Thr 359/Ser 363) and phosphorylated MAPK (42/44) cytoplasmic 
expression.
Scatter plot of pP90R SK  (Thr 3 5 9 /S er  363) sc o res  
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Figure 34. Scatter plot showing the association betM’een cytoplasmic expression 
pP90RSK (Thr 359/Ser 363) andpBad (Ser 112) cytoplasmic expression.
Scatter plot of pP90R SK  (Thr 3 5 9 /S er  363) nuc 
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Figure 35. Scatter plot showing the association between cytoplasmic expression 
pP90RSK (Thr 359/Ser 363) andp-mTor cytoplasmic expression.
117
3.8 IHC for P70S6K
3.8.1 P70S6K expression and staining patterns using IHC
The specificity of the antibody was checked using Western Blotting. Two bands were 
seen at VOkDa and 85kDa respectively (Figure 33c). Both bands corresponded to 
P70S6K; the 85kDa band corresponded to P85S6K, a second isoform that is identical 
to P70S6K except for 23 extra amino acids at the amino-terminus. For analyses of 
P70S6K, 125 out of 456 (27.4%) cases were unavailable for analysis either due to 
core loss or insufficient tumour material in cores and these patients were therefore 
excluded from further analysis. Nuclear and cytoplasmic staining was noted (Figure 
36d). Staining for the antibody was confined to the invasive tumour components, with 
no staining in normal breast epithelial cells. The staining was scored as described 
previously and scores for each core were then averaged. 15% of the cores were double 
scored by T.K achieving an ICCC of 0.85(excellent).
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Figure36. a) Histogram showing distribution o f nuclear scores for P70S6K IHC b) 
Histogram showing distribution o f cytoplasmic scores for P70S6K IHC, c) Western 
blot o f P70S6K antibody showing two bands at 70kDa and SOkDa (L=ladder, 
MCFS=MCF-7 cells stimulated by oestrogen. MCFU = MCF-7 cells unstimulated, 
36IS=MDA-MB36I cells stimulated by oestrogen, 36111= MDA-MB361 cells 
unstimulated), d) Breast tissue stained with P70S6K antibody
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3.8.2 P70S6K and patient outcome 
Nuclear scores
When patients were divided into those with high or low levels of nuclear P70S6K 
(above or below median histoscore) there was no significant association with overall 
or disease free survival.
Survival Category P Value
Overall survival 0.463
Disease free survival 0.436
Disease free survival on tamoxifen 0.455
Disease free survival off tamoxifen 0.676
Disease free survival after 3 years 
tamoxifen
0.450
Overall survival after 3 yeais tamoxifen 0.118
Table 14. OS and DFS p- values for P70S6K nuclear scores 
Cytoplasmic scores
When patients were divided into those with high or low levels of cytoplasmic P70S6K 
(above or below median histoscore) there was no significant association with overall 
or disease free survival. However there was a trend towards significance (p=0.065) for 
those patients whose tumours had high levels of P70S6K expression as compared to 
those with low levels of P70S6K expression for overall survival after three years of 
tamoxifen treatment.
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Survival Category F Value
Overall survival 0.540
Disease free survival 0.580
Disease free survival on tamoxifen 0.683
Disease free survival off tamoxifen 0.848
Disease free survival after 3 years 
tamoxifen
0.848
Overall Survival after 3 years tamoxifen 0.065
Table 15. OS and DFSp~values for P70S6K cytoplasmic scores
P 7 0 S 6 K  cyto O S  after 3 y e a r s  T am oxifen
^  ' Low P70S6K  (n=141)
High P70S6K
(n=120)
P=0.065
OS follow up after 3 y ears  on tamoxifen
Figure 37. Graph showing percentage survival after 3 years Tamoxifen (y axis) 
plotted against time in years (x axis) for P70S6K cytoplasmic scores.
3,8.2 Correlations between P70S6K and other members of the 
PI3K/Akt pathway
Nuclear and cytoplasmic P70S6K scores weakly but significantly correlated with Akt 
2 expression (R=0.129, p=0.024 and R=0.213, p<0.0001, respectively). Cytoplasmic 
P70S6K scores weakly but significantly correlated with pAkt (473) (R=0.114, p= 
0.044). However scatter plots revealed that the main reason for the correlations was 
the significant number of tumours with low expression. There was no correlation 
between P70S6K scores and p-mTOR scores (p-mTOR scores obtained from other 
member of our group, Dr T Kirkegaard).
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Scatter plot of P70S6K nuc scores 
correlated against Akt 2 cyt scores
.«-'I. .*
Akt2 cy top lasm ic  h is lo sc o re s
Figure 38. Scatter plot showing the association hetM'een nuclear expression o f 
P70S6K and Akt 2 cytoplasmic expression.
S ca tter  plot o f  P 7 0 S 6 K  cyt s c o r e s  
correlated  a g a in st  Akt 2 cyt s c o r e s
3 # ;
100 200
Akt2 cytoplasmic h istoscores
Figure 39. Scatter plot showing the association between cytoplasmic expression o f 
P70S6K and Akt 2 cytoplasmic expression.
Scatter plot of P 70S6K  cyt sc o r e s  
correlated again st pAkt (473) cyt sc o r e s
300
200
100
0
100 2000
P-Akt (473) cytoplasmic histoscores
Figure 40. Scatter plot showing the association between cytoplasmic expression o f 
P70S6K andpAkt (473) cytoplasmic expression.
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3.9 IHC for pP70S6K (Thr 389)
3.9.1 pP70S6K (Thr 389) expression and staining patterns using IHC
The specificity of the antibody was checked using Western Blotting. Two bands were 
seen at 70kDa and 85kDa respectively (Figure 38b). Both bands corresponded to 
P70S6K. The 85kDa band corresponded to pP85S6K, a second isoform that is 
identical to P70S6K except for 23 extra amino acids at the amino-terminus. For 
analyses of pP70S6K (Thi'389), 73 out of 456 (16.0%) cases were unavailable for 
analysis either due to core loss or insufficient tumour material in cores and these 
patients were therefore excluded from further analysis. Only nuclear staining was 
noted (Figure 41c). Staining for the antibody was confined to the invasive tumour 
components, with no staining in normal breast epithelial cells. The staining was 
scored as described previously and scores for each core were then averaged. 15% of 
the cores were double scored by T.K achieving an ICCC of 0.94 (excellent).
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Figure 4L a) Histogram showing distribution of nuclear scores for pP70S6K (Thr 
389) IHC, b) Western blot ofpP70S6K (Thr 389) antibody showing a bands at 7()kDa 
and 80kDa, (L=ladder, MCFS=MCF-7 cells stimulated by oestrogen, MCFU =MCF- 
7 cells unstimulated, 36IS=MDA-MB361 cells stimulated by oestrogen, 361 U= 
MDA-MB361 cells unstimulated) c) Breast tissue stained with pP70S6K (thr389) 
antibody
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3.9.2 P-P70S6K (thr 389) and patient outcome
When patients were divided into those with high or low levels of nuclear pP70S6K 
(Thr389) (above or below median histoscore) there was no significant association 
with overall or disease free survival. However there was a trend towards significance 
(p=0.082) for those patients whose tumours had a high (above the median) level of 
expression of pP70S6K (Thr389) as compared to those with a low level (below the 
median) expression for overall survival after three years tamoxifen treatment.
Survival Category P Value
Overall survival 0.214
Disease free survival 0.149
Disease free survival on tamoxifen 0.426
Disease free survival off tamoxifen 0.205
Disease free survival after 3 years 
tamoxifen
0.140
Overall survival after 3 years tamoxifen 0.082
Table 16. OS and DFS p-values for pP70S6K (Thr389)
pP70S6K nuc OS after 3 years Tamoxifen
High PP70S6K (n=139)
L.qvy PP7OS6K (Of 143)
P=0 082
OS follow up after 3 years on tamoxifen
Figure 42. Graph showing percentage survival after 3 years Tamoxifen (y axis) 
plotted against time in years (x axis) for pP70S6K (Thr389).
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3.9.3 C orrelations between p-P70S6K and o ther m em bers of the 
PI3K /A kt pathw ay
P-P70S6K scores correlated weakly but significantly with Aktl and pAkt (473)
(R=0.113, p=0.034 and R=0.189, p<0.0001, respectively). PP70S6K scores also
correlate weakly with p-mTOR cytoplasmic expression, R=0.213, p<0.0001 (p-
mTOR scores obtained from other member o f our group. Dr T Kirkegaard). However
scatter plots revealed that the main reason for the correlations was the significant
number of cores with low expression. There was no correlation between P70S6K and
HER2 expression.
Scatter plot of p P 70S 6K  (Thr 3 8 9 ) cyt sc o r e s  
correlated aga in st Akt 1 cyt s c o r e s
i
0 100 200 300
Aktl cytoplasmic histoscores
Figure 43. Scatter plot showing the association between nuclear expression o f
pP70S6K (Thr 389) and Akt 1 cytoplasmic expression
S ca tter  plot o f p P 7 0 S 6 K  (Thr 3 8 9 )  cyt s c o r e s  
correlated  a g a in st  pAkt (4 7 3 ) cyt s c o r e s
P-Akt (473) cy toplasm ic h istoscores
Figure 44. Scatter plot showing the association between nuclear expression o f  
pP70S6K (Thr 389) andpAkt (473) cytoplasmic expression
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Scatter plot of pP70S6K  (Thr 389) cyt sc o res  
correlated against p-mTor cyt sc o res
20 40 60 80
p-mTOR cytoplasmic histoscores
Figure 45. Scatter plot showing the association betM>een nuclear expression o f  
pP70S6K (Thr 389) andp-mTor cytoplasmic expression
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3.10 IHCforPI3K
3.10.1 PI3K expression and staining patterns using IHC
To test the specificity of the antibody Western Blotting was performed. A single band 
was obtained at llOkDa, corresponding to PI3K (Figure 43b). For analyses of PI3K, 
114 out of 456 (25.0%) cases were unavailable for analysis either due to core loss or 
insufficient tumour material in cores and these patients were therefore excluded from 
further analysis. Only cytoplasmic staining was noted (Figure 46c). Staining for the 
antibody was confined to the invasive tumour components, with no staining in normal 
breast epithelial cells. The staining was scored as described previously and scores for 
each core were then averaged. 15% of the cores were double scored by T.K achieving 
an ICCC of 0.83 (excellent).
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Figure 46. a) Histogram showing distribution o f cytoplasmic scores for PI3K IHC,
b) Western Blot o f P13K antibody showing a single band at llOkDa , (L=ladder, 
MCFS=MCF-7 cells stimulated by oestrogen, MCFU =MCF-7 cells unstimulated, 
361S^MDA-MB361 cells stimulated by oestrogen, 361 U=^  MDA-MB361 cells 
unstimulated c) Breast tissue stained with P13K antibody showing cytoplasmic 
staining only
3.10.2 PI3K and patient outcome
When patients were divided into those with high or low levels of cytoplasmic PI3K 
(above or below median histoscore) there was no significant association with overall 
or disease free survival.
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Survival Category P Value
Overall survival 0.254
Disease free survival 0.614
Disease free survival on tamoxifen 0.897
Disease free survival off tamoxifen 0.289
Disease free survival after 3 years 
tamoxifen
0.712
Overall survival after 3 years tamoxifen 0.459
Table 17. OS and DFS p-values for PI3K cytoplasmic scores
3.10.3Correlations between PI3K and other members of the 
PI3K/Akt pathway
PI3K cytoplasmic histoscores weakly but significantly correlated with Aktl and Akt3 
(R=0.187, p=0.001 and R=0.189, p<0.0001 respectively). The scatter plot for these 
correlation showed that the main reason for the correlation was the large number of 
cores with low PI3K expression. There was a stronger correlation between PI3K and 
pAkt (Ser-473), R=0.425, p<0.0001 (figure 47).
Scatter plot of PI3K cytoplasmic scores 
correlated against Akt 1 cytoplasmic scores
Ê  100I k A -7. JL
Akt1 cy toplasm ic h is to sco res
Figure 47. Scatter plot o f P13K cytoplasmic histoscores correlated against Akt 1 
cytoplasmic histoscores
130
Scatter plot of PI3K cytoplasmic scores
correlated against Akt 3 cytoplasmic scores
Ê 100i
Akl3 cy top lasm ic h is to sco re s
Figure 48. Scatter plot o f P BK  cytoplasmic histoscores correlated against Akt 3) 
cytoplasmic histoscores
Scatter Plot of PI3K cyt scores correlated 
with pAkt(473) cyt scores
'.v:.
P-Akt (473) cy top lasm ic  h is to sc o re s
Figure 49. Scatter plot o f P B K cytoplasmic histoscores correlated against pAkt (473) 
cytoplasmic histoscores
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3.11 FISH for HER2 
3.11.1HER2 Am plification
For analyses of HER2 gene amplification, 70 out of 456 (15.4%) cases were 
unavailable for analysis either due to core loss, poor penetration o f probe or 
insufficient tumour material in cores and these patients were therefore excluded from 
further analysis. The number of orange (HER2) and green (chromosome) signals were 
counted in 20 cells of each TMA core (a total of 60 cells per pations). The ratio of 
green to orange signals was calculated. A ratio greater or equal to 2.0 was counted as 
an amplification. All of the cores were double scored by T.K achieving an ICCC of 
0.93 (excellent). 26 cores showed amplification of Her 2.
200
100 -
I  S td  D ev =
N = 3 86  00
s t  98
H E R2 FISH
Figure 50. Histogram showing the distribution of amplifications for Her 2FISH 
(curve shows normal distribution)
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3.11.2Her 2 and patient outcome
There was no significant correlation between OS and DFS and Her 2 amplification in 
this patient cohort.
Survival Category P Value
Overall survival 0.6691
Disease free survival 0.5420
Disease free survival on tamoxifen 0.8758
Disease free survival off tamoxifen 0.2817
Disease free survival after 3 years 
tamoxifen
0.1696
Overall survival after 3 years tamoxifen 0.6287
Table 18. OS and DFS p-values fo r  Her 2 amplification binary scores
3.11.3 Correlations between Her 2 and other members of the 
PI3K/Akt pathway
When the HER2 FISH binary scores were correlated with the HER2 herceptest binary 
scores significant correlation was seen (CC=0.307, p<0.0001). HER2 Herceptest was 
taken as positive if 2+.
Correlations
Her2 
m em brane 
binary sco res
Her2 fish 
binary
S pearm an 's  rank Her2 m em brane Correlation Coefficient 
binary sco res  gjg (s.taiied)
N
Her2 fish binary Correlation Coefficient 
Sig. (2-tailed)
N
1.000
395
.307(**)
.000
350
.307(**)
.000
350
1.000
355
** Correlation is significant at the  0.01 level (2-tailed).
Table 19. Table showing correlation between Her 2 FISH binary scores and 
Herceptest binary scores.
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Herceptest score Her 2 FISH 
amplified
Her 2 FISH not 
amplified
Total
0 0 275 275
1 6 40 46
2 4 21 25
3 16 8 24
Total 26 344 370
Table 20. Table showing the correlations between the various Herceptest and FISH 
scores.
There was a 100% correlation between those cases with a herceptest score of zero and 
no amplification with FISH. There were 6 cases that were amplified with FISH but 
only Herceptest 1+. Of the 25 HER2 2+ cases only 4 were amplified with FISH. Out 
of the 24 HER2 3+ cases 8 were not amplified with FISH.
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3.12 FISH for PI3K
3.12.1 PI3K amplification
Initially, PI3K was only analysed in TMA B. If the percentage of PI3K amplifications 
had been above 10%, then the whole data set would have been analysed for PI3K 
gene alterations. For analyses of PI3K, 57 out of 119 (47.9 %) cases were unavailable 
for analysis either due to core loss, poor penetration of probe or insufficient tumour 
material in cores and these patients were therefore excluded from further analysis. 
The number of red (PI3K) and green (chromosome) signals were counted in 20 cells 
of each TMA core (a total of 60 cells per patient). All of the cores were scored by 
E.C, with 20% being double scored by F.C achieving an ICCC of 0.90 (excellent). 
The ratio of green to red signals was calculated and a ratio of greater or equal to 2.0 
was counted as an amplification. Out of the 62 samples analysed only two were 
amplified
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3 .1 3  FISH for PTEN
3.13.1 PTEN deletions
Like FISH for PI3K, PTEN FISH was only analysed in TMA B. For analyses of 
PTEN, 55 out of 119 (46.2%) cases were unavailable for analysis either due to core 
loss, poor penetration of probe or insufficient tumour material in cores and these 
patients were therefore excluded from further analysis. The number of red (PTEN) 
and green (chromosome) signals were counted in 20 cells of each TMA core (a total 
of 60 cells per patient). The ratio of red to green signals was calculated and a ratio of 
less than or equal to 0.8 was counted as a deletion. All of the cores were scored by 
E.C and 20% of the cores were double scored by F.C achieving an ICCC score of 0.94 
(excellent)
Out of the samples analysed only 3 were found to have deletions of PTEN.
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Chapter 4 Discussion
4.1 PTEN
The PTEN data presented here shows that a high cytoplasmic PTEN expression is 
associated with a decreased overall (p=0.013, log-rank test) and disease free (p=0.018, 
log-rank test) survival. This is in contrast to the perceived wisdom(Panigrahi et al., 
2004b; Lu et al., 1999; Sansal and Sellers, 2004) that loss of PTEN leads to an 
activation of AKT, which in turn promotes anti-apoptosis, essential in 
tumourogenesis. In a study by Depowski et al(Depowski et al., 2001 a)looking at the 
tumours of 151 women a loss rate of 48% was seen and they found that loss of PTEN 
was associated with disease related death in univariate analysis. However the 
association was lost in multivariate analysis against known prognostic markers. In a 
study looking at several series of sporadic breast cancers(Perren et al., 1999a) the 
PTEN mutation frequency was less than 5%. In IHC analysis of the same tumours 
15% were PTEN negative and 18% showed absent or reduced expression. This is in 
line with our data showing 18% had no PTEN expression and 22% reduced or absent 
expression. Another study on primary operable breast cancers(Panigrahi et al.,
2004c).showed no association between patient, tumour and outcome variables such as 
tumour grade. No association of PTEN expression and overall survival was noted , 
supporting our data that showed no association between PTEN expression and overall 
or disease free survival in multivariate analysis. This study suggests that loss of PTEN 
is infrequent and argues against the current model of a simple linear tumourigenic 
PTEN-PI3K-AKT-mTOR pathway in breast cancer. Our data however shows a 
positive link between high levels of PTEN and reduced survival after 3 years of 
tamoxifen treatment -  a late effect (in multivariate analysis against known prognostic
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indicators, p=0.01). We found both cytoplasmic and nuclear PTEN expression but 
only cytoplasmic PTEN expression was significant associated with both OS and DFS. 
Chung et al(Chung and Eng, 2005) have suggested that subcellular localization of 
PTEN may regulate its function. They found that cytoplasmic PTEN down-regulates 
phosphorylation of Akt and up-regulates p27(kipl), whereas nuclear PTEN down- 
regulates cyclin D1 and prevents the phosphorylation of MAPK. They also observed 
that nuclear PTEN is required for cell cycle arrest, but that cytoplasmic PTEN is 
required for apoptosis. They concluded that nucleai-cytoplasmic partitioning 
differentially regulated the cell cycle and that nucleai- import of PTEN may play a role 
in carcinogenesis. To further clarify the role of PTEN in cai'cinogenesis, we intended 
to look at the expression and localisation of phospho-PTEN (activated PTEN) but 
unfortunately we were not able to find an antibody that was specific in IHC. Another 
small study(Bose et al., 2002b) (34 patients)showed a PTEN loss rate of 38%. The 
study found an association between reduced PTEN expression and stage and ploidy. 
Initially it was thought that PTEN mutations were the key to disease progression, 
however the PTEN mutation rate in sporadic breast cancer is around 5%(Perren et al., 
1999b), and this is also confirmed in analysis of breast cancer cell lines (Li et al., 
1997a). In hereditary cancer syndromes such as Cow den disease the rate is much 
higher(Liaw et al., 1997b). We did not assess the mutation rate in our tumours as this 
theory seems to have been discredited with numerous studies showing a low rate of 
mutation in sporadic cancers(Liaw et al., 1997a; Perren et al., 1999c). There was also 
a series of studies(Bose et al., 2002a; Leslie and Downes, 2004) looking at loss of 
heterozygosity within the PTEN gene -  the small study by Bose et al showed no 
correlation with reduced PTEN expression. It seems clear that mutation or loss of 
hererozygosity alone is not sufficient to reduce PTEN expression. Our data further
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adds to the confusion around PTEN by showing significant associations between high 
levels of PTEN expression and overall and disease-free survival. It would be 
interesting to look at the level of loss of heterozygosity in the tumour samples we 
analysed.
There is evidence(Garcia et al., 2004a; Perren et al., 1999d; Salvesen et al., 2001; 
Soria et al., 2002; Bay lin and Herman, 2000) that expression of tumour suppressing 
genes can be greatly decreased in some tumours by promoter méthylation and it has 
been a matter of debate if this is the case for PTEN. To further investigate the 
hypothesis that méthylation of PTEN could be responsible for lack of expression, we 
are currently doing méthylation studies on a similar cohort of tumours. There are no 
studies in the literature looking at FISH for PTEN. Our pilot study looking at PTEN 
deletions using FISH showed so few deletions that it was not considered worthwhile 
performing FISH on the whole tumour cohort so further comment cannot be made. In 
view of the differing results associated with decreased PTEN expression, ranging 
from a positive, to no effect through to a negative effect on overall or disease free 
survival, it is still controversial if PTEN is a prognostic maiker and further and larger 
studies need to be performed. It may be that the current model of a simple linear 
tumourigenic PTEN-PBK-AKT-mTOR pathway in breast cancer is not so simple 
after all and has many other areas of crosstalk and interaction.
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4.2 Bad, Bax, Bcl-2 and Bcl-xl
In the current study we report that patients whose tumours have high Bad expression 
have a significantly increased DFS when compared to those with low expression, in 
univariate analysis. This supports our hypothesis that high levels of Bad result in the 
sequestration of Bcl-2/Bcl-xl which allows Bax:Bax homodimerisation leading to a 
higher apoptotic index and improved DFS. Our results show an association between 
over-expression of Bad and DFS. This appears to be a late effect, which has greater 
significance after three years of tamoxifen treatment but is not significant in 
multivariate analysis (p=0.083). We have also shown ans association between over­
expression of Bad and improved OS after 3 years Tamoxifen treatment (p=0.010) but 
again this is not significant in multivariate analysis. In the current climate of debate 
about switching endocrine treatment from tamoxifen to aromatase inhibitors it would 
appeal' that further studies of Bad in a larger patient population are warranted 
Increased expression of Bad leads to increased sequestration of Bcl-2 
(heterodimerisation) and therefore increases the amount of available Bax to promote 
apoptosis. The improved disease free survival after three years on tamoxifen in those 
tumours with increased expression of Bad is interesting in the context of the 
Intergroup Exemestane Study (lES) trial. The lES trial was designed to investigate if 
there was a survial advantage in giving postmenopausal women Exemestane after 2-3 
years of tamoxifen therapy as compared to continuing tamoxifen therapy for 5 years. 
Exemestane therapy after 2-3 years of tamoxifen therapy significantly improved 
disease free survival as compared with the standard 5 year of tamoxifen treatment. 
Overall survival was not initially significantly different between the two groups 
(Coombes et al., 2004a) however it was in a later update of the trial.
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Previous in-vitro studies suggest that long term treatment with tamoxifen modulates 
the expression of apoptotic key genes impairing the apoptotic response of MCF-7 
breast cancer cells(Treeck et al., 2004a). In this study we performed Western Blots 
using cells treated with oestrogen alone, heregulin alone and oestrogen and heregulin 
combined and found no changes in the expression levels of Bad, Bcl-2, Bcl-xl and 
Bax. In contrast, stimulation with heregulin alone or in combination with oestrogen 
induced phosphorylation of Bad at Ser 112 whilst oestrogen alone had no effect. 
Expression of pBad (ser 112) positively correlated with apoptosis (as measured by 
TUNEL assay), however this correlation was shown to be mainly due to the 
signigicant number of negative results when a scatter graph was drawn. As there aie 
multiple phosphorylation sites on Bad and the literature suggests that more than one 
site is reqiured to be activated to prevent apoptosis it is perhaps not particularly 
surprising that pBad (ser 112) alone is not associated with DFS/OS.
In vitro studies have shown that oestrogen-mediated phosphorylation of Bad prevents 
apoptosis(Fernando and Wimalasena, 2004d). The ability of oestrogen to prevent 
apoptosis was blocked by over expression of Bad where the phosphorylation sites 
have been mutated (S112A/S136A) but not by the wild type Bad. Bad S 112A/S136A, 
which lacks the phosphorylation sites, was not phosphorylated in response to 
oestrogen in vi7ro(Fernando and Wimalasena, 2004c).
The anti-apoptotic proteins Bcl-2 and Bcl-xl aie thought to play important roles in 
inhibiting mitochondria-dependent pathways(Kim, 2005b). Some studies suggest that 
these two proteins have distinct functions for inhibiting extrinsic and intrinsic cell 
death pathways. The over expression of Bcl-2 has been shown to be associated with 
cell cycle arrest in the G1 phase, which may promote cellular senescence. The over 
expression of Bcl-2 may also have the ability to enhance cell death in the interaction
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of Bcl-xl with other factors(Kim, 2005c). Consistent with our findings an earlier study 
looking at the prognostic significance of p53, Bcl-2 and Bax expression in early breast 
cancer(Linjawi et al., 2004c), did not find a correlation between Bax or Bcl-2 and OS 
or DFS. However Bcl-2 correlated significantly with favourable tumour features such 
as DNA diploid status and expression of oestrogen and progesterone 
receptors(Linjawi et al., 2004d). This has also been seen in other studies(Baccouche et 
al., 2003a).Our results do not demonstrate a link between expression of Bcl-2 and 
Bcl-xl and apoptosis measured by TUNEL experiment. Possibly due to the interaction 
of these proteins with Bad being complicated and involving cross talk with other 
pathways (in addition to PI3K/Akt and Ras/RAF-1).
Imbalance between pro-apoptotic and anti-apoptotic proteins, causing altered 
apoptosis, may lead to tumour development and tumour progression, and reduced 
response to adjuvant therapy (Cameron et al., 2000b). Our results do not demonstrate a 
link with Bcl-xl and Bcl-2 and OS or DFS.
Whilst this study represents one of the larger cohorts used to investigate apoptotic 
mai'kers, it failed to clearly identify a predictive marker of response in this cohort. 
This may be related to the low event rate (22% over >10 years) in this low risk 
population. Results form the literature suggest that reduced expression of Bax 
(p=0.03) and Bcl-2 (p=0.03) was associated with lymph node metastasis in 
multivariate analysis(Bukholm et al., 2002a). Expression of Bcl-2 was associated with 
better patient survival in univariate analysis (p=0.04) but lost its predictive value in 
multivariate analysis (p=0.2) (Cameron et al., 2000a). Both this previous study and 
our own are suggestive of a link between apoptotic proteins and patient outcome. 
Based on our data (and that from the literature on Bax/Bcl2), it is now possible, for 
the first time to estimate the appropriate sample size to definitively test this. Based on
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an assumption that the hazard ratio for the Bad cytoplasmic binary scores, adjusted for 
nodal status, tumour size and grade remains unchanged with increased patient 
numbers, the required patient population is estimated to be 1100 (for an 80% powered 
study).
Here we highlight a possible link between the apoptotic parts of the PBK/Akt/mTOR 
pathway by linking Bad expression to disease free survival of tamoxifen treated breast 
cancer patients. It would be interesting to test these markers in a larger data set to see 
if low Bad expression is a marker of late (after 3 yeai's), relapse of breast cancer. In 
this centre we are currently constructing a TMA that will consist of tumour samples 
from 1700 patients to allow us to further test this hypothesis.
143
4.3 pP90RSK (Thr 359/Ser 363)
In this study we report that phosphorylated P90RSK (Thr 359/Ser 363) expression is 
not associated with changes in OS or DFS in this patient cohort 
P90RSK expression is not widely reported in the literature, and the data from the 
current study does not support a role for phospho-P90RSK influencing patient 
survival. Activated (phosphorylated) p90RSK phosphorylate Bad at Seri 12 and 
thereby influence apoptosis (Harada et al., 2001b). The majority of studies (Tan et al., 
1999b; Fernando and Wimalasena, 2004b; She et al., 2005a; Bonni et al., 1999b) 
reporting on the relationship between P90RSK and phospho- Bad are therefore also 
looking at the phosphorylation of Bad at Seri 12 by P90RSK and the effect on 
apoptosis and not the expression of P90RSK per se in breast cancer. The 
literature(Tan et al., 1999a; Fernando and Wimalasena, 2004a; She et al., 2005b; 
Bonni et al., 1999a) suggests that P90RSK phosphorylates Bad at Seri 12, and we also 
found a correlation, although weak, between pP90RSK expression and Bad 
phosphorylated at Seri 12. That expression of p-P90RSK also correlates with 
phospho-MAPK (CC=0.231, p<0.0001) also fits with the proposed structure of the 
EGFR/MAPK pathway. That both P70S6K and P90RSK phosphorylate Bad (at sites 
ser 136 and 112 respectively) and that both are needed to maximally prevent the 
apoptotic action of Bad indicates that they are unlikely to be the control steps in the 
process. Other studies have shown that there are other phosphorylation sites on Bad 
that may be important(Berndtsson et al., 2005; Dramsi et al., 2002; Tan et al., 2000b). 
The role of these sites has however, not been fully established. In this study we have 
only investigated a single phosphorylation site on p90RSK, however, to more fully 
assess the role of Bad it would be necessary to look at all of the phosphorylation sites 
alone and in combination as activation of Bad may require a specific sequence of
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phosphorylation. Again the current model of the PI3K/Akt and MAPK pathways may 
be too simplistic with a greater degree of crosstalk than previously thought
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4.4 P70S6K/pP70S6K (Thr 389)
In this study we found that there was no significant correlation between expression of 
either P70S6K or pP70S6K (Thr 389) and overall or disease free survival. This is in 
contrast to an earlier study (Lin et al., 2005a) showing that pP70S6K was increased in 
primai'y breast cancers and missing in normal breast epithelial tissues. In this study, 
enhanced phosphorylation was positively associated with disease progression from 
normal breast epithelial tissue to invasive breast caicinoma (p<0.05)(Lin et al.,
2005c). In line with our data showing 52% P70S6K over expression, 56%of the breast 
tumours from this study had p70S6K over-expression The RPS6KB1 gene encodes 
for the mTOR effector P70S6K and is amplified in approximately 10% of breast 
cancers(Barlund et al., 2000b; Andersen et al., 2002a). RPS6KB1 gene amplification 
has been found to correlate with Her2 over expression in breast tumours possibly due 
to co-amplification of RPS6KB1 with Her2 (both genes reside on 17q). In another 
study(van der Hage et al., 2004b) that looked at 452 node negative tumours from pre­
menopausal women (drawn from the EORTEC trial) over-expression of P70S6K was 
found to be associated with an increased risk of loco-regional recurrence (HR 2.50, 
95% Cl 1.30 -  4.8, P=0.006) and distant metastasis (HR 1.80, 95% Cl 1.08 -  3.01, 
p=0.025). On multivariate analysis over-expression of P70S6K was independently 
predictive for loco-regional recurrence only (HR 2.67, 95% Cl 1.39 -  5.14, p=0.003). 
It also found a significant association between p70S6K and Her2 expression (p=0.01). 
This was not borne out by our study in which there was no significant correlation 
between the two. It is known that P70S6K is important for cell growth and survival. 
Activation of P70S6K requires sequential phosphorylation of multiple serine and 
threonine sites often triggered by growth factors and hormones (Le et al., 2003). In a 
study by Le et al Paclitaxel was found to induce phosphorylation of P70S6K at Thr
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421 and Ser 424 in a time and concentration manner. Phosphorylation at these sites 
caused INACTIVATION of P70S6K. Paclitaxel did not induce phosphorylation at 
sites Thr 389 and Ser 411. Phosphorylation of these sites leads to activation of 
P70S6K. Inhibitors of mTOR impair P70S6K activity. Inhibitors of PKC and INK 
prevent paclitaxel induced P70S6K inactivation. We looked at the phosphorylation of 
P70S6K at Thr 389 -  this is an activation site. As there are many phosphorylation 
sites on P70S6K it may be that there is a specific sequence of activation and that the 
site we looked at is not the rate limiting site. Rapamycin has been found to inhibit 
mitochondrion bound P70S6K, this prevents the phosphorylation of Bad at Ser 136 
and hence blocked cell survival induced by insulin-like growth factor 1 (IGF- 
1)(Harada et al., 2001a). This proved that P70S6K signals cell survival as well as 
growth inactivating the pro-apoptotic molecule Bad. Unfortunately we were unable to 
obtain a pBad (ser 136) antibody. It would have been interesting to see how pP70S6K 
(Thr 389) over-expression correlated with expression of p-Bad (ser 136). When we 
correlated the expression levels of pP70S6K (Thr389) with p-mTOR there was a weak 
but significant correlation (CC 0.213, p<0.0001). This is supported by the literature 
that shows that elevated levels of pP70S6K (Thr 389) are indicative of increased 
mTOR activity(Klos et al., 2006). The same study also demonstrated that tumours 
with increased levels of pP70S6K expression were more likely to develop metastasis 
(p<0.05). This study looked at 155 tumour samples. Our results do not show any link 
with metastasis and over-expression of pP70S6K although there is a trend toward 
significance for recurrence after 3 years Tamoxifen treatment in patients with elevated 
levels of phosphorylated P70S6K (p=0.085). Although our study did not find any link 
between expression of P70S6K and pP70S6K (thr 389) it did find similar levels of 
over-expression in tumour cells. It is becoming increasingly apparent that the
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PBK/Akt pathway is not a simple linear pathway and that there are feed back loops 
and cross talk involved. Activation of P70S6K involves multi-site phosphorylation 
and phosphorylation of some sites (Thr 421 and Ser 424) causes inactivation. More 
work needs to be done on the sequence of activation of these sites and the role of 
feedback loops before this part of the pathway is fully understood.
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4.5 PI3K
In this study we have investigated the role of PI3K in mediating tamoxifen resistance, 
and found no association between over expression of PI3K and disease free or overall 
survival.
In addition we also investigated a subset of the patients for genetic changes (gene 
amplifications and deletions) of PI3K and observed only 2 (3.2%) tumours with PI3K 
gene amplifications The literature suggests that the PI3K is amplified in breast cancer 
however no studies have suggested a role for PI3K as predictive marker of hormone 
relapse. Mutations in the PIK3CA gene which encodes the PI3K p i 10a catalytic 
subunit are seen in 20-40% of breast tumours(Crowder and Ellis, 2005; Samuels and 
Velculescu, 2004b; Bachman et al., 2004b; Campbell et al., 2004b; Saal et al., 2005c). 
This study was not set up to look at the levels of PI3K in breast tumour cells 
compared with normal tissues -  we were looking specifically at ER positive tumours 
and looking for proteins that would be predictive of relapse on hormonal treatment. 
One study involving a large cohort of breast tumour samples(Saal et ah, 2005a) 
reported that PIK3CA mutations are mutually exclusive with PTEN loss, and that 
PIK3CA mutations correlate with Her2 expression and ER positive status in breast 
tumours although similar correlations were not seen in other studies involving smaller 
sample sizes (Crowder and Ellis, 2005; Bachman et ah, 2004a; Saal et ah, 2005d) 
Considering the small number of cases where genetic status for both PTEN and PI3K 
were investigated, PTEN loss and PI3K amplification were mutually exclusive though 
it should be noted that the small number of cases prevents this from being anything 
more than an interesting observation. We also did not look at PI3K mutation just 
amplification. Looking at the IHC data for Her 2 and PI3K expression there is no 
association between Her 2 and PI3K over-expression. Activated PI3K generates
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membrane bound phosphoinositides which act as second messengers and serve to 
recruit second messengers such as Akt(Thompson and Thompson, 2004b). PI3K has 
also been found to act as a viral oncoprotein(Thompson and Thompson, 2004d;
Chang et ah, 1997). Previsouly, we found that Akt activation predicts outcome in 
breast cancer patients treated with tamoxifen (Kirkegaard et ah, 2005a). PI3K is 
crucial for the activation of Akt via the production of membranous phosphoinositides 
, which phosphorylate (activate) Akt. . AKT is first phosphorylated at Thr 308 but 
additional phosphorylation at Ser 473 is necessary for full activation(Luo et al., 
2003b). Supporting the pathway we found that PI3K protein expression significantly 
correlated with pAkt (Ser 473). Looking at the mechanism of PI3K and its 
involvement at the initial stages of the PI3K/Akt pathway it is more likely that 
amplification/over-expression of PI3K is involved in initial oncogenic transformation 
rather than being related to hormonal resistance. The therapeutic use of PI3K is more 
likely to be as a target for prevention of activation of the PI3K/AKT pathway and 
indeed there is ongoing research into this area(Daub et ah, 2004). It is increasingly 
being thought that there is a negative feedback loop in the PI3K/AKT 
pathway(Manning, 2004b). It is thought that this loop involves S6K protein inhibiting 
1RS proteins, which in turn inhibit PI3K. This leads to the question of whether 
inhibition of mTOR (with Rapamycin) could have a detrimental effect on tumours. A 
further area of study would be to look at PI3K activation and the association between 
activated Akt and PI3K. Previous results do not suggest that PI3K is likely to prove 
predictive for hormone resistance in breast cancer. Our results do, however support 
the current model of the PI3K/AKT pathway.
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4.6 Her2 FISH
Her 2 gene amplifications taken as a single marker did not have a role in predicting 
overall or disease free survival in this patient cohort of tamoxifen treated breast 
cancer patients. It should be noted that our cohort of tumours were low malignant as 
shown by the total number of events (74 deaths). There is a fair correlation between 
FISH and the herceptest but these results show that some Her 2 positive cores may be 
missed by the accepted practice of performing FISH on all Her 2 2+ cores only. There 
may also be some false positives with the Her 2 3+ cases. In the published literature 
Bartlett et al (Bartlett et al., 2001) compares herceptest with FISH and CBl 1 IHC. 
12.6% of the tumours were positive using herceptest (2+/3+), 19.4% were positive 
using FISH and 28.5% were positive using CBl 1 IHC. Two experienced scorers 
scored all the tumours and the IHC methods were more susceptible to intra-observer 
variation (k =0.67 and 0.74 for the herceptest and CBl 1 respectively) than FISH ( k =  
0.973). Overall test accuracy for CBl 1 IHC was 83.8%, herceptest was 87.1% and 
FISH was 93.2%. FISH predicted pl85 Her 2 overexpression (determined by 
quantitative IHC) (concordance index 0.90) better than CBl 1 IHC (0.85 or herceptest 
(0.81). Of the 42 cases with gene amplification measured by FISH, 67% were positive 
with the herceptest (2+/3+). Of the 174 cases negative by FISH, 96% were negative 
when using the herceptest. Another study(Birner et al., 2001)showed that of 35 cases 
that had gene amplification by FISH, 97.1% were positive with the herceptest 
(although interestingly no cases were scored as 2+ that were also FISH positive). Of 
the 172 cases negative by FISH 76.2 % were negative with the herceptest. 16.9% of 
the tumour specimens analysed by FISH showed amplification of Her 2, 26.8% were 
overexpressed with the Herceptest (2+ or 3+). The Her2 herceptest data from our 
group shows 13.4% positivity 2+ or 3+) whilst with FISH I have a positivity rate of
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7%. Of the 26 cases with gene amplification by FISH 76% were positive with the 
herceptest (2+ or 3+). Of the 344 cases negative by FISH, 92% were negative with the 
herceptest. Another study(Press et al., 2002) found the accuracy of Vysis FISH to be 
97.4% and that of the herceptest to be 88.9%. In a correlation(Dowsett et ah, 2003) 
between immunohistochemistry (HercepTest) and FISH for Her 2 in 426 breast 
carcinomas from 37 centres 0.7% of IHC 0/1+ tumours were FISH positive and 5.9% 
of IHC 2+ were FISH negative. The results from our tumour group are similar for the 
Her 2 0/1+ group, 1.8% were FISH positive. However many more of the 3+ group 
were FISH negative (33%). 48% of the study’s Her 2+ tumours were FISH positive 
compared with 16% of mine. With Dowsett et al’s study 29% of their tumours 
showed gene amplification with FISH compared to 7% of mine. It has been shown 
that Her2 neu gene amplification or over expression predicts shorter disease free or 
overall survival in both axillary lymph node negative(Gusterson et ah, 1992) and node 
positive breast cancer(Slamon et ah, 1987a; Slamon et ah, 1989; Slamon, 1990). In a 
study from Nottingham(Abd El-Rehim et ah, 2004a) 31.8% of the tumours studied 
were Her 2 positive. Her 2 had an independent prognostic effect on overall and 
disease free survival however in lymph node negative patients it lost its predictive 
power for overall survival but still predicted disease free survival. This study used 
IHC on TMAs. It has been shown(Zhou et ah, 2000a) that HerZ/nan constitutively 
activates the Akt/NF-xP anti-apoptotic cascade to confer resistance to TNF on cancer 
cells and to decrease host defences against neoplasia. Tovey et al(Tovey et ah, 2005a) 
showed that Her 1-3 (but not Her 4) over expression predicts for early relapse on 
tamoxifen (p=0.0060). PR negative cancers were also more likely to relapse on 
tamoxifen (p=0.017). Her 1-3 positive and/or PR negative patients combined as a 
‘high risk’ group were significantly more likely to relapse on tamoxifen. This applied
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to early relapse only, as any relapse after 3 years of tamoxifen treatment was 
unrelated to PR/Her status. The data for Her2 FISH does not show any significant 
correlation between gene over expression and OS or DFS, despite the fact that the 
same tumour set was used in both studies. Following publication of the first large 
multi centre trial of adjuvant Herceptin(Piccart-Gebhait et ah, 2005b) which showed a 
significant improvement in disease free survival in Her2 positive breast cancer 
patients it is now increasingly important to accurately identify those patients who are 
likely to benefit from treatment with Herceptin. The current standar d of HercepTest 
on all tumours followed by FISH of all Her2 2+ tumours has been shown to be 
accurate however there will always be some patients who are either falsely positive or 
negative. The HercepTest has greater intra-observer variation than FISH and it may 
be possible (and financially viable) in the future to FISH all specimens, as missing out 
on a highly effective treatment is obviously undesirable (false negatives) as is being 
exposed to a potentially dangerous drug if you are not going to respond to it (false 
positives). This is especially relevant in an increasingly well-informed and litigious 
society.
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Chapter 5
Conclusions
The importance of the main body of this work lies in the fact that there has been 
limited research so far, looking at the role of the distal part of the PI3K/Akt and Raf-1 
pathways in hormone resistant breast cancer. Most of the work in the published 
literature has looked at the more proximal end of the pathway or used cell line work to 
establish a hypothetical model for the pathway. We used a large (402) cohort of 
patients on whom we had pathological and survival data. I worked as part of a team 
looking at various proteins within the pathway and this enabled me to correlate 
expression levels of the proteins, I was investigating with others in the pathway. I 
have highlighted a possible link between the apoptotic parts of the PI3 K/Akt/mTOR 
pathway by linking Bad expression to disease free survival of tamoxifen treated breast 
cancer patients (and OS after 3 year's tamoxifen treatment). It would be interesting to 
test these markers in a larger data set to see if low Bad expression is a marker of late 
(after 3 years), relapse of breast cancer. In this centre we are currently constructing a 
TMA that will consist of 1700 patients that will allow us to further test this 
hypothesis. That the other proteins in the lower end of the pathway did not correlate 
with overall or disease free survival supports the hypothesis that the PI3K7Akt 
pathway is more complicated than first thought and unfortunately is not a simple, 
linear model and that crosstalk between the various steps in likely. The proteins 
looked at, have multiple activation sites and it is may be (as in the case of P70S6K) 
that it is the sequence of activation that determines the activity rather than simply the 
levels of phosphorylated and unphosphorylated proteins.
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Increased PTEN expression was shown to be significantly associated with decreased 
OS and DFS. This association was maintained in multivariate analysis for DFS after 3 
years Tamoxifen treatment. There are many conflicting reports in the literature (see 
chapter 4.2) ranging from increased expression having a positive effect on OS and 
DFS through to having no or (as in our results) a negative effect. Expression of PTEN 
does not seem to be a reliable prognostic marker and the role of PTEN remains poorly 
understood. Our group is in the process of starting méthylation studies on PTEN in 
the hope that the role of PTEN may be further elucidated.
The FISH studies on Her 2 did not show a significant correlation between gene over­
expression and OS or DFS. It should be noted that there is a low level of recurrence in 
the cohort we looked at. This result is interesting in the context of the results for 
HercepTest on the same cohort of tumours which showed a significant association 
between increased expression of Her 2 and reduced OS and DFS (Tovey et al.,
2004a). The current standard is to perform FISH on all samples that are 2+ using the 
HercepTest. According to my data using this approach, may miss some Her positive 
patients (false negatives) and expose others to a potentially dangerous drug (false 
positives). There is a greater degree of intra-observer variation with the HercepTest 
than with FISH and in an increasingly litigious society it may be possible and 
financially viable to perform FISH on all specimens.
From this study it has become increasingly clear that the PI3K/Akt pathway is not as 
simple as first thought. It is likely that IHC and FISH alone are not going to be 
adequate to fully investigate it and that further cell line work and alternate 
investigations such as méthylation may be required. The phosphorylation sites of the 
individual proteins need to be more closely examined and the degree of cross-talk
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between the Pi3K/Akt and Raf-1 pathways need to be more fully investigated. 
Negative feedback loops may also play a role (Manning, 2004a).
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Appendix 1
Patient Clinical & Pathological Variables
Number/Total %
GRADE 1 99/391 25.32
2 193/391 49.36
3 99/391 25.32
Unknown 11
NODAL STATUS 0 193/369 53.1
1-3 107/369 29.1
4+ 69/369 17.8
Unknown 33
Size T1 (<20mm) 154/380 40.53
T2 (20-50mni) 204/380 53.68
T3 (>50mm) 22/380 5.79
Unknown 22
NPI <3.5 128/344 37.21
3.5-5.5 106/344 30.81
5.5+ 110/344 31.98
Missing 58
AGE <50 years 73/402 36.5
>50 years 328/402 63.5
Grade = Bloom and Richardson grade 
Nodal Status = Number of positive nodes
NPI = Nottingham Prognostic Index = (size in cm)0.2 + Grade + Nodal Status
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Appendix 2
Raw data for Her 2 FISH and Bcl-2, Bax, pBad (Ser 112), Bcl-xl, pP70S6K (Thr 
389), P70S6K, PI3K and pP90RSK (Thr 363/Ser 359) histoscores
Key:
Path no. 
Her 2 F 
PTEN n 
PTENc 
Bcl-2 c 
Bax c 
Bad c 
pBad c 
Bcl-xl c 
pP70S6K 
P70S6K n 
P70S6KC 
PI3K 
pP90RSK
Pathology number
Her 2 FISH scores
PTEN nuclear histoscores
PTEN cytoplasmic histoscores
Bcl-2 cytoplasmic histoscores
Bax cytoplasmic histoscores
Bad cytoplasmic histoscores
pBad (Ser 112) cytoplasmic histoscores
Bcl-xl cytoplasmic histoscores
pP70S6K nuclear histoscores
P70S6K nuclear histoscores
P70S6K cytoplasmic histoscores
PI3K cytoplasmic histoscores
pP90RSK cytoplasmic histoscores
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Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
8008137. 0 0 20 0 14 8 13.33
8207635 0.96 10 33 35 66 94 4 124
8304707 0.98 65 75 11 58 96 8 116
8310775 0.98 10 13.33 60 13 72 0 41
8400199 1.02 45 36.67 129 70 142 60 87.5
8400387 1.23 0 16.67 97 0 34 0 112.5
8408902 0.96 35 10 36 14 54 0 93.33
8501076 0.89 0 15 23 35 86.67 13 145
8505021 1.25 16.67 33 74 6 95 4 47
8505709 0.97 60 60 28 30 20 6 73.33
8507604.
8507901 1.16 40 36.67 0 51.67 133.33 13 141.67
8510490 1.11 35 36.67 33 33 87 53 175
8610595 1.01 75 50 98 30 96 62 91.25
8612132 1.06 20 60 0 55 56.67 35 143.33
8700790 1.06 5 45 53 0. 0 112.5
8701087 2.11 68.33 93.33 87 89 90 84 91.25
8704950 1.04 0 50 7 0 60 43 165
8705943 1.15 0 0 60 40 48 0 65
8706410. 0.
8708872 0.85 0 0 10. 36.67. 110
8709046 1.17 70 56.67 33 45 80 28 23.33
8709490 1.24 13.33 26.67 30 17 55 12 117.5
8711800 1.02 20 30 0 10 33.33 3 150
8800033 1.13 55 70 44 42 110 100 72.5
8802163 0.99 20 10 80 0 24 7 10
8803618. 55 50. 33.33.
8804484 1.05 73.33 90 85 0 0 0 111.67
8806919 1.2 0 20 50 60 10 0 150
8808120 1.19 0 0. 33 134 32 106
8808858 1.06 66.67 110 112 82 153 6 140
8809213 1.02 10 30 0 33 93 40 190
8900716 1.2 36.67 56.67 126 90 101 47 98.75
8901273 1.13 93.33 190 95 97 56.67 67 195
8901400 1.15 81.67 140 113 43 23.33 37 166.67
8904878 1.13 10 25 42 30 74 57 35
8907245 1.17 80 120 20 40. 40
8907716 1.55 5 0 17 60 7 43 190
8908418 1.27 78.33 66.67 128 0 0 0 176.67
8909319. 2.5 5 30 10 20 20.
8909417. 52 28 0
8909430 1.12 80 123.33 153 26.67 10 7 166.67
8910355 0.9. 0 7. 0 110
8910865. 0.
8911078. 0. 53.
8911083 1.29 25 95. 0
8911515. 25 110 74 15 42 116 72.5
8912036.
9000072. 0 0. 43.33 0 0.
Î
■
ii
ris,:
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Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9000073.
9003516 2.64 16.67 30 66 26 66 4 37.5
9003988 0.92. 0 33.33 50 0.
9004119 0.95 50 75 7 13 70 10 190
9004589 1.09 96.67 136.67 140 7 66.67 0 125
9005059 1.06 93.33 93.33 80 0 180 33 205
9005575 1.09 70 126.67 95 10 93.33 10 156.67
9005576 1.1 11.67 128.33 20 43.33 0 3 156.67
9005607 1.25 23.33 43.33 76 40 96 4 82.5
9006603 1. 20.
9006722 1.1 85 170 104 90 60 0 153.33
9007890 1.08 25 25 17 3.33 53.33 17 182.5
9007905 1.07. 20 60 50 40 200
9007996 1.12 0 33 44 34 82 4 116.25
9010055 1.14 16.67 33 179 34 58 4 71.25
9010281 1.17 0 0 0 0 33.33 0 150
9011029.
9011054 6.41 13.33 26.67 4 40 46 20 121.25
9011814 0.98 50 50 4 38 143 96 74
9012080 1.09 60 30 23 50 133 33 190
9100036. 150 50 0 23 37 17 175
9100823 1.03 33.33 16.67 20 14 92 12 82
9101094.
9101357 1.18 10 25 58 26 134 82 70
9101891.
9102250 1.05 16.67 33 142 38 144 26 52
9102372. 0.
9102602 1.2 30 45 86 26.67 10 0 170
9102889 1.09. 55 10 105 42 82.5
9103112 1.15 3.33 23.33 132 68 107 35 81
9103262 1.08 0 0 0 33 50 0 170
9103744 1.39.
9104030. 0 0 0 17 50 0.
9104337 1.12 11.67 60 75 0 0 3 97.5
9105576 1.12 25 65 32 62 36 54 128.75
9106709 4.55 60 50 10 88 80 51 0
9106712. 0
9106880 1.09 0 50 48 4. 0
9107442 1.17 100 83.33 10. 150. 185
9108014 1.13. 10 90 5 73 4 76.67
9109046 0.97 0 0 17. 170
9109185 2.59 66.67 53.33 148 66 105 40 96.25
9109446 1.12 48.33 53.33 128 17 16.67 0 190
9109520 1.1 16.67 36.67 152 40 87 54 106
9110219 2.35 0 96.67 0 33.33 66.67 0 183.33
9110376 1.04 45 60 23 63 87 33 200
9110864. 130 150 13 67 67 67 205
9200106 1.26 30 40 4 70 144 29 110
9200946.
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Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9201756 1.13 0 43.33 130 7 84 8 130
9201866 1.2 10 25 150 88 134 78 141.25
9202007 1.05 0 0 13. 30. 215
9202261 1.1 52.5 95 103 0 0 3 190
9202681 0.98 0 0 17 40 73.33 8 200
9202922 1.1 81.67 123.33 70 17 123.33 95 106.67
9203176. 33.33. 0.
9203184 1.13 10 73.33 133 27 0 0 186.67
9203254 1.03 40 25 52 20 60 40 128.75
9203590 1.1 5 20 13 40 46.67 0 215
9203954 3.93 0 0 5 4 75 0 45
9204054 1.11 0 20 30 33.33 40 38 190
9204266 0.96 0 0 0 10 0 7 220
9204364 1.13 98.33 180 158 3 10 23 195
9204491 1.14 61.67 130 113 33 0 30 188.33
9204693 1.14 10 2.5 23 27 77 20 200
9204716 0.93 16.67 6.67 27 73 57 0 198.33
9204717 1.18 65 83.33 163 33 66.67 0 146.67
9205324 1.14.
9205594 1.11 100 115 35 0 0 0 185
9205687 1.02 21.67 35 0 13.33 116.67 0 200
9205835 1.14 0 0 17 20 53 50 205
9206189 0.99 0 30 28 4 69 0 33.33
9207128 6.96 6.67 26.67 67 96 132 89 139
9207359.
9207829 0.97 25 23.33 144 45 88 16 136
9208073 1.35 122.5 105 85. 36.67. 200
9208160 1.14 10 10 64 34 72. 33.33
9208255 0.97. 10 16.67 33.33 27 170
9208691 1.1 15 12.5 95 0 6.67 30 170
9208751. 0 0. 40. 0.
9208764. 0 50 0.
9208915 1.05 75 80 23 40 70 32 120
9209466 1.41 0 10 143 52 58 20 41.67
9209746 1.19 30 0 3 6.67 40 13 175
9210214 1.15 0 0 17 16.67 76.67 32 210
9210338 1.76 10 5 37 116.67 40 35 156.67
9211015 1.32 33.33 16.67 169 28 108 0 108
9211284 1.16 33.33 33.33 88 53 106 36 118
9211307 1.22 16.67 13.33 4 24 114 2 63
9300038 1.18 50 40. 10 30 4 78.33
9300203 1.2 75 115 5 44 82 68 105
9300414 1.21 40 100 138 92 139 122 95
9300505 1.06 0 10 7 20 86.67 0 195
9300517 1.11 30 0 0 33 80 0 200
9300806 1.03.
9300946 1.02 6.67 43.33 36 50 154 110 78
9301463 1.11 50 20 0 23 23 3 200
9301496 1.18 10 25 10 46.67 80 0 181.67
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Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9301709 1.16 33.33 23.33 136 62 67 34 47.5
9301742 1.11 25 25 68 0 38 12 37.5
9302004 1.21 3.33 10 37 46.67 96.67 30 183.33
9302281 1.3 30 30. 63 60 27 175
9303058. 7.
9303305 1.15 40 16.67 172 22 101 12 103.75
9303334 1.16 0 0 0 37 17 0 200
9303835 1.04 0 0. 0
9303848 1.02 92.5 75 30 16.67 66.67 0 170
9303995 0.97 58.33 73.33 146 60 152 20 106.25
9304892 1.04 57.5 77.5 0 33 43 63 200
9305263 1.05 45 75 158 13 0 37 178.33
9305697 1.07 55 35 33 70 46.67 20 200
9305719.
9305937 6.75 35 20 17 73 35 17 215
9305972 0.98 0 0 0 0. 0 200
9306294 6.49. 73 0 0 0 192.5
9306938.
9308293 0.93. 13. 0. 60
9308295 1.03 30 38.33 47 23.33 101.67 33 163.33
9309731 1.01 25 55 40 71 110 58 63.75
9309739 1.23 42.5 75 114 20 80 76 43.33
9310797.
9310816. 0 0 0. 0.
9310859 1.11 3.33 23.33 161 17 96 10 36
9311333. 0 30 40 0 37 0 36.67
9311343 0.99 51.67 80 114 108 138 46 97.5
9312194 1.11 63.33 70 133 3 23.33 0 115
9312208 1.13 3.33 23.33 152 14 122 19 94
9312498 6.69 40 23.33 120 8 82 25 100
9400251 1.15 35 25 20 0 13 10 170
9401076 1.06 43.33 46.67 5 73.33 50 60 198.33
9401443. 30 50 17.
9401646 1.08 30 35 13 53 67 43 207.5
9401940 1.48 10 40 104 17 6.67 0 148.33
9403539 1.11 0 10 92 35 86 20 26.67
9403796 1.14 98.33 93.33 32 63.33 43.33 60 177.5
9404046 1.05 100 100 0. 33.33. 157.5
9404065 1.41 113.33 90 156 37 53.33 53 180
9404346 1.18 47.5 50 77 40 56.67 33 142.5
9404349 1.08 0 0. 0 0 0 110
9404604 1.1 33.33 26.67 33 57 33 27 200
9405719 1.07. 0 33 0.
9405958 1.01 81.67 116.67 105 35 23.33 55 190
9405960.
9406536 1.05. 0. 0. 142.5
9406665 0.99 60 50 34. 64 2 26.67
9406692 1.1 28.33 33.33 134 27 135 12 48
9406790. 60 50. 16.67 36.67 0 215
183
Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9406805 1.12 23.33 26.67 153 51 178 82 106
9407111 1.16 46.67 66.67 190 86 202 100 137
9408178 1.14 102.5 125 0 20 56.67 70 205
9408557. 0. 0 3 17 10 205
9408685 5.56 80 50 0 23.33 60 13.
9409104 1.09 41.67 83.33 99 10 16.67 0.
9409109 1.05 100 130 10 33.33 16.67 23 170
9409112 1.11 75 50. 0 33.33 0 210
9409346.
9409784 1.04 45 25 0 43.33 50 0 190
9410051. 10 53.33 53 70 73.33 95 122.5
9410252. 0 25 27 0. 0 200
9410430 1.2 63.33 10 155 3 0 3 153.33
9410568 1.1 0 0 0 6.67 103.33 0 158.33
9410701 1.13 0 0. 0. 0 20
9410706 1.27 0 23.33 23 0 83.33 10 135
9410823. 0 0 0 0 100 3 130
9410890. 25 15 7. 200
9410906 1.04 0 0 17 0 50 0 92.5
9410953 1.04 35 150 113 17 0 3 190
9411100. 10 0 0 0 60 33 65
9411449 0.98 0 3.33 63 50 110 38 135
9411476 1.15 0 50 13 30 60 27 120
9411819 2.6 0 0 0 0 13.33 0 130
9412034. 0 0. 10 50 0 100
9412265 3.63 23.33 20 97 40 130 0 90
9412269 1.85 0 20 13 27 50 37 120
9412313 1.14 105 70 133 10 93.33 7 166.67
9412422 3.65 25 20 10 0 53.33 33 135
9412614 3.88 50 50 0 3.33 56.67 0 110
9413539 1.01 72.5 100 108 115 170 57 120
9500073. 20 140 33 37 0 0.
9500228 2.15. 0.
9500763 1.27 0 0 17. 170
9500955. 0 0 0 0 7 13.
9501106 6.42 68.33 80 118 20 46.67 3 141.67
9501108 1 40 20 47 53.33 66.67 55 70
9501958 1.01 43.33 33.33 0 7 90 17 113.33
9501978 3.2 20 16.67 37 67 113 67 170
9502003 3.9.
9502205 1.13 0 0 33 27 90 55 117.5
9502318 1.24 0 0 7 0 47 0 105
9502659 1.09 53.33 43.33 139 0 0 3 137.5
9502985 1.23 0 0 33 30 30 20 180
9503407 0.98 0 0 17 0 43.33 0 100
9503884 1.13 35 110 10 77 123 40 165
9504207 1.19 80 123.33 76 50 40 20 146.67
9504214 3.53 10 35 10 47 73 17 110
9504389 3.8. 160
184
Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9505535 1.15 20 16.67 93 0 66.67 37 100
9505600 1.16 31.67 16.67 92 13 50 7 130
9506010 0.95 26.67 33.33 67 10 43.33 0 110
9506050 1.12 0 0 33 0 33.33 33 110
9507243 1.11 50 70. 17 33.33 0 85
9507433. 2.5 0 17. 33.33 7 23.33
9507574 1.2 95 123.33 38 43 33.33 23 153.33
9507835 2.39 60 50 57 33.33 90 57 103.33
9509140 3.8 26.67 58.33 7 90 116.67 7 90
9510723. 85 96.67 90 63 153.33 20 72.5
9510764 1.14 0 16.67 33 35 100 27 90
9511536 0.99 30 46.67 100 77 80 10 125
9511736 8.03 16.67 53.33 13 67 103.33 0 101.67
9511896 1.12 0 0. 3 60 27 53.33
9512307 1.06 26.67 16.67 108 17 90 3 90
9512526 1.16 10 20 93 26.67 100 0 176.67
9512539 1.06 0 13.33 153 23 26.67 0 156.67
9512595 1.05 16.67 23.33 105 67 153.33 23 175
9513175 1.18 13.33 6.67 98 37 120 0 93.33
9514124 1.16 0 50 100 33 0 0 107.5
9514572 1.34 68.33 35 63 48 40 7 125
9600346 1.09 26.67 23.33 77 10 83.33 0 161.67
9601048 1.11 20 40 123 40 100 0 126.67
9601571 1.21 76.67 120 73 26.67 90 43 127.5
9601591 1.03 0 0 0 0. 0 90
9601927. 0 0 17 7 33.33 0 125
9602066 1.15 5 0 53 0 73 0 155
9602566. 55 165 133 23.33 16.67 0 142.5
9602691 1.1 23.33 20 30 0 153 3 161.67
9603454 1 20 50 20. 13. 200
9603840 1.18 30 25 0 67 187 3 160
9603856 1.29 15 30 0 36.67 93.33 57 130
9603877 1.14 0 20 20 27 67 0 210
9603882 1.44 0 10 63 7 97 0 153.33
9604092 1.08 16.67 0 13 0 67 0 106.67
9604189 1.25 5 0. 0.
9605089 1 75 86.67 154 33 20 0 158.33
9605413 1.05 30 20 20 3.33 73.33 33 140
9605556 1.78 3.33 43.33 0 32 160 0 196.67
9606350. 0 0 50 0 73 0 165
9607449 1.13 0 0 37 20 73.33 0 200
9608209 1.07 25 15 43 43.33 43.33 0 155
9608671 1.03 0 110 109 96 130 77 125
9609194 1.13 13.33 20 90 36.67 130 0 160
9609268 0.97. 0 0.
9609341 1.55. 0.
9609370 0.98 115 146.67 129 140 26.67 120 186.67
9610658 1.06 20 46.67 83 30 76.67 35 170
9610680 1.08 10 20 97 20 93.33 0 190
185
Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9610687 1.16 95 66.67 80 30 116.67 33 150
9611280 1.24 10 6.67 0 0 97 38 183.33
9611545 1.09 0 25 42 20. 10 205
9611561 1.11 5 0 17 83 87 17 95
9612201 3.6 16.67 13.33 0 33.33 50 7 105
9612530 1.69 35 25 73 0 33.33 0 156.67
9612556 1.1 0 33.33 7 13 120 3 145
9612761 1.08 16.67 13.33 110 30 103.33 23 180
9613408 1.18. 38.
9613574 1.23 43.33 70 83 20 23 33 185
9613576 1.05 0 0 33. 23. 120
9613866 1.04 0 0 17 0 33 28.
9613959 1.08 26.67 73.33 60 97 157 60 195
9614053 1.18 43.33 50 97 10 120 40 190
9614055 1.18 0 0 50 3 143 0 155
9614063 1.07 5 80 111 0 0 0 170
9614565 1.25 10 0 90 0 83 0 160
9614775 1.09. 0 6.67. 205
9614882. 200 200 50.
9615087 1.45 0 0 30 3 53 40 145
9615245. 3 10 7.
9615255 1.08 26.67 16.67 120 13 57 0 170
9615632 1.31. 40 0. 0.
9615643 1.02 20 16.67 67 0 76.67 0 186.67
9700110 1.16 25 50 87 10 50 0 200
9701798 1.04 0 10 17. 180
9702089 1.02 0 30 17 0 110 0 180
9702111 1.08 6.67 33.33 115 23.33 146.67 70 186.67
9702489 1.11 0 0 10 0 66.67 0 45
9702830 1.08 75 50 33 50 150 0 143.33
9703425 3.51 40 80 23 83 200 58 150
9703943 1.06 40 43.33 47 13 100 77 146.67
9704092 1.28 25 57.5 45 43 36.67 0 165
9704237 1.05 6.67 40 63 90 156.67 78 200
9704247 1.29 0 0 43 13 113 0 155
9704740 1.18 35 35 43 0 80 47 173.33
9704850 1.13 0 0 27 0 50 0 185
9704894 1.23 10 26.67 63 72 133 67 176.67
9705111 1.1 5 50 0 61.67 96.67 0 165
9705250 1.06 63.33 76.67 27 67 150 73 146.67
9705308 1.16 0 25 0 17 117 0 195
9705652 1.06 43.33 50 23 27 67 0 200
9706167 2.6 70 50 0 0 66.67 0 180
9706176. 0 20 0 16.67 83.33 0 170
9706414 1.16 0 0 53 0 73.33 0 200
9706430 1.4 30 25 40 20 66.67 0 120
9707082 1.31 3.33 0 0 3.33 73.33 0 163.33
9707685 2.46 0 0. 0. 0 135
9707724. 33.33. 100
186
Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9707729 3.77 23.33 20 120 0 70 0 170
9708066 1.18 0 0 27 10 66.67 0 50
9708349. 0.
9708498 3.29 42.5 70 147 0 60 33 160
9708537 0.98 0 0 20 0 10 0 200
9708552 1.14 26.67 20 133 0 86.67 0 140
9709182 1.23 23.33 40 30 123 173 43 166.67
9709188 1.14 36.67 50 77 36.67 133.33 47 136.67
9709380 1.07 61.67 170 174 113 60 3 140
9709398 1.17 16.67 50 77 36.67 83.33 37 193.33
9709804. 23 0 33.33 0 140
9709871 1.23 10 20 43 17 50 0 140
9710196 1.91 0 0 33 0 90 10 126.67
9710733 1.17 6.67 0 140 93 147 30 100
9711814 1.24 30 53.33 87 63.33 96.67 95 156.67
9712045 1.21 0 0 33 10 47 0 135
9712067 1.15 50 80 38 50 143.33 65 126.67
9712386 1.1 83.33 50 60 90 120 95 126.67
9712389 1.1 45 25 40 30 87 0 143.33
9712913 1.22 0 0 83 16.67 76.67 0 143.33
9713464 1.74 0 0 47 13 127 0 130
9714535 1.03 0 0 28 20 43 0 100
9714864 1.27 0 0 93 20 80 0 153.33
9715190 1.21 0 33.33 10 106.67 170 103 183.33
9715210 1.01 105 160 124 53 23.33 37 153.33
9715546 1.23 0 0 23 63 143 40 156.67
9715565 1.38.
9715848 0.95 30 42.5 0 70 67 60 152.5
9800088 1.31 70 75 38 40 0 50 120
9800098. 15 50 60 0. 0 50
9800394.
9800402. 60 60 5 40 16.67 0 125
9800752 1.2 46.67 100. 73 133.33 33 113.33
9800760. 0 0 60 0 0 3.
9801850 1.04 26.67 20 53 33.33 110 0 85
9802148 1.12 75 20 70 10 33.33 0 115
9802155 1.14 36.67 40 92 10 86.67 17 85
9802172 4.06 23.33 40 10 33 143.33 7 160
9802362 1.15 20 70 21 10 0 0 140
9802721 2.55 33.33 56.67 125 97 56.67 3 155
9802841 1.11 58.33 81.67 70 75 110 57 148.33
9803066 1.01 30 33.33 72 20 56.67 0 106.67
9804234 1.02 53.33 61.67 93 100 100 110 145
9804284 1.23 65 50 20 26.67 33.33 20 65
9805156 1.11 10 10 40 0 30 0 97.5
9805159 1.28 3.33 6.67 27 7 53.33 0 90
9806071 1.13 0 0 7 0 33.33 0 30
9806110 1.19 0 0 160 7 83.33 0 110
187
Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9806239 1.09 23.33 63.33 107 6.67 116.67 43 117.5
9806264. 17.5 35 53 50 73.33 0 93.33
9806475. 19.5 25 80 0 16.67 0 105
9806498 1.08 73.33 86.67 100 80 126.67 0 153.33
9807077. 45 50 20 0 30 0 60
9807270 1.14 0 50.
9807703 1.28 16.67 0 75 60 120 0 105
9808040 1.86 6.67 0 90 0 3.33 0 103.33
9808389 1.06 6.67 43.33 43 10 96.67 0 106.67
9808452 1.03 6.67 6.67 153 0 116.67 0 80
9808762 1.03 36.67 40 93 20 70 0 73.33
9809087 1.45 10 0 17 0 50. 87.5
9809105 1.17 16.67 53.33 27 70 100 37 108.33
9809341 1.23 23.33 43.33 133 77 113.33 7 132.5
9809686 1.11 68.33 73.33 110 87 16.67 0 158.33
9810005 1.06 6.67 20 180 3. 0 108.33
9810111 1.1 53.33 60 33 45 90 0 128.33
9810371 1.11 58.33 60 170 66.67 106.67 40 100
9810382 1.15 56.67 40 30 0 33.33. 95
9810399. 0 33.33.
9810674 1.04 51.67 76.67 129 33 43.33 7 160
9810735 5.66 20 63.33 105 80 13.33 10 200
9811712 1.33 27.5 35 13 16.67 40 0 105
9811724 1.15 56.67 66.67 57 76.67 81.67 0 117.5
9811988 1.06 53.33 56.67 150 76.67 136.67 10 140
9812002 1.15 63.33 46.67 97 66.67 36.67 3 128.33
9812059 1.01 83.33 86.67 43 66.67 140 0 143.33
9812603 1.12 105 143.33 165 153 16.67 40 176.67
9812688 1.37 26.67 23.33 120 66.67 50 3 105
9813075 1.14 15 0 57. 0 35
9814086 1.52 26.67 26.67 117 0 86.67 10 153.33
9814456 1.11 20 0 23 0 73.33 0 156.67
9814740 1.11 60 36.67 48 13 116.67 17 93.33
9814780 2.91 0 50 60. 80 0 87.5
9815130 1.06 78.33 26.67 95 33.33 63.33 3 81.67
9815137 1.03 101.67 86.67 115 13.33 0 23 155
9815874 1 90 80 47 50 66.67 33 95
9815885 1.32 60 42.5 133 83.33 0 0 200
9815921. 30 130 67. 60
9815991 1.05 45 30 142 43.33 36.67 0 70
9816264 1.32 46.67 53.33 103 40 50 3 200
9816428.
9816701. 115 60 120 16.67 16.67 0 110
9816797 1.2 31.67 76.67 43 73.33 60 15 163.33
9816834 1.14 18.33 10 143 36.67 90 0 106.67
9900235 1.24 33.33 93.33 123 0 66.67 17 200
9900879. 27.5 30 120 50 123.33 43 163.33
9901023. 7.5 25 107 0 43.33 10 115
9901042 1.04 85 83.33 132 17 126.67 17 121.67
188
Path no. Her2 F PTEN n PTEN c Bcl-2 c Bax c Bad c pBad c Bcl-xl c
9901655 1.22 66.67 96.67 77 10 133.33 27 150
9901847 1.36 62.5 50 170 0 73.33 3 170
9902012 1.27 78.33 93.33 117 77 105 37 146.67
9902576 1.24 86.67 133.33 33 135 100 87 145
9902708 1.67 96.67 130 188 77 23.33 20 151.67
9903328. 40 0 173 67 23.33. 165
9903476 1.13 95 90 133 87 126.67 7 190
9903477 1.05 53.33 126.67 183 113 180 43 173.33
9903684. 50 20 200 17 76.67 0 163.33
9905581 1.05 47.5 45 73 0 33.33 0 90
9905633 1.05 20 40 87 46.67 56.67 0 200
9905838 1.09 33.33 40 97 27 50 0 111.67
9906151 1.24 40 16.67 87 33 66.67 0 33.33
9906165 1.05 123.33 96.67 78 53 43.33 0 173.33
9906168 1.17 58.33 63.33 110 43 150 47 163.33
9910349 1.03 0 0 47. 140
189
Path no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
8008137. 40 10 0 0
8207635 6.67 0 18 123 50
8304707 0 0 2 101 0
8310775 0 0 40 130 75
8400199 81.67 18 45 131 17.5
8400387 0 25 33 69 73
8408902 75 10 8 108 75
8501076 50 0 0 50 70
8505021 43.33 53 51 75 108
8505709 10 0 20 123 165
8507604. 20.
8507901 37 75 160 30 13
8510490 37 73 123 13 50
8610595 67.5 0 47 99 35
8612132 27 0 103 0 30
8700790 42.5. 60 45
8701087 0 0 30 56 128
8704950 43 0 115 15 25
8705943 55. 0.
8706410.
8708872. 0.
8709046 105 20 20 95 80
8709490 15 20 50. 80
8711800 45 0 30 0 70
8800033 5 5 25 83 18
8802163. 0 0.
8803618.
8804484 13.33 0 0 0 0
8806919 30.
8808120 32.5. 0 129 0
8808858 0 180 104 135 52
8809213 25 50 115 58 30
8900716 132.5 0 43 143 83
8901273 75 7 110 167 135
8901400 26.67 0 100 157 138
8904878 0 0 33. 10
8907245 0 0 23. 0
8907716 98 75 100 20 113
8908418 40 20 100 160 60
8909319 40. 0 90
8909417.
8909430 40 3 83 160 50
8910355 0.
8910865.
8911078.
8911083.
8911515 40 35 55 115 30
8912036. 20
9000072 0.
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ath no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
9000073. 20.
9003516 10 10 58 64 101
9003988 0 0 140 0 25
9004119 55 10 110 80 65
9004589 86.67 0 105 163 147
9005059 85 52 157 53 167
9005575 76.67 0 57 148 128
9005576 3.33 0 160 180 45
9005607 0 13 50 124 62
9006603.
9006722 3.33 7 123 130 52
9007890 10 0 20 0.
9007905 83 0 80 25 95
9007996 0 17 70 103 90
9010055 0 0 24 44 44
9010281 90 20 180 0.
9011029.
9011054 70 38 25 80 118
9011814 75 50 43 116 188
9012080 8 0 130 55 30
9100036 75 0 140 105 170
9100823 0 7 22 59 35
9101094. 0.
9101357 90 30 48 118 82
9101891.
9102250 3.33 0 22 70 77
9102372.
9102602 10 0 130 120 88
9102889 75 0 13 80 100
9103112 25 20 46 113 73
9103262 73 10 35 38 95
9103744.
9104030 0.
9104337 0 0 0 50 83
9105576 10 0 27 0 0
9106709. 120 60 83 160
9106712.
9106880. 15 43.
9107442. 12. 123
9108014 0. 0 50 107
9109046.
9109185 107.5 7 28 94 90
9109446 55 17 80 123 22
9109520 56.67 0 50 59 135
9110219 0. 0
9110376 63 0 100 50 160
9110864 0. 115.
9200106 0 0 8 95 136
9200946.
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Path no. pP70S6K P70S6K n P70S6K c P13K pPQORSK
9201756 20 5 50 75 49
9201866 101.67 10 40 99 138
9202007.
9202261 60 0 50 90 25
9202681 0 0 20 0.
9202922 30 0 17 72 100
9203176.
9203184 75 15 133 153 17
9203254 115. 0 50 30
9203590 15 0 140 90 110
9203954 0 3 0 80 0
9204054 53 0 70 20 110
9204266 0. 0 0
9204364 26.67 7 67 98 95
9204491 15 45 145 150 130
9204693 10 0 180 10 170
9204716 48 48 103 35 127
9204717 0 15 60 120 63
9205324.
9205594 55. 30 155
9205687 5 0 0 13 0
9205835 53. 140 205
9206189 0 0 0 16 0
9207128 50 40 49 98 100
9207359.
9207829 6.67 33 46 73 77
9208073 67.5 80. 135
9208160 0. 0.
9208255 10 15 100 0 150
9208691 35 20 140 150 130
9208751 0.
9208764.
9208915 30 135 165 53 180
9209466 0 45 50. 110
9209746 15 17 67 0.
9210214 45 20 130 45 180
9210338 70 70 100 12 170
9211015 0 7 14 94 106
9211284 30 27 23 81 122
9211307 0 0 4 51 33
9300038 0 30 20 15 75
9300203 25 0 0 120 133
9300414 135. 0 90 130
9300505 8 40 80 0 105
9300517 5 95 185 20 165
9300806.
9300946 0 0 6 35 73
9301463 0 70 100 8.
9301496 3 20 105 0 27
192
ath no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
9301709 87.5 10 56 71 123
9301742 0 0 23 33 100
9302004 70 50 130 37 135
9302281 15 0 40 100 65
9303058.
9303305 132.5 73 53 93 95
9303334 80 0 50 0 90
9303835.
9303848 13 0 0 35 105
9303995 0 0 8 101 10
9304892 80 20 70 130 148
9305263 45 15 130 140 143
9305697 53 35 68 75 193
9305719.
9305937 53 30 105 68 140
9305972 0. 0.
9306294. 0 0
9306938.
9308293. 0.
9308295 40 0 80 27 90
9309731 0 0 38 43 30
9309739 0 0 10 143 30
9310797. 40
9310816.
9310859 30 27 34 98 5
9311333 0 0 0. 10
9311343 0 10 27 75 44
9312194 70 0 87 103 137
9312208 53.33 23 44 100 112
9312498 17.5 60 42 83 113
9400251 13 65 150 10 148
9401076 50 20 143 82 150
9401443.
9401646 38 0 115 130 50
9401940 40 73 97 173 28
9403539 155 15 53. 160
9403796 30 30 145 30 115
9404046. 0
9404065 98.33 60 65 177 97
9404346 55 8 110 60 123
9404349 0 0 0 0.
9404604 50 0 115 30 55
9405719.
9405958 106.67 3 93 163 138
9405960.
9406536.
9406665 25 10. 110 18
9406692 41.67 10 73 61 131
9406790 40 120 200 100 180
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Path no. pP70S6K P70S6K n P70S6K o PI3K pP90RSK
9406805 56.67 42 40 116 143
9407111 40 0 45 100 104
9408178 30 50 100. 150
9408557.
9408685 0 0 0 0 0
9409104 68.33 0 40 120 145
9409109 90 10 95 20 10
9409112 20.
9409346. 180
9409784 50 30 100 30 110
9410051 37.5 10 90 0 37
9410252 20. 0
9410430 91.5 0 40 53 100
9410568 8.33. 30 0
9410701.
9410706 0 0 180. 115
9410823 42.5 90 150. 78
9410890.
9410906 0 20 20 0 35
9410953 37.5. 90 120
9411100 20. 0.
9411449 68.33 0 120 30 90
9411476 10 0 100 40 50
9411819 0. 180
9412034.
9412265 21.67 60 190 50 10
9412269 0 70 180 50 140
9412313 48.33 23 67 123 140
9412422 5 0 100. 55
9412614 0. 100.
9413539 31.67 48 145 110 137
9500073 73.33.
9500228.
9500763.
9500955 0 0 0 0 0
9501106 18.33 0 103 122 28
9501108 20 0 77 50 73
9501958 13.33 65 110 35 10
9501978 40 13 68 45 105
9502003.
9502205 0 40 90. 180
9502318 0 0 100 65.
9502659 60 30 40 43.
9502985 45.
9503407 2.5 0 93 0.
9503884 0 0 135. 120
9504207 50 7 123 133 72
9504214 36.67 10 100 0.
9504389.
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Path no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
9505535 0 0 10 33 20
9505600 0 10 40 8 0
9506010 0. 60
9506050 0 0 0 30 15
9507243 0.
9507433. 0
9507574 100 13 80 143 117
9507835 0 40 70 7 52
9509140 3.33 0 20 45 55
9510723 0 0 13 57 115
9510764 0 0 70 58 100
9511536 20. 0 118
9511736 3.33 0 27 60 13
9511896 0 0 10 30 30
9512307 21.67 0 45 43 70
9512526 20 17 97 107 117
9512539 0 0 30 27 20
9512595 0 0 123 87 127
9513175 1.67 0 43 60 122
9514124 0. 20.
9514572 15 15 25 75 123
9600346 3.33 0 50 30 5
9601048 23.33 0 67 113 70
9601571 25 0 60 75 60
9601591 0. 0
9601927 36.67. 75 40
9602066 5 58 130 0 0
9602566 5 0 100 108 20
9602691 31.67. 73.
9603454. 30
9603840 0 5 0 63 7
9603856 40 90 120 37 80
9603877 0. 110 100
9603882 1.67 0 0 0 103
9604092 0 0 0 30 0
9604189.
9605089 40 0 25 103 90
9605413 0 50 60 7 0
9605556 20 20 123 100 20
9606350 0. 0.
9607449 30 0 10 0 40
9608209 20 0 15 60 10
9608671 0 0 0. 0
9609194 28.33 3 20 0 7
9609268 0. 70 0
9609341.
9609370 65 7 127 173 138
9610658 75 15 140 23 148
9610680 5 0 15 5 0
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Path no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
9610687 85 0 120 80.
9611280 30 0 0 28 152
9611545 0 0 15 20 130
9611561 6.67 10 60 23 75
9612201 15 0 0 0 133
9612530 7.5 0 0 0 0
9612556 0 133 168 27 30
9612761 16.67 5 95 23 88
9613408 200.
9613574 3.33 0 90 63 115
9613576.
9613866 5 10 55 0 15
9613959 48.33 12 112 83 180
9614053 28.33 82 158 33 140
9614055 6.67 20 80 0 0
9614063 25. 115 150
9614565 15 0 50 70 117
9614775 65. 20.
9614882 60.
9615087 0 0 35 23 65
9615245 0.
9615255 5 5 0 17 22
9615632. 80 140.
9615643 3.33 75 100 0 25
9700110 0 0 70 0 30
9701798.
9702089 0 68 100 0 7
9702111 0 13 123 33 78
9702489 0 30 40 0 10
9702830 8.33 15 90 63 38
9703425 15 25 100 23 163
9703943 55 10 50 33 115
9704092 42.5 0 60 25 60
9704237 48.33 50 180 70 150
9704247 5 20 85 100 10
9704740 80. 100.
9704850. 0 85
9704894 5 3 147 43 88
9705111 0 0 0 80 20
9705250 8.33 7 52 30 55
9705308 0.
9705652 10 . 0 20
9706167 0. 100
9706176 0. 0 25
9706414 3.33 5 25 20 10
9706430 0 45 70 50 95
9707082 0 155 190 0 2
9707685 10. 0.
9707724.
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Path no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
9707729 5 60 180 30 30
9708066 0.
9708349.
9708498 20. 100 40
9708537 0 50 110 0 50
9708552 0 0 80 0 10
9709182 26.67 13 33 53 98
9709188 31.67 27 67 43 113
9709380 36.67 0 30 83 128
9709398 31.67 8 163 73 35
9709804 0 40 130 0 0
9709871 0 10 70. 0
9710196 23.33 65 150 40 17
9710733 25 35 147 63 3
9711814 13.33 7 60 40 125
9712045 0 0 120 0 158
9712067 30 0 127 83 60
9712386 41.67 30 43 32 30
9712389 36.67 55 140 0 90
9712913 0 10 10 0 0
9713464 0 80 120 10 8
9714535 0. 0
9714864 3.33 17 37 7 53
9715190 18.33 10 125 97 120
9715210 48.33 0 85 137 140
9715546 11.67 10 135 20 103
9715565. 0.
9715848 95 0 0 38 0
9800088 145 20 80 40 200
9800098 0. 20
9800394.
9800402 85 7 120 83 90
9800752 31.67 0 47 95 30
9800760 0. 0 35
9801850 0 0 0 50 17
9802148 0.
9802155 5 0 20 0 25
9802172 50 90 160 100 150
9802362 35 10 80 70 113
9802721 0 0 0 50 0
9802841 63.33 7 53 60 150
9803066 0. 15 0
9804234 13.33 0 50 93 113
9804284 20 0 0 0 0
9805156 0 50 30 25 35
9805159 0 0 0 0 10
9806071 0 0 40 50 10
9806110 20 32 33 20 78
9806239 0 7 107 73 153
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Path no. pP70S6K P70S6K n P70S6K c PI3K pP90RSK
9806264 30 60 120 10 5
9806475 0.
9806498 3.33 13 57 70 0
9807077 30. 50 15
9807270. 0
9807703 0 0 27 27 30
9808040 0 3 5 0 50
9808389 0. 0 5
9808452 0 20 53 63 8
9808762 0 0 0 17 17
9809087 0 0 0.
9809105 0 0 87 85 160
9809341 3.33 35 85 43 38
9809686 60 40 107 105 175
9810005 1.67 0 0 0 0
9810111 0. 57 8
9810371 0 0 100 90 100
9810382 0 0 30.
9810399.
9810674 1.67 0 30 90 17
9810735 160 23 40 108 130
9811712 0 0 10 10 5
9811724 0 30 67 7 88
9811988 0 3 133 37 12
9812002 8.33 20 120 43 102
9812059 0 10 50 57 2
9812603 176.67 5 15 137 135
9812688 0 0 0. 0
9813075. 40
9814086 25 15 57 33 55
9814456 56.67. 75
9814740 25 90 130 70 130
9814780. 15
9815130 0 30 80 10 38
9815137 7.5 20 85 113 50
9815874 3.33 0 45 35 65
9815885.
9815921.
9815991 0 15 80 50 70
9816264 36.67 27 83 57 43
9816428.
9816701 0. 0
9816797 21.67 0 67 87 88
9816834 0 25 88 60 48
9900235 0 0 30 80 50
9900879 26.67 20 150 115 90
9901023 40. 50 10
9901042 36.67 183 180 57 60
9901655 0 7 60 43 38
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Path no. pP70S6K P70S6K n P70S6K c P13K pP90RSK
9901847 12.5 13 43 55 78
9902012 98.33 0 110 48 85
9902576 0 0 50 40 90
9902708 5 7 93 73 30
9903328. 0 100 60.
9903476 6.67 0 110 25 35
9903477 45 17 143 117 43
9903684 81.67 35 145 90 33
9905581 0 0 78 55 18
9905633 0 0 140 100 30
9905838 11.67 0 43 23 40
9906151 8.33 10 23 23 38
9906165 70 147 120 163 135
9906168 40 13 43 63 67
9910349. 40.
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